> top > docs > PMC:7228307 > annotations

PMC:7228307 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 35188-35194 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T2 46137-46143 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T3 46173-46179 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T4 47296-47302 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
1 33-37 Gene denotes FcγR Gene:2213
16 1754-1761 Gene denotes FcγRIIb Gene:2213
17 1870-1874 Gene denotes FcγR Gene:2213
18 1800-1804 Gene denotes FcγR Gene:2213
19 1385-1389 Gene denotes FcγR Gene:2213
20 940-944 Gene denotes FcγR Gene:2213
21 583-587 Gene denotes FcγR Gene:2213
22 164-169 Species denotes human Tax:9606
23 1189-1236 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
24 1238-1248 Species denotes SARS‐CoV‐2 Tax:2697049
25 1593-1599 Chemical denotes glycan MESH:D011134
26 680-686 Disease denotes cancer MESH:D009369
27 1127-1134 Disease denotes cancers MESH:D009369
28 1136-1157 Disease denotes inflammatory diseases MESH:D007249
29 1170-1180 Disease denotes infections MESH:D007239
31 2372-2376 Gene denotes FcγR Gene:2213
35 2796-2817 Disease denotes inflammatory diseases MESH:D007249
36 2830-2837 Disease denotes cancers MESH:D009369
37 2868-2880 Disease denotes malignancies MESH:D009369
42 3934-3938 Gene denotes FcγR Gene:2213
43 3302-3320 Disease denotes autoimmune disease MESH:D001327
44 3363-3372 Disease denotes infection MESH:D007239
45 3400-3407 Disease denotes allergy MESH:D004342
48 4471-4475 Gene denotes FcγR Gene:2213
49 4259-4263 Gene denotes FcγR Gene:2213
58 4974-4981 Gene denotes FcγRIIb Gene:2213
59 5487-5494 Gene denotes FcγRIIb Gene:2213
60 5143-5147 Gene denotes FcγR Gene:2213
61 4686-4690 Gene denotes FcγR Gene:2213
62 4544-4548 Gene denotes FcγR Gene:2213
63 5521-5533 Species denotes participants Tax:9606
64 5042-5050 Chemical denotes tyrosine MESH:D014443
65 4793-4805 Disease denotes cytotoxicity MESH:D064420
84 5888-5896 Gene denotes FcγRIIIa Gene:2214
85 6051-6059 Gene denotes FcγRIIIa Gene:2214
86 6279-6286 Gene denotes FcγRIIb Gene:2213
87 6580-6587 Gene denotes FcγRIIb Gene:2213
88 7021-7028 Gene denotes FcγRIIb Gene:2213
89 6411-6415 Gene denotes FcγR Gene:2213
90 6038-6042 Gene denotes FcγR Gene:2213
91 5789-5793 Gene denotes FcγR Gene:2213
92 7134-7138 Gene denotes FcγR Gene:2213
93 6626-6633 Gene denotes FcγRIIb Gene:2213
94 7451-7454 Gene denotes BCR Gene:613
95 6064-6071 Gene denotes FcγRIIa Gene:2212
96 6307-6315 Chemical denotes tyrosine MESH:D014443
97 6649-6657 Chemical denotes tyrosine MESH:D014443
98 6749-6753 Chemical denotes ITAM
99 5871-5883 Disease denotes cytotoxicity MESH:D064420
100 6910-6913 Disease denotes APC MESH:D011125
101 7424-7436 Disease denotes cytotoxicity MESH:D064420
119 7762-7770 Gene denotes FcγRIIIa Gene:2214
120 7863-7871 Gene denotes FcγRIIIa Gene:2214
121 7873-7880 Gene denotes FcγRIIa Gene:2212
122 7882-7887 Gene denotes FcγRI Gene:2214
123 7959-7964 Gene denotes FcγRI Gene:2214
124 7966-7974 Gene denotes FcγRIIIa Gene:2214
125 8105-8108 Gene denotes BCR Gene:613
126 8174-8181 Gene denotes FcγRIIb Gene:2213
127 8242-8249 Gene denotes FcγRIIb Gene:2213
128 8487-8494 Gene denotes FcγRIIb Gene:2213
129 8501-8508 Gene denotes FcγRIIa Gene:2212
130 8510-8515 Gene denotes FcγRI Gene:2214
131 8461-8465 Gene denotes FcγR Gene:2213
132 8139-8143 Gene denotes FcγR Gene:2213
133 7591-7595 Gene denotes FcγR Gene:2213
134 7950-7957 Gene denotes FcγRIIa Gene:2212
135 7717-7729 Disease denotes cytotoxicity MESH:D064420
137 7522-7526 Gene denotes FcγR Gene:2213
140 8517-8520 Gene denotes BCR Gene:613
141 8560-8568 Chemical denotes tyrosine MESH:D014443
143 8601-8605 Gene denotes FcγR Gene:2213
145 8756-8764 Disease denotes COVID-19 MESH:C000657245
150 9314-9318 Gene denotes FcRn Gene:2217
151 9443-9459 Gene denotes Fc receptor‐like Gene:84824
152 9113-9117 Gene denotes FcγR Gene:2213
153 9097-9102 Species denotes human Tax:9606
156 9477-9481 Gene denotes FcγR Gene:2213
157 9471-9476 Species denotes Human Tax:9606
170 9616-9621 Gene denotes FcγRI Gene:2214
171 9632-9639 Gene denotes FcγRIIc Gene:9103
172 9641-9649 Gene denotes FcγRIIIa Gene:2214
173 9694-9699 Gene denotes CD32a Gene:2212
174 9701-9706 Gene denotes CD32c Gene:9103
175 9708-9713 Gene denotes CD16a Gene:2214
176 9718-9723 Gene denotes CD16b Gene:2215
177 9793-9800 Gene denotes FcγRIIb Gene:2213
178 9813-9818 Gene denotes CD32b Gene:2213
179 9623-9630 Gene denotes FcγRIIa Gene:2212
180 9505-9510 Species denotes human Tax:9606
181 9654-9662 Gene denotes FcγRIIIb Gene:2215
189 10684-10688 Gene denotes FcγR Gene:2213
190 11168-11172 Gene denotes FcγR Gene:2213
191 10946-10950 Gene denotes FcγR Gene:2213
192 10788-10792 Gene denotes FcγR Gene:2213
193 10455-10459 Gene denotes FcγR Gene:2213
194 10668-10673 Species denotes human Tax:9606
195 10940-10945 Species denotes human Tax:9606
213 11318-11323 Gene denotes FcγRI Gene:2214
214 11337-11341 Gene denotes IgG3 Gene:3502
215 11360-11372 Gene denotes interferon‐γ Gene:3458
216 11475-11479 Gene denotes IgG3 Gene:3502
217 11624-11628 Gene denotes IgG3 Gene:3502
218 11645-11653 Gene denotes FcγRIIIa Gene:2214
219 11666-11670 Gene denotes IgG3 Gene:3502
220 11860-11864 Gene denotes IgG3 Gene:3502
221 11878-11885 Gene denotes FcγRIIb Gene:2213
222 11898-11902 Gene denotes IgG3 Gene:3502
223 12062-12070 Gene denotes FcγRIIIb Gene:2215
224 11537-11543 Species denotes people Tax:9606
225 11839-11847 Gene denotes FcγRIIIb Gene:2215
226 11455-11462 Gene denotes FcγRIIa Gene:2212
227 11819-11822 Chemical denotes Phe MESH:D010649
228 11736-11753 Disease denotes myeloid dendritic MESH:D007635
229 12003-12020 Disease denotes myeloid dendritic MESH:D007635
231 11257-11261 Gene denotes FcγR Gene:2213
233 12235-12241 Species denotes people Tax:9606
235 12348-12356 Disease denotes COVID-19 MESH:C000657245
246 13217-13222 Gene denotes FcγRI Gene:2214
247 13224-13231 Gene denotes FcγRIIb Gene:2213
248 13242-13245 Gene denotes CH1 Gene:51430
249 12881-12884 Gene denotes CH1 Gene:51430
250 12740-12744 Gene denotes FcγR Gene:2213
251 12643-12647 Gene denotes FcγR Gene:2213
252 13233-13240 Gene denotes FcγRIIc Gene:9103
253 12865-12872 Gene denotes FcγRIIa Gene:2212
254 12960-12969 Chemical denotes disulfide MESH:D004220
255 13199-13209 Chemical denotes disulfides MESH:D004220
257 13498-13506 Disease denotes COVID-19 MESH:C000657245
259 13725-13729 Gene denotes FcγR Gene:2213
262 13809-13813 Gene denotes FcγR Gene:2213
263 13793-13798 Species denotes human Tax:9606
275 14445-14450 Gene denotes FcγRI Gene:2214
276 14455-14462 Gene denotes FcγRIIb Gene:2213
277 14570-14575 Gene denotes FcγRI Gene:2214
278 14577-14584 Gene denotes FcγRIIa Gene:2212
279 14589-14597 Gene denotes FcγRIIIa Gene:2214
280 14605-14612 Gene denotes FcγRIIb Gene:2213
281 14528-14535 Gene denotes FcγRIIa Gene:2212
282 14411-14415 Gene denotes FcγR Gene:2213
283 14157-14161 Gene denotes FcγR Gene:2213
284 14027-14031 Gene denotes FcγR Gene:2213
285 14103-14108 Species denotes human Tax:9606
287 14659-14663 Gene denotes FcγR Gene:2213
293 14702-14707 Gene denotes FcγRI Gene:2214
294 14768-14780 Gene denotes interferon‐γ Gene:3458
295 14903-14908 Gene denotes FcγRI Gene:14129
296 14912-14924 Gene denotes interferon‐γ Gene:15978
297 15009-15014 Species denotes mouse Tax:10090
305 15170-15177 Gene denotes FcγRIIa Gene:2212
306 15487-15492 Species denotes human Tax:9606
307 15675-15680 Species denotes human Tax:9606
308 15506-15511 Species denotes human Tax:9606
309 15420-15437 Disease denotes thrombocytopenias MESH:D013921
310 15756-15784 Disease denotes systemic lupus erythematosus MESH:D008180
311 15838-15854 Disease denotes hyper‐responsive MESH:D012130
318 16264-16271 Gene denotes FcγRIIb Gene:2213
319 16385-16392 Gene denotes FcγRIIc Gene:9103
320 15965-15969 Gene denotes FcγR Gene:2213
321 15940-15947 Gene denotes FcγRIIc Gene:9103
322 16079-16085 Species denotes humans Tax:9606
323 16371-16378 Gene denotes FcγRIIa Gene:2212
335 16632-16639 Gene denotes FcγRIII Gene:2214
336 16684-16692 Gene denotes FcγRIIIa Gene:2214
337 16697-16705 Gene denotes FcγRIIIb Gene:2215
338 16711-16719 Gene denotes FcγRIIIa Gene:2214
339 16834-16842 Gene denotes FcγRIIIa Gene:2214
340 17282-17289 Gene denotes FcγRIIa Gene:2212
341 16954-16960 Species denotes humans Tax:9606
342 17098-17103 Species denotes human Tax:9606
343 17202-17210 Gene denotes FcγRIIIb Gene:2215
344 16932-16940 Gene denotes FcγRIIIb Gene:2215
345 17181-17188 Gene denotes FcγRIIa Gene:2212
354 17684-17691 Gene denotes FcγRIIb Gene:2213
355 17744-17752 Gene denotes FcγRIIb1 Gene:1555
356 17898-17921 Gene denotes B‐cell antigen receptor Gene:613
357 17923-17926 Gene denotes BCR Gene:613
358 18149-18157 Gene denotes FcγRIIb1 Gene:1555
359 17619-17623 Gene denotes FcγR Gene:2213
360 17337-17341 Gene denotes FcγR Gene:2213
361 18307-18312 Species denotes human Tax:9606
369 18556-18564 Gene denotes FcγRIIIa Gene:2214
370 18599-18606 Gene denotes FcγRIIa Gene:2212
371 18608-18615 Gene denotes FcγRIIb Gene:2213
372 18619-18627 Gene denotes FcγRIIIa Gene:2214
373 18376-18380 Gene denotes FcγR Gene:2213
374 18526-18530 Gene denotes FcγR Gene:2213
375 18569-18573 Disease denotes αβ T MESH:D001260
382 18963-18967 Gene denotes FcγR Gene:2213
383 19167-19174 Gene denotes FcγRIIb Gene:2213
384 19388-19395 Gene denotes FcγRIIb Gene:2213
385 19425-19432 Gene denotes FcγRIIb Gene:2213
386 19837-19844 Gene denotes FcγRIIb Gene:2213
387 18801-18805 Gene denotes FcγR Gene:2213
389 19998-20002 Gene denotes FcγR Gene:2213
395 20514-20517 Gene denotes BCR Gene:613
396 20209-20212 Gene denotes BCR Gene:613
397 20455-20459 Gene denotes FcγR Gene:2213
398 20100-20104 Gene denotes FcγR Gene:2213
399 20577-20585 Chemical denotes tyrosine MESH:D014443
402 20707-20715 Gene denotes FcγRIIb1 Gene:1555
403 20810-20813 Gene denotes BCR Gene:613
405 21477-21481 Gene denotes FcγR Gene:2213
410 21819-21823 Gene denotes FcγR Gene:2213
411 22508-22512 Gene denotes FcγR Gene:2213
412 22075-22079 Gene denotes FcγR Gene:2213
413 21945-21949 Gene denotes FcγR Gene:2213
418 23408-23413 Disease denotes flush MESH:D005483
419 23648-23660 Disease denotes cytotoxicity MESH:D064420
420 23711-23723 Disease denotes cytotoxicity MESH:D064420
421 23830-23835 Disease denotes flush MESH:D005483
426 24326-24330 Gene denotes FcγR Gene:2213
427 24217-24221 Gene denotes FcγR Gene:2213
428 24167-24171 Chemical denotes ADCP
429 24150-24162 Disease denotes cytotoxicity MESH:D064420
432 24480-24484 Gene denotes FcγR Gene:2213
433 24728-24734 Chemical denotes glycan MESH:D011134
443 25128-25136 Gene denotes FcγRIIIa Gene:2214
444 25389-25396 Gene denotes FcγRIIa Gene:2212
445 25401-25406 Gene denotes FcγRI Gene:2214
446 25607-25614 Gene denotes FcγRIII Gene:2214
447 25637-25644 Gene denotes FcγRIIa Gene:2212
448 25649-25654 Gene denotes FcγRI Gene:2214
449 25032-25036 Gene denotes FcγR Gene:2213
450 25505-25513 Species denotes patients Tax:9606
451 25336-25342 Disease denotes cancer MESH:D009369
463 25840-25847 Gene denotes FcγRIIb Gene:2213
464 26007-26014 Gene denotes FcγRIIb Gene:2213
465 26147-26150 Gene denotes BCR Gene:613
466 26228-26236 Gene denotes FcγRIIb1 Gene:1555
467 26307-26312 Gene denotes FcγRI Gene:2214
468 26314-26321 Gene denotes FcγRIIa Gene:2212
469 26332-26339 Gene denotes FcγRIII Gene:2214
470 26661-26664 Gene denotes BCR Gene:613
471 26793-26796 Gene denotes BCR Gene:613
472 26856-26864 Gene denotes FcγRIIB1 Gene:1555
473 26323-26330 Gene denotes FcγRIIc Gene:9103
481 27225-27232 Gene denotes FcγRIIb Gene:14130
482 27465-27472 Gene denotes FcγRIIb Gene:14130
483 27190-27194 Gene denotes FcγR Gene:2213
484 27052-27056 Gene denotes FcγR Gene:2213
485 26965-26971 Species denotes humans Tax:9606
486 27500-27504 Species denotes mice Tax:10090
487 27509-27515 Species denotes humans Tax:9606
493 28125-28129 Gene denotes FcγR Gene:2213
494 28005-28009 Species denotes mice Tax:10090
495 28083-28091 Species denotes patients Tax:9606
496 28041-28054 Disease denotes recall memory MESH:D008569
497 28183-28188 Disease denotes tumor MESH:D009369
504 28595-28600 Gene denotes FcγRI Gene:2214
505 28360-28364 Gene denotes FcγR Gene:2213
506 28269-28273 Gene denotes FcγR Gene:2213
507 28589-28594 Species denotes human Tax:9606
508 28644-28648 Species denotes mice Tax:10090
509 28604-28609 Species denotes human Tax:9606
511 29022-29029 Gene denotes FcγRIIb Gene:2213
513 29248-29255 Gene denotes FcγRIIb Gene:2213
515 29475-29479 Gene denotes FcγR Gene:2213
524 30571-30576 Gene denotes CD357 Gene:8784
525 30408-30412 Gene denotes FcγR Gene:2213
526 30370-30374 Gene denotes FcγR Gene:2213
527 30231-30235 Gene denotes FcγR Gene:2213
528 29860-29864 Gene denotes FcγR Gene:2213
529 29592-29596 Gene denotes FcγR Gene:2213
530 29487-29491 Gene denotes FcγR Gene:2213
531 29539-29551 Species denotes participants Tax:9606
535 30622-30626 Gene denotes FcγR Gene:2213
536 30849-30860 Chemical denotes daratumumab MESH:C556306
537 30790-30795 Disease denotes death MESH:D003643
544 31776-31781 Gene denotes FcγRI Gene:2214
545 32041-32046 Gene denotes FcγRI Gene:2214
546 32112-32124 Gene denotes interferon‐γ Gene:3458
547 31479-31483 Gene denotes FcγR Gene:2213
548 31339-31343 Gene denotes FcγR Gene:2213
549 32181-32193 Disease denotes inflammation MESH:D007249
554 32386-32390 Gene denotes IgG3 Gene:3502
555 32641-32648 Gene denotes FcγRIIb Gene:2213
556 32690-32697 Gene denotes FcγRIII Gene:2214
557 32208-32213 Species denotes human Tax:9606
562 32900-32908 Gene denotes FcγRIIIa Gene:2214
563 32829-32833 Gene denotes FcγR Gene:2213
564 33004-33017 Chemical denotes phenylalanine MESH:D010649
565 33018-33024 Chemical denotes valine MESH:D014633
572 33263-33270 Gene denotes FcγRIIb Gene:2213
573 33311-33316 Gene denotes FcγRI Gene:2214
574 33448-33455 Gene denotes FcγRIIa Gene:2212
575 33183-33187 Gene denotes FcγR Gene:2213
576 33534-33543 Chemical denotes histidine MESH:D006639
577 33764-33772 Chemical denotes arginine MESH:D001120
579 33870-33874 Gene denotes FcγR Gene:2213
583 34022-34027 Gene denotes FcγRI Gene:2214
584 33970-33974 Gene denotes FcγR Gene:2213
585 33921-33925 Gene denotes FcγR Gene:2213
588 34150-34154 Gene denotes FcγR Gene:2213
589 34191-34196 Species denotes human Tax:9606
602 34456-34461 Gene denotes FcγRI Gene:2214
603 34473-34480 Gene denotes FcγRIII Gene:2214
604 35128-35136 Gene denotes FcγRIIIa Gene:2214
605 34463-34469 Gene denotes FcγRII Gene:2214
606 35004-35008 Gene denotes FcγR Gene:2213
607 34600-34604 Gene denotes FcγR Gene:2213
608 34427-34432 Species denotes human Tax:9606
609 34798-34813 Chemical denotes N‐linked glycan
610 34817-34827 Chemical denotes asparagine MESH:D001216
611 34833-34837 Chemical denotes N297
612 35188-35194 Chemical denotes fucose MESH:D005643
613 35212-35227 Chemical denotes oligosaccharide MESH:D009844
617 35306-35310 Gene denotes FcγR Gene:2213
618 35477-35481 Gene denotes FcγR Gene:2213
619 35354-35358 Gene denotes FcγR Gene:2213
621 35655-35664 Chemical denotes disulfide MESH:D004220
624 36272-36281 Chemical denotes disulfide MESH:D004220
625 36670-36679 Chemical denotes disulfide MESH:D004220
630 36930-36933 Gene denotes CH1 Gene:51430
631 37072-37075 Gene denotes CH1 Gene:51430
632 37384-37388 Gene denotes FcγR Gene:2213
633 36795-36804 Chemical denotes disulfide MESH:D004220
635 37471-37475 Gene denotes IgG3 Gene:3502
639 37883-37887 Gene denotes FcγR Gene:2213
640 38252-38256 Gene denotes FcγR Gene:2213
641 38082-38086 Gene denotes FcγR Gene:2213
645 39109-39116 Gene denotes FcγRIIb Gene:2213
646 39039-39043 Gene denotes FcγR Gene:2213
647 38734-38739 Species denotes human Tax:9606
652 39268-39272 Gene denotes FcγR Gene:2213
653 39842-39846 Gene denotes FcγR Gene:2213
654 39790-39794 Gene denotes FcγR Gene:2213
655 39499-39507 Species denotes patients Tax:9606
680 40514-40518 Gene denotes HER2 Gene:2064
681 40525-40529 Gene denotes EGFR Gene:1956
682 40687-40691 Gene denotes HER2 Gene:2064
683 40713-40717 Gene denotes EGFR Gene:1956
684 40997-41005 Gene denotes FcγRIIIa Gene:2214
685 41026-41033 Gene denotes FcγRIIb Gene:2213
686 41086-41093 Gene denotes FcγRIIb Gene:2213
687 41108-41113 Gene denotes FcγRI Gene:2214
688 41115-41122 Gene denotes FcγRIIa Gene:2212
689 41279-41286 Gene denotes FcγRIIb Gene:2213
690 41563-41567 Gene denotes FcγR Gene:2213
691 41329-41333 Gene denotes FcγR Gene:2213
692 40986-40990 Gene denotes FcγR Gene:2213
693 40791-40795 Gene denotes FcγR Gene:2213
694 40554-40558 Gene denotes FcγR Gene:2213
695 40739-40744 Species denotes human Tax:9606
696 40646-40655 Chemical denotes rituximab MESH:D000069283
697 40669-40680 Chemical denotes trastuzumab MESH:D000068878
698 40697-40706 Chemical denotes cetuximab MESH:D000068818
699 40282-40302 Disease denotes Cytotoxic mAb cancer MESH:D064420
700 40429-40448 Disease denotes death of the cancer MESH:D009369
701 40601-40606 Disease denotes tumor MESH:D009369
702 41154-41159 Disease denotes tumor MESH:D009369
703 41211-41217 Disease denotes cancer MESH:D009369
714 42164-42172 Gene denotes FcγRIIIa Gene:2214
715 42302-42309 Gene denotes FcγRIIb Gene:2213
716 42473-42480 Gene denotes FcγRIII Gene:2214
717 42516-42524 Gene denotes FcγRIIIa Gene:2214
718 42344-42348 Gene denotes FcγR Gene:2213
719 42145-42149 Gene denotes FcγR Gene:2213
720 41994-41998 Gene denotes FcγR Gene:2213
721 42584-42591 Species denotes patient Tax:9606
722 42231-42236 Disease denotes tumor MESH:D009369
723 42649-42655 Disease denotes cancer MESH:D009369
725 42800-42815 Chemical denotes N‐linked glycan
793 43108-43134 Gene denotes Matrix Metalloproteinase 9 Gene:4318
794 43136-43140 Gene denotes MMP9 Gene:4318
795 43518-43525 Gene denotes FcγRIII Gene:2214
796 43943-43950 Gene denotes FcγRIII Gene:2214
797 44147-44151 Gene denotes HER2 Gene:2064
798 44214-44221 Gene denotes FcγRIII Gene:2214
799 44270-44299 Gene denotes C–C chemokine receptor type 4 Gene:1233
800 44301-44305 Gene denotes CCR4 Gene:1233
801 44348-44355 Gene denotes FcγRIII Gene:2214
802 44490-44497 Gene denotes FcγRIII Gene:2214
803 44542-44546 Gene denotes PD‐1 Gene:5133
804 44682-44689 Gene denotes FcγRIII Gene:2214
805 44794-44801 Gene denotes FcγRIII Gene:2214
806 44850-44854 Gene denotes PD‐1 Gene:5133
807 44982-44989 Gene denotes FcγRIII Gene:2214
808 45602-45609 Gene denotes FcγRIII Gene:2214
809 45399-45403 Gene denotes FcγR Gene:2213
810 45374-45378 Gene denotes FcγR Gene:2213
811 45195-45199 Gene denotes FcγR Gene:2213
812 45097-45101 Gene denotes FcγR Gene:2213
813 43740-43744 Gene denotes FcγR Gene:2213
814 43416-43420 Gene denotes FcγR Gene:2213
815 43323-43327 Gene denotes FcγR Gene:2213
816 45482-45486 Gene denotes PD‐1 Gene:5133
817 45253-45257 Gene denotes PD‐1 Gene:5133
818 43655-43660 Gene denotes PD‐L1 Gene:29126
819 43373-43378 Gene denotes PD‐L1 Gene:29126
820 43564-43589 Disease denotes ear nose throat disorders MESH:D004427
821 43852-43871 Disease denotes Metabolic disorders MESH:D008659
822 44097-44122 Disease denotes musculoskeletal disorders MESH:D009140
823 44583-44601 Disease denotes Infectious disease MESH:D003141
824 44891-44900 Disease denotes Infection MESH:D007239
825 45003-45026 Disease denotes Hematological disorders MESH:D006402
826 45209-45228 Disease denotes Metabolic disorders MESH:D008659
827 45494-45499 Mutation denotes S228P rs1469294455
828 43668-43673 Mutation denotes L234F p.L234F
829 43675-43680 Mutation denotes L235E p.L235E
830 43682-43687 Mutation denotes P331S p.P331S
831 43401-43406 Mutation denotes N297A p.N297A
832 43251-43256 Mutation denotes L234F p.L234F
833 43258-43263 Mutation denotes L235E p.L235E
834 43265-43270 Mutation denotes P331S p.P331S
835 45265-45270 Mutation denotes S228P rs1469294455
836 44862-44867 Mutation denotes S228P rs1469294455
837 44159-44164 Mutation denotes F243L p.F243L
838 44166-44171 Mutation denotes L235V p.L235V
839 44173-44178 Mutation denotes R292P p.R292P
840 44180-44185 Mutation denotes Y300L p.Y300L
841 44187-44192 Mutation denotes P396L p.P396L
842 44456-44461 Mutation denotes S239D p.S239D
843 44463-44468 Mutation denotes I332E p.I332E
844 44554-44559 Mutation denotes S228P rs1469294455
845 44760-44765 Mutation denotes P247I p.P247I
846 44767-44772 Mutation denotes A339Q p.A339Q
847 44043-44048 Mutation denotes S228P rs1469294455
848 45174-45179 Mutation denotes L234A p.L234A
849 45286-45291 Mutation denotes L235A p.L235A
850 45076-45081 Mutation denotes L234A p.L234A
851 45181-45186 Mutation denotes L235A p.L235A
852 43823-43828 Mutation denotes S228P rs1469294455
853 45272-45277 Mutation denotes E233P p.E233P
854 45279-45284 Mutation denotes F234V rs755807976
855 45083-45088 Mutation denotes L235A p.L235A
856 45293-45298 Mutation denotes D265A p.D265A
857 45300-45305 Mutation denotes L309V p.L309V
858 45307-45312 Mutation denotes R409K p.R409K
859 43149-43154 Mutation denotes S228P rs1469294455
861 45792-45800 Disease denotes COVID-19 MESH:C000657245
863 46042-46048 Chemical denotes glycan MESH:D011134
879 46227-46235 Gene denotes FcγRIIIa Gene:2214
880 46240-46248 Gene denotes FcγRIIIb Gene:2215
881 46321-46328 Gene denotes FcγRIIb Gene:2213
882 46426-46434 Gene denotes FcγRIIIa Gene:2214
883 46531-46535 Gene denotes HER2 Gene:2064
884 46542-46546 Gene denotes EGFR Gene:1956
885 46688-46695 Gene denotes FcγRIII Gene:2214
886 46799-46806 Gene denotes FcγRIII Gene:2214
887 46943-46951 Gene denotes FcγRIIIa Gene:2214
888 46997-47004 Gene denotes FcγRIIa Gene:2212
889 46927-46935 Gene denotes FcγRIIIb Gene:2215
890 46069-46084 Chemical denotes N‐linked glycan
891 46137-46143 Chemical denotes fucose MESH:D005643
892 46173-46179 Chemical denotes fucose MESH:D005643
893 46497-46502 Disease denotes tumor MESH:D009369
900 47266-47274 Species denotes patients Tax:9606
901 47147-47159 Chemical denotes obinutuzumab MESH:C543332
902 47296-47302 Chemical denotes fucose MESH:D005643
903 47314-47323 Chemical denotes rituximab MESH:D000069283
904 47397-47403 Chemical denotes glycan MESH:D011134
905 47237-47265 Disease denotes chronic lymphocytic leukemia MESH:D015451
914 47847-47855 Gene denotes FcγRIIIa Gene:2214
915 47891-47899 Gene denotes FcγRIIIa Gene:2214
916 47937-47944 Gene denotes FcγRIII Gene:14131
917 48017-48022 Species denotes mouse Tax:10090
918 47728-47756 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 47990-48013 Disease denotes reduced lymphoma growth MESH:D006130
920 47802-47807 Mutation denotes S329D p.S329D
921 47812-47817 Mutation denotes I332E p.I332E
941 48112-48116 Gene denotes HER2 Gene:2064
942 48150-48154 Gene denotes HER2 Gene:2064
943 48271-48279 Gene denotes FcγRIIIa Gene:2214
944 48357-48364 Gene denotes FcγRIIb Gene:2213
945 48518-48522 Gene denotes HER2 Gene:13866
946 48589-48593 Gene denotes HER2 Gene:13866
947 48399-48403 Gene denotes FcγR Gene:2213
948 48620-48624 Species denotes mice Tax:10090
949 48031-48043 Chemical denotes Margetuximab MESH:C000617981
950 48121-48132 Chemical denotes trastuzumab MESH:D000068878
951 48459-48470 Chemical denotes trastuzumab MESH:D000068878
952 48476-48488 Chemical denotes margetuximab MESH:C000617981
953 48166-48173 Disease denotes cancers MESH:D009369
954 48605-48610 Disease denotes tumor MESH:D009369
955 48213-48218 Mutation denotes L235V p.L235V
956 48220-48225 Mutation denotes F243L p.F243L
957 48227-48232 Mutation denotes R292P p.R292P
958 48234-48239 Mutation denotes Y300L p.Y300L
959 48244-48249 Mutation denotes P396L p.P396L
967 48933-48941 Gene denotes FcγRIIIa Gene:2214
968 48640-48652 Chemical denotes ocaratuzumab MESH:C550337
969 48744-48751 Disease denotes cancers MESH:D009369
970 48763-48783 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 48788-48816 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 48838-48843 Mutation denotes P247I p.P247I
973 48848-48853 Mutation denotes A339Q p.A339Q
976 49060-49068 Gene denotes FcγRIIIa Gene:2214
977 49040-49046 Chemical denotes glycan MESH:D011134
979 49186-49190 Gene denotes FcγR Gene:2213
984 49889-49893 Gene denotes FcγR Gene:2213
985 49575-49579 Gene denotes FcγR Gene:2213
986 49431-49435 Gene denotes FcγR Gene:2213
987 49257-49261 Gene denotes FcγR Gene:2213
1003 50422-50428 Gene denotes CTLA‐4 Gene:1493
1004 50436-50441 Gene denotes PD‐L1 Gene:29126
1005 50442-50446 Gene denotes PD‐1 Gene:5133
1006 50656-50660 Gene denotes PD‐1 Gene:5133
1007 50888-50894 Gene denotes CTLA‐4 Gene:1493
1008 50222-50226 Gene denotes FcγR Gene:2213
1009 50085-50089 Gene denotes FcγR Gene:2213
1010 49976-49980 Gene denotes FcγR Gene:2213
1011 50603-50616 Chemical denotes Pembrolizumab MESH:C582435
1012 50618-50627 Chemical denotes nivolumab MESH:D000077594
1013 50632-50642 Chemical denotes cemiplimab MESH:C000627974
1014 50864-50876 Chemical denotes tremelimumab MESH:C520704
1015 50544-50549 Disease denotes tumor MESH:D009369
1016 50691-50697 Disease denotes cancer MESH:D009369
1017 50790-50795 Mutation denotes S228P rs1469294455
1022 51112-51117 Gene denotes FcγRI Gene:2214
1023 51321-51326 Gene denotes FcγRI Gene:2214
1024 51404-51411 Gene denotes FcγRIIb Gene:2213
1025 51298-51302 Gene denotes PD‐1 Gene:5133
1031 51957-51962 Gene denotes PD‐L1 Gene:29126
1032 52027-52031 Gene denotes FcγR Gene:2213
1033 51855-51859 Gene denotes FcγR Gene:2213
1034 51811-51826 Chemical denotes N‐linked glycan
1035 51930-51942 Chemical denotes Atezolizumab MESH:C000594389
1044 52408-52412 Gene denotes FcγR Gene:2213
1045 52164-52168 Gene denotes FcγR Gene:2213
1046 52116-52120 Gene denotes FcγR Gene:2213
1047 52236-52243 Chemical denotes leucine MESH:D007930
1048 52311-52318 Chemical denotes alanine MESH:D000409
1049 52466-52476 Chemical denotes teplizumab MESH:C502540
1050 52481-52491 Chemical denotes spesolimab
1051 52320-52331 Mutation denotes L234A L235A p.L234,235A,A
1063 52770-52775 Gene denotes PD‐L1 Gene:29126
1064 53087-53090 Gene denotes C1q Gene:712
1065 53034-53038 Gene denotes FcγR Gene:2213
1066 52638-52642 Gene denotes FcγR Gene:2213
1067 52997-53001 Gene denotes FcγR Gene:2213
1068 52577-52581 Gene denotes FcγR Gene:2213
1069 52753-52763 Chemical denotes durvalumab MESH:C000613593
1070 52781-52792 Chemical denotes anifrolumab MESH:C582345
1071 52879-52884 Mutation denotes L234F p.L234F
1072 52918-52923 Mutation denotes L235E p.L235E
1073 52947-52952 Mutation denotes P331S p.P331S
1088 53182-53187 Gene denotes FcγRI Gene:2214
1089 53192-53199 Gene denotes FcγRIIb Gene:2213
1090 53455-53459 Gene denotes FcγR Gene:2213
1091 53254-53258 Gene denotes FcγR Gene:2213
1092 53757-53761 Gene denotes FcγR Gene:2213
1093 53579-53589 Chemical denotes disulfides MESH:D004220
1094 53215-53241 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 53370-53375 Mutation denotes E233P p.E233P
1096 53377-53382 Mutation denotes F234V rs755807976
1097 53384-53389 Mutation denotes L235A p.L235A
1098 53417-53422 Mutation denotes D265A p.D265A
1099 53520-53525 Mutation denotes S228P rs1469294455
1100 53538-53543 Mutation denotes L309V p.L309V
1101 53548-53553 Mutation denotes R409K p.R409K
1104 53981-53985 Gene denotes FcγR Gene:2213
1105 53850-53854 Gene denotes FcγR Gene:2213
1107 54073-54080 Gene denotes FcγRIIb Gene:2213
1110 54136-54143 Gene denotes FcγRIIb Gene:2213
1111 54164-54168 Gene denotes FcγR Gene:2213
1113 54312-54320 Chemical denotes tyrosine MESH:D014443
1122 54420-54427 Gene denotes FcγRIIb Gene:2213
1123 54622-54625 Gene denotes BCR Gene:613
1124 55011-55018 Gene denotes FcγRIIb Gene:2213
1125 55112-55119 Gene denotes FcγRIIb Gene:2213
1126 54775-54779 Gene denotes FcγR Gene:2213
1127 55127-55129 Chemical denotes Fc
1128 54664-54692 Disease denotes systemic lupus erythematosus MESH:D008180
1129 54742-54751 Disease denotes allergies MESH:D004342
1136 55382-55385 Gene denotes BCR Gene:613
1137 55508-55515 Gene denotes FcγRIIb Gene:2213
1138 55592-55595 Gene denotes BCR Gene:613
1139 55322-55340 Disease denotes autoimmune disease MESH:D001327
1140 55431-55436 Mutation denotes S267E p.S267E
1141 55441-55446 Mutation denotes L328F p.L328F
1147 56262-56269 Gene denotes FcγRIIb Gene:2213
1148 56214-56217 Gene denotes BCR Gene:613
1149 55659-55677 Disease denotes IgE mAb omalizumab MESH:D007589
1150 55723-55741 Disease denotes allergic disorders MESH:D004342
1151 56484-56491 Disease denotes allergy MESH:D004342
1162 56694-56701 Gene denotes FcγRIIb Gene:2213
1163 57237-57244 Gene denotes FcγRIIb Gene:2213
1164 56974-56981 Gene denotes FcγRIIa Gene:2212
1165 57009-57017 Species denotes patients Tax:9606
1166 56647-56655 Chemical denotes arginine MESH:D001120
1167 57173-57178 Mutation denotes P238D p.P238D
1168 57180-57185 Mutation denotes E233D p.E233D
1169 57187-57192 Mutation denotes G237D p.G237D
1170 57201-57206 Mutation denotes P271G p.P271G
1171 57211-57216 Mutation denotes A330R p.A330R
1176 57369-57376 Gene denotes FcγRIIb Gene:2213
1177 57510-57517 Gene denotes FcγRIIb Gene:2213
1178 57968-57975 Gene denotes FcγRIIb Gene:2213
1179 57909-57917 Species denotes patients Tax:9606
1181 58057-58061 Gene denotes FcγR Gene:2213
1188 58324-58328 Gene denotes OX40 Gene:7293
1189 58401-58404 Gene denotes DR4 Gene:3126
1190 58406-58409 Gene denotes DR5 Gene:8795
1191 58317-58322 Gene denotes 4‐1BB Gene:3604
1192 58363-58368 Disease denotes death MESH:D003643
1193 58382-58388 Disease denotes cancer MESH:D009369
1197 58513-58520 Gene denotes FcγRIIb Gene:2213
1198 58645-58652 Gene denotes FcγRIIb Gene:2213
1199 58432-58436 Gene denotes FcγR Gene:2213
1206 59005-59012 Gene denotes FcγRIIb Gene:2213
1207 59145-59148 Gene denotes DR5 Gene:8795
1208 59344-59351 Gene denotes FcγRIIb Gene:2213
1209 59409-59413 Gene denotes OX40 Gene:7293
1210 59196-59201 Disease denotes death MESH:D003643
1211 59206-59228 Disease denotes decreased tumor growth MESH:D006130
1215 59499-59506 Gene denotes FcγRIIb Gene:2213
1216 59583-59588 Gene denotes CD137 Gene:3604
1217 59610-59614 Gene denotes OX40 Gene:7293
1220 59942-59946 Gene denotes FcγR Gene:2213
1221 60070-60076 Chemical denotes glycan MESH:D011134
1233 60872-60876 Gene denotes FcγR Gene:2213
1234 61597-61601 Gene denotes Her2 Gene:2064
1235 61131-61178 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
1236 61180-61190 Species denotes SARS‐CoV‐2 Tax:2697049
1237 61561-61571 Chemical denotes pertuzumab MESH:C485206
1238 61576-61587 Chemical denotes trastuzumab MESH:D000068878
1239 60978-60996 Disease denotes infectious disease MESH:D003141
1240 61104-61122 Disease denotes infectious disease MESH:D003141
1241 61192-61201 Disease denotes infection MESH:D007239
1242 61457-61475 Disease denotes infectious disease MESH:D003141
1243 61509-61523 Disease denotes adenocarcinoma MESH:D000230
1246 61770-61774 Gene denotes FcγR Gene:2213
1247 61954-61958 Gene denotes FcγR Gene:2213

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 15-28 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T2 246-260 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T3 261-266 Body_part denotes (Ig)G http://purl.org/sig/ont/fma/fma62872
T4 262-264 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T5 687-692 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T6 702-710 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T7 845-854 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T8 1603-1610 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T9 1879-1882 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T10 2019-2033 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T11 2034-2039 Body_part denotes (Ig)G http://purl.org/sig/ont/fma/fma62872
T12 2035-2037 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T13 2447-2455 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T14 3289-3298 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T15 3376-3390 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T16 3391-3396 Body_part denotes (Ig)E http://purl.org/sig/ont/fma/fma62875
T17 3392-3394 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T18 3438-3442 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T19 3601-3604 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T20 3712-3718 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T21 3903-3915 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T22 3903-3907 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T23 4027-4030 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T24 4752-4756 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T25 4760-4768 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T26 4779-4783 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T27 4827-4835 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T28 4846-4850 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T29 5042-5050 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T30 5243-5251 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T31 5336-5341 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T32 5351-5375 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T33 5370-5375 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T34 5741-5745 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T35 5818-5837 Body_part denotes Natural killer cell http://purl.org/sig/ont/fma/fma63147
T36 5833-5837 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T37 5838-5846 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T38 5857-5861 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T39 5902-5910 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T40 5921-5925 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T41 6209-6233 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T42 6228-6233 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T43 6260-6264 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T44 6307-6315 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T45 6364-6368 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T46 6441-6446 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T47 6455-6466 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T48 6471-6480 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T49 6497-6500 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T50 6649-6657 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T51 6803-6807 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T52 7069-7073 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T53 7118-7126 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T54 7146-7150 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T55 7195-7199 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T56 7277-7282 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T57 7309-7318 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T58 7369-7377 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T59 7391-7399 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T60 7410-7414 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T61 7438-7440 Body_part denotes Ag http://purl.org/sig/ont/fma/fma61898
T62 7458-7462 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T63 7473-7475 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T64 7477-7491 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T65 7684-7692 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T66 7703-7707 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T67 7756-7760 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T68 7771-7779 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T69 7790-7794 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T70 7857-7861 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T71 7996-8000 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T72 8025-8029 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T73 8044-8052 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T74 8083-8087 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T75 8421-8425 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T76 8481-8485 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T77 8524-8528 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T78 8560-8568 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T79 9009-9013 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T80 9074-9077 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T81 9103-9112 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T82 9190-9193 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T83 9234-9244 Body_part denotes antibody’s http://purl.org/sig/ont/fma/fma62871
T84 9268-9273 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T85 9511-9520 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T86 9961-9965 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T87 10322-10326 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T88 10366-10370 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T89 10674-10683 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T90 11283-11286 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T91 11300-11304 Body_part denotes Cell http://purl.org/sig/ont/fma/fma68646
T92 11376-11385 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T93 11387-11398 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T94 11400-11411 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T95 11413-11427 Body_part denotes dendritic cell http://purl.org/sig/ont/fma/fma273565
T96 11423-11427 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T97 11444-11454 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T98 11449-11454 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T99 11550-11560 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T100 11565-11574 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T101 11588-11601 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T102 11636-11644 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T103 11639-11644 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T104 11673-11681 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T105 11676-11681 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T106 11683-11694 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T107 11725-11734 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T108 11744-11759 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T109 11754-11759 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T110 11761-11772 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T111 11866-11877 Body_part denotes Neutrophils http://purl.org/sig/ont/fma/fma62860
T112 11910-11923 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T113 11930-11939 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T114 11962-11971 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T115 11973-11984 Body_part denotes eosinophils http://purl.org/sig/ont/fma/fma62861
T116 12011-12026 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T117 12021-12026 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T118 12028-12036 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T119 12031-12036 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T120 12071-12075 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T121 12112-12118 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T122 12126-12134 Body_part denotes placenta http://purl.org/sig/ont/fma/fma63934
T123 12136-12161 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T124 12157-12161 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T125 12162-12164 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T126 12166-12180 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T127 12182-12189 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T128 12185-12189 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T129 12191-12210 Body_part denotes natural killer cell http://purl.org/sig/ont/fma/fma63147
T130 12206-12210 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T131 12602-12605 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T132 12629-12632 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T133 13351-13354 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T134 13373-13375 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T135 13377-13391 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T136 13744-13761 Body_part denotes hemopoietic cells http://purl.org/sig/ont/fma/fma83598
T137 13756-13761 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T138 13766-13772 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T139 13799-13808 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T140 14067-14071 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T141 14109-14119 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T142 14125-14134 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T143 14339-14344 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T144 14374-14382 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T145 14487-14495 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T146 14550-14561 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T147 14649-14658 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T148 14750-14759 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T149 14784-14793 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T150 14795-14806 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T151 14808-14819 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T152 14821-14837 Body_part denotes microglial cells http://purl.org/sig/ont/fma/fma54539
T153 14832-14837 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T154 14845-14850 Body_part denotes brain http://purl.org/sig/ont/fma/fma50801
T155 14852-14867 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T156 14862-14867 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T157 14872-14882 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T158 14877-14882 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T159 15284-15294 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T160 15318-15327 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T161 15596-15607 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T162 15681-15691 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T163 15881-15891 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T164 15914-15916 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T165 16007-16017 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740
T166 16155-16160 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T167 16181-16185 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T168 16319-16330 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T169 16669-16673 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T170 16736-16744 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T171 16739-16744 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T172 16787-16798 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T173 16859-16870 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T174 17002-17015 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T175 17002-17006 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T176 17104-17115 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T177 17222-17233 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T178 17366-17370 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T179 17548-17552 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T180 17643-17648 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T181 17716-17722 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T182 17781-17794 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T183 17809-17819 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T184 17820-17831 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T185 17900-17904 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T186 17986-17995 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T187 18000-18011 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T188 18045-18055 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T189 18050-18055 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T190 18057-18072 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T191 18067-18072 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T192 18082-18091 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T193 18092-18103 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T194 18124-18135 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T195 18315-18320 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T196 18348-18354 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T197 18397-18402 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T198 18493-18505 Body_part denotes T‐lymphocyte http://purl.org/sig/ont/fma/fma62870
T199 18542-18547 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T200 18574-18579 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T201 18695-18703 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T202 18774-18779 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T203 18869-18887 Body_part denotes hematopoietic cell http://purl.org/sig/ont/fma/fma83598
T204 18883-18887 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T205 18997-19002 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T206 19197-19222 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T207 19218-19222 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T208 19238-19244 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T209 19249-19254 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T210 19255-19266 Body_part denotes endothelium http://purl.org/sig/ont/fma/fma63916
T211 19295-19300 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T212 19301-19311 Body_part denotes sinusoidal http://purl.org/sig/ont/fma/fma63131
T213 19312-19329 Body_part denotes endothelial cells http://purl.org/sig/ont/fma/fma66772
T214 19324-19329 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T215 19518-19523 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T216 19616-19622 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T217 20219-20223 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T218 20247-20250 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T219 20270-20273 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T220 20543-20556 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T221 20543-20547 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T222 20577-20585 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T223 20750-20754 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T224 20910-20918 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T225 20945-20956 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T226 21041-21049 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T227 21134-21142 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T228 21160-21168 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T229 21218-21223 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264
T230 21227-21234 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T231 21235-21243 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T232 21297-21301 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T233 21673-21676 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T234 21731-21736 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T235 21901-21904 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T236 22584-22589 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T237 22618-22636 Body_part denotes actin cytoskeleton http://purl.org/sig/ont/fma/fma84684
T238 22659-22676 Body_part denotes glycosaminoglycan http://purl.org/sig/ont/fma/fma63011
T239 22677-22687 Body_part denotes glycocalyx http://purl.org/sig/ont/fma/fma66838
T240 22732-22745 Body_part denotes glycoproteins http://purl.org/sig/ont/fma/fma62925
T241 22918-22922 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T242 23171-23175 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T243 23559-23567 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T244 23694-23702 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T245 23851-23864 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T246 23851-23855 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T247 24223-24228 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T248 24505-24518 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T249 24505-24509 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T250 25140-25148 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T251 25143-25148 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T252 25185-25196 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T253 25237-25244 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T254 25240-25244 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T255 25688-25692 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T256 25813-25817 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T257 26072-26076 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T258 26249-26253 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T259 26265-26275 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T260 26363-26366 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T261 26392-26395 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T262 26563-26567 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T263 26606-26611 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T264 26692-26696 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T265 26877-26881 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T266 27400-27406 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T267 27646-27649 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T268 27751-27760 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T269 27764-27767 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T270 27794-27802 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T271 27856-27864 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T272 28728-28736 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T273 28831-28855 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T274 28850-28855 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T275 28888-28903 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T276 28898-28903 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T277 28917-28930 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T278 28957-28989 Body_part denotes major histocompatibility complex http://purl.org/sig/ont/fma/fma84079
T279 29037-29043 Body_part denotes stroma http://purl.org/sig/ont/fma/fma81494
T280 29052-29078 Body_part denotes follicular dendritic cells http://purl.org/sig/ont/fma/fma83037
T281 29073-29078 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T282 29090-29098 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T283 29129-29137 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T284 29155-29167 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T285 29155-29159 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T286 29208-29213 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T287 29344-29355 Body_part denotes lymphocytes http://purl.org/sig/ont/fma/fma62863
T288 29456-29460 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T289 29481-29486 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T290 29503-29508 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T291 29610-29613 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T292 29652-29664 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T293 29652-29656 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T294 29677-29681 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T295 29796-29800 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T296 29903-29907 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T297 30009-30013 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T298 30071-30075 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T299 30196-30200 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T300 30248-30253 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T301 30271-30280 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T302 30298-30302 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T303 30317-30325 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T304 30386-30391 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T305 30691-30695 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T306 30808-30812 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T307 30924-30929 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T308 30969-30972 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T309 31114-31117 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T310 31150-31153 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T311 31300-31312 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T312 31300-31304 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T313 31611-31614 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T314 31724-31727 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T315 31854-31857 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T316 31955-31958 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T317 31969-31972 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T318 32095-32100 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T319 32214-32217 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T320 32283-32293 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T321 33004-33017 Body_part denotes phenylalanine http://purl.org/sig/ont/fma/fma82754
T322 33018-33024 Body_part denotes valine http://purl.org/sig/ont/fma/fma82766
T323 33058-33061 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T324 33534-33543 Body_part denotes histidine http://purl.org/sig/ont/fma/fma82755
T325 33567-33570 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T326 33764-33772 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T327 33797-33800 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T328 33862-33865 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T329 34084-34087 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T330 34127-34130 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T331 34338-34341 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T332 34907-34910 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T333 35107-35110 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T334 35188-35194 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T335 35212-35227 Body_part denotes oligosaccharide http://purl.org/sig/ont/fma/fma82742
T336 36327-36338 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T337 36387-36395 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T338 36401-36404 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T339 37745-37752 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T340 37821-37829 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T341 38074-38077 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T342 38130-38135 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T343 38576-38579 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T344 38740-38743 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T345 38802-38805 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T346 39217-39225 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T347 39439-39447 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T348 39868-39871 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T349 39902-39905 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T350 40424-40428 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T351 40449-40453 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T352 40750-40758 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T353 41065-41070 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T354 41173-41183 Body_part denotes macrophage http://purl.org/sig/ont/fma/fma63261
T355 41218-41222 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T356 41400-41404 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T357 41436-41440 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T358 41599-41603 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T359 42237-42242 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T360 42823-42833 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T361 43001-43004 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T362 43005-43013 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T363 43463-43476 Body_part denotes Interleukin 5 http://purl.org/sig/ont/fma/fma264830
T364 43463-43474 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T365 43564-43567 Body_part denotes ear http://purl.org/sig/ont/fma/fma52780
T366 43568-43572 Body_part denotes nose http://purl.org/sig/ont/fma/fma46472
T367 43573-43579 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T368 43806-43813 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T369 43964-43986 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T370 44020-44031 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T371 44274-44283 Body_part denotes chemokine http://purl.org/sig/ont/fma/fma241981
T372 44369-44391 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T373 45623-45645 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T374 45667-45669 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T375 45671-45685 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T376 46137-46143 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T377 46147-46157 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T378 46173-46179 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T379 46851-46858 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T380 46854-46858 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T381 46886-46896 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T382 46972-46982 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T383 47245-47256 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T384 47296-47302 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T385 47507-47518 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 47537-47548 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T387 47581-47584 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T388 47646-47654 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T389 47736-47747 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T390 48200-48211 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T391 48524-48529 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T392 48796-48807 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T393 49212-49215 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T394 49336-49339 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T395 49712-49715 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T396 50014-50023 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T397 50170-50173 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T398 50312-50321 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T399 50593-50601 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T400 50895-50903 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T401 50925-50933 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T402 50976-50981 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T403 51183-51193 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T404 52089-52099 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T405 52236-52243 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T406 52311-52318 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749
T407 52548-52558 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T408 52724-52735 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T409 53220-53228 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T410 53650-53652 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T411 53929-53938 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T412 54312-54320 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T413 54551-54559 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T414 54639-54644 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T415 54707-54716 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T416 54721-54730 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T417 54726-54730 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T418 54803-54813 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T419 54817-54825 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T420 54835-54841 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T421 54978-54990 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T422 54978-54982 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T423 55641-55646 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T424 55659-55662 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T425 55946-55949 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T426 55998-56006 Body_part denotes basophil http://purl.org/sig/ont/fma/fma62862
T427 56011-56020 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T428 56016-56020 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T429 56135-56138 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T430 56160-56164 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T431 56165-56168 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T432 56210-56213 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T433 56227-56239 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T434 56227-56231 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T435 56351-56354 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T436 56369-56372 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T437 56376-56381 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T438 56423-56426 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T439 56514-56517 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T440 56647-56655 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T441 56674-56677 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T442 57545-57555 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T443 57569-57577 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T444 57648-57651 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T445 57655-57664 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T446 57881-57884 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T447 57940-57943 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T448 58116-58121 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T449 58269-58293 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T450 58288-58293 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T451 58299-58304 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T452 58389-58394 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T453 59589-59597 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T454 59915-59923 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T455 60055-60058 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T456 60410-60418 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T457 60694-60702 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T458 61869-61882 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T459 61968-61976 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 15-28 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T2 9268-9273 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T3 12126-12134 Body_part denotes placenta http://purl.obolibrary.org/obo/UBERON_0001987
T4 13766-13772 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T5 14845-14850 Body_part denotes brain http://purl.obolibrary.org/obo/UBERON_0000955
T6 15608-15612 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T7 16331-16335 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T8 17716-17722 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T9 18348-18354 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T10 19249-19254 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T11 19255-19266 Body_part denotes endothelium http://purl.obolibrary.org/obo/UBERON_0001986
T12 19295-19300 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T13 19616-19622 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T14 20957-20961 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T15 23546-23550 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T16 23681-23685 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T17 27400-27406 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T18 29037-29043 Body_part denotes stroma http://purl.obolibrary.org/obo/UBERON_0003891
T19 36401-36404 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T20 37710-37715 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T21 38130-38135 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T22 43564-43567 Body_part denotes ear http://purl.obolibrary.org/obo/UBERON_0001690
T23 43568-43572 Body_part denotes nose http://purl.obolibrary.org/obo/UBERON_0000004
T24 43573-43579 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T25 43964-43986 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T26 43972-43986 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T27 44369-44391 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T28 44377-44391 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T29 45623-45645 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T30 45631-45645 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T31 54835-54841 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T32 61869-61882 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 121-123 Disease denotes AM http://purl.obolibrary.org/obo/MONDO_0020320
T2 680-686 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T3 1136-1157 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T4 1170-1180 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T5 1189-1236 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T6 1189-1222 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T7 1238-1242 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T8 2796-2817 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T9 3302-3320 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T10 3354-3372 Disease denotes virus in infection http://purl.obolibrary.org/obo/MONDO_0005108
T11 3363-3372 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T12 3400-3407 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T13 4282-4288 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T14 4609-4612 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T15 4711-4714 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T16 4807-4811 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T17 4890-4894 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T18 5541-5544 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T19 7385-7389 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T20 8756-8764 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T21 10403-10406 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T22 12348-12356 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T23 13498-13506 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T24 15115-15118 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T25 15413-15437 Disease denotes immune thrombocytopenias http://purl.obolibrary.org/obo/MONDO_0002048|http://purl.obolibrary.org/obo/MONDO_0008558
T27 15756-15784 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T28 15765-15784 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T29 15899-15910 Disease denotes anaphylaxis http://purl.obolibrary.org/obo/MONDO_0100053
T30 19079-19082 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T31 22414-22418 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T32 23328-23332 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T33 23337-23341 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T34 23345-23349 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T35 23606-23610 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T36 23771-23775 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T37 23886-23890 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T38 24035-24039 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T39 24044-24048 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T40 24167-24171 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T41 24355-24358 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T42 24964-24968 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T43 24986-24990 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T44 24995-24999 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T45 25245-25249 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T46 25294-25297 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T47 25336-25342 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T48 25365-25369 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T49 25498-25501 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T50 26521-26524 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T51 27669-27672 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T52 28183-28188 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T53 29559-29562 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T54 30842-30845 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T55 32181-32193 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T56 38402-38405 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T57 38783-38786 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T58 39202-39206 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T59 39208-39212 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T60 39573-39576 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T61 40225-40229 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T62 40296-40302 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T63 40442-40448 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T64 40589-40593 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T65 40601-40606 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T66 41154-41159 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T67 41211-41217 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T68 42206-42210 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T69 42231-42236 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T70 42649-42655 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T71 43564-43589 Disease denotes ear nose throat disorders http://purl.obolibrary.org/obo/MONDO_0024623
T72 43852-43871 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T73 44097-44122 Disease denotes musculoskeletal disorders http://purl.obolibrary.org/obo/MONDO_0002081
T74 44583-44601 Disease denotes Infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T75 44891-44900 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T76 45003-45026 Disease denotes Hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T77 45209-45228 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T78 45792-45800 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T79 46497-46502 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T80 46868-46872 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T81 47237-47265 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T82 47245-47265 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T83 47257-47265 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T84 47728-47756 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T85 47736-47756 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T86 47748-47756 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T87 47954-47958 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T88 47998-48006 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T89 48050-48054 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T90 48505-48509 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T91 48605-48610 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T92 48763-48783 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0011508|http://purl.obolibrary.org/obo/MONDO_0018908
T94 48767-48783 Disease denotes Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0004952
T95 48775-48783 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T96 48788-48816 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T97 48796-48816 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T98 48808-48816 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T99 48971-48975 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T100 49299-49302 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T101 50544-50549 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T102 50691-50697 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T103 50953-50957 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T104 54664-54692 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T105 54673-54692 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T106 55182-55185 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T107 55322-55340 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T108 55723-55731 Disease denotes allergic http://purl.obolibrary.org/obo/MONDO_0004980
T109 56484-56491 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T110 57593-57596 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T111 58382-58388 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T112 59216-59221 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T113 60978-60996 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T114 61104-61122 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T115 61131-61178 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T116 61131-61164 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T117 61180-61184 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T118 61192-61201 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T119 61457-61475 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T120 61509-61523 Disease denotes adenocarcinoma http://purl.obolibrary.org/obo/MONDO_0004970

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 15-28 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T2 33-35 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T3 66-67 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 93-95 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T5 164-169 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T6 195-197 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T7 283-291 http://purl.obolibrary.org/obo/CLO_0001658 denotes activate
T8 305-306 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 583-585 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T10 687-692 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T11 897-900 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T12 915-916 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T13 940-942 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T14 1323-1324 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T15 1385-1387 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T16 1447-1449 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T17 1450-1452 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T18 1585-1592 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T19 1630-1632 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T20 1719-1729 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T21 1730-1732 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T22 1733-1735 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T23 1754-1756 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T24 1800-1802 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T25 1870-1872 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T26 2001-2003 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T27 2040-2048 http://purl.obolibrary.org/obo/CLO_0001658 denotes activate
T28 2062-2063 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T29 2347-2357 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T30 2372-2374 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T31 2717-2718 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T32 3007-3010 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T33 3354-3359 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T34 3438-3442 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T35 3443-3453 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T36 3712-3718 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T37 3742-3752 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T38 3878-3880 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T39 3903-3907 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T40 3934-3936 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T41 4009-4010 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T42 4046-4056 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T43 4098-4108 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T44 4114-4116 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T45 4117-4119 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T46 4259-4261 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T47 4359-4369 http://purl.obolibrary.org/obo/CLO_0001658 denotes activities
T48 4468-4470 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T49 4471-4473 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T50 4544-4546 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T51 4686-4688 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T52 4743-4744 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T53 4752-4756 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T54 4779-4783 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T55 4846-4850 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T56 4974-4976 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T57 5051-5061 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T58 5094-5103 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T59 5143-5145 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T60 5157-5158 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T61 5255-5260 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T62 5336-5341 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T63 5370-5375 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T64 5467-5469 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T65 5470-5472 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T66 5487-5489 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T67 5613-5614 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T68 5682-5683 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T69 5718-5719 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T70 5720-5726 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T71 5741-5745 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T72 5789-5791 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T73 5815-5816 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T74 5818-5837 http://purl.obolibrary.org/obo/CL_0000623 denotes Natural killer cell
T75 5857-5861 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T76 5888-5890 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T77 5899-5900 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T78 5921-5925 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T79 6012-6022 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T80 6027-6037 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T81 6038-6040 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T82 6051-6053 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T83 6064-6066 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T84 6228-6233 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T85 6260-6264 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T86 6265-6275 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T87 6279-6281 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T88 6316-6326 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T89 6349-6358 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T90 6362-6368 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T91 6400-6410 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T92 6411-6413 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T93 6441-6446 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T94 6501-6503 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T95 6539-6549 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T96 6580-6582 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T97 6626-6628 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T98 6761-6770 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T99 6803-6807 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T100 6974-6976 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T101 6977-6979 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T102 6985-6986 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T103 7021-7023 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T104 7033-7039 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T105 7069-7073 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T106 7134-7136 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T107 7146-7150 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T108 7161-7162 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T109 7163-7169 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T110 7195-7199 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T111 7240-7250 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T112 7277-7282 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T113 7323-7330 http://www.ebi.ac.uk/efo/EFO_0000876 denotes extreme
T114 7410-7414 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T115 7456-7462 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T116 7522-7524 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T117 7591-7593 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T118 7672-7682 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activation
T119 7703-7707 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T120 7756-7760 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T121 7762-7764 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T122 7790-7794 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T123 7857-7861 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T124 7863-7865 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T125 7873-7875 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T126 7882-7884 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T127 7950-7952 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T128 7959-7961 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T129 7966-7968 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T130 7994-8000 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T131 8025-8029 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T132 8030-8040 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T133 8083-8087 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T134 8088-8098 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T135 8113-8123 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T136 8139-8141 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T137 8145-8147 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T138 8152-8154 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T139 8174-8176 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T140 8220-8230 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T141 8242-8244 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T142 8312-8314 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T143 8320-8321 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T144 8421-8425 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T145 8461-8463 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T146 8481-8485 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T147 8487-8489 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T148 8501-8503 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T149 8510-8512 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T150 8522-8528 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T151 8569-8579 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T152 8587-8588 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T153 8590-8600 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activating
T154 8601-8603 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T155 8994-9013 http://purl.obolibrary.org/obo/CLO_0009985 denotes focuses on the cell
T156 9097-9102 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T157 9113-9115 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T158 9194-9196 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T159 9327-9337 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T160 9443-9445 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T161 9471-9476 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes Human
T162 9477-9479 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T163 9505-9510 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T164 9589-9599 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T165 9616-9618 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T166 9623-9625 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T167 9632-9634 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T168 9641-9643 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T169 9654-9656 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T170 9793-9795 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T171 9875-9877 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T172 9878-9880 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T173 9961-9965 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T174 10067-10069 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T175 10070-10072 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T176 10084-10085 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T177 10298-10300 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T178 10301-10303 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T179 10322-10332 http://purl.obolibrary.org/obo/CL_0000000 denotes cell types
T180 10366-10370 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T181 10455-10457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T182 10668-10673 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T183 10684-10686 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T184 10733-10734 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T185 10788-10790 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T186 10853-10855 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T187 10940-10945 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T188 10946-10948 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T189 10978-10986 http://purl.obolibrary.org/obo/NCBITaxon_9443 denotes primates
T190 10988-10994 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T191 11158-11167 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humanized
T192 11168-11170 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T193 11257-11259 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T194 11300-11304 http://purl.obolibrary.org/obo/GO_0005623 denotes Cell
T195 11318-11320 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T196 11376-11385 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T197 11413-11427 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T198 11449-11454 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T199 11455-11457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T200 11513-11515 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T201 11588-11589 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T202 11602-11604 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T203 11610-11611 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T204 11636-11644 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T205 11645-11647 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T206 11673-11681 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T207 11725-11734 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T208 11736-11759 http://purl.obolibrary.org/obo/CL_0000782 denotes myeloid dendritic cells
T209 11839-11841 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T210 11878-11880 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T211 11910-11911 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T212 11930-11939 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T213 12003-12026 http://purl.obolibrary.org/obo/CL_0000782 denotes myeloid dendritic cells
T214 12028-12036 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T215 12062-12064 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T216 12071-12075 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T217 12098-12104 http://purl.obolibrary.org/obo/UBERON_0001005 denotes Airway
T218 12112-12118 http://purl.obolibrary.org/obo/UBERON_0001630 denotes muscle
T219 12112-12118 http://purl.obolibrary.org/obo/UBERON_0005090 denotes muscle
T220 12112-12118 http://www.ebi.ac.uk/efo/EFO_0000801 denotes muscle
T221 12112-12118 http://www.ebi.ac.uk/efo/EFO_0001949 denotes muscle
T222 12126-12134 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
T223 12126-12134 http://www.ebi.ac.uk/efo/EFO_0001407 denotes placenta
T224 12147-12161 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T225 12182-12189 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T226 12191-12210 http://purl.obolibrary.org/obo/CL_0000623 denotes natural killer cell
T227 12212-12213 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T228 12615-12617 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T229 12643-12645 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T230 12708-12710 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T231 12740-12742 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T232 12791-12793 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T233 12865-12867 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T234 12881-12884 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T235 13159-13160 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T236 13217-13219 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T237 13224-13226 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T238 13233-13235 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T239 13242-13245 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T240 13725-13727 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T241 13756-13761 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T242 13793-13798 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T243 13809-13811 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T244 13875-13877 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T245 14027-14029 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T246 14067-14071 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T247 14103-14108 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T248 14157-14159 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T249 14315-14325 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T250 14339-14344 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T251 14411-14413 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T252 14445-14447 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T253 14455-14457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T254 14463-14465 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T255 14487-14495 http://purl.obolibrary.org/obo/CL_0000576 denotes monocyte
T256 14528-14530 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T257 14540-14549 http://purl.obolibrary.org/obo/CLO_0001658 denotes activated
T258 14570-14572 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T259 14577-14579 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T260 14589-14591 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T261 14605-14607 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T262 14659-14661 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T263 14702-14704 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T264 14784-14793 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T265 14821-14837 http://purl.obolibrary.org/obo/CL_0000129 denotes microglial cells
T266 14845-14850 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T267 14845-14850 http://www.ebi.ac.uk/efo/EFO_0000302 denotes brain
T268 14852-14867 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T269 14877-14882 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T270 14903-14905 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T271 14951-14959 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T272 14986-14996 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T273 15009-15014 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T274 15046-15049 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T275 15050-15051 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T276 15170-15172 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T277 15199-15207 http://purl.obolibrary.org/obo/NCBITaxon_9443 denotes primates
T278 15249-15251 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T279 15252-15254 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T280 15439-15440 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T281 15487-15492 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T282 15506-15511 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T283 15608-15612 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T284 15640-15642 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T285 15654-15655 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T286 15675-15680 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T287 15817-15826 http://purl.obolibrary.org/obo/OBI_0100026 denotes organisms
T288 15817-15826 http://purl.obolibrary.org/obo/UBERON_0000468 denotes organisms
T289 15827-15829 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T290 15830-15831 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T291 15863-15864 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T292 15937-15939 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T293 15940-15942 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T294 15954-15964 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T295 15965-15967 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T296 16079-16085 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T297 16153-16160 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T298 16161-16163 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T299 16167-16170 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T300 16181-16185 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T301 16264-16266 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T302 16331-16335 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T303 16351-16361 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T304 16371-16373 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T305 16385-16387 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T306 16415-16425 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T307 16455-16456 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T308 16574-16581 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T309 16632-16634 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T310 16669-16673 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T311 16684-16686 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T312 16697-16699 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T313 16711-16713 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T314 16736-16744 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T315 16762-16772 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T316 16834-16836 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T317 16904-16905 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T318 16932-16934 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T319 16954-16960 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T320 16978-16980 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T321 16981-16983 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T322 17002-17006 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T323 17007-17015 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T324 17020-17021 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T325 17098-17103 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T326 17181-17183 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T327 17202-17204 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T328 17282-17284 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T329 17304-17306 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T330 17337-17339 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T331 17357-17358 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T332 17366-17370 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T333 17408-17417 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T334 17546-17552 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T335 17553-17563 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T336 17603-17613 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T337 17619-17621 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T338 17643-17648 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T339 17684-17686 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T340 17744-17746 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T341 17781-17782 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T342 17804-17808 http://purl.obolibrary.org/obo/CLO_0001564 denotes a 20
T343 17804-17808 http://purl.obolibrary.org/obo/CLO_0050194 denotes a 20
T344 17856-17864 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T345 17898-17904 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T346 17929-17931 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T347 18050-18055 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T348 18057-18072 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T349 18082-18091 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T350 18105-18107 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T351 18149-18151 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T352 18218-18228 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T353 18263-18265 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T354 18307-18312 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T355 18313-18320 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T356 18376-18378 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T357 18395-18402 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T358 18403-18406 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T359 18526-18528 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T360 18540-18547 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T361 18556-18558 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T362 18572-18579 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T363 18599-18601 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T364 18608-18610 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T365 18619-18621 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T366 18737-18739 http://purl.obolibrary.org/obo/CLO_0050509 denotes 27
T367 18774-18779 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T368 18801-18803 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T369 18869-18887 http://purl.obolibrary.org/obo/CL_0000988 denotes hematopoietic cell
T370 18963-18965 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T371 18997-19002 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T372 19167-19169 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T373 19208-19222 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T374 19224-19230 http://purl.obolibrary.org/obo/UBERON_0001005 denotes airway
T375 19238-19244 http://purl.obolibrary.org/obo/UBERON_0001630 denotes muscle
T376 19238-19244 http://purl.obolibrary.org/obo/UBERON_0005090 denotes muscle
T377 19238-19244 http://www.ebi.ac.uk/efo/EFO_0000801 denotes muscle
T378 19238-19244 http://www.ebi.ac.uk/efo/EFO_0001949 denotes muscle
T379 19249-19254 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T380 19249-19254 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T381 19255-19266 http://purl.obolibrary.org/obo/UBERON_0001986 denotes endothelium
T382 19295-19300 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T383 19295-19300 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T384 19312-19329 http://purl.obolibrary.org/obo/CL_0000115 denotes endothelial cells
T385 19388-19390 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T386 19425-19427 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T387 19465-19474 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T388 19518-19523 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T389 19721-19722 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T390 19786-19791 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T391 19837-19839 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T392 19998-20000 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T393 20003-20013 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T394 20028-20037 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T395 20084-20094 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T396 20100-20102 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T397 20114-20123 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T398 20217-20223 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T399 20260-20262 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T400 20283-20285 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T401 20351-20353 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T402 20398-20408 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T403 20409-20415 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T404 20444-20454 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T405 20455-20457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T406 20543-20547 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T407 20548-20556 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T408 20617-20620 http://purl.obolibrary.org/obo/CLO_0009132 denotes Src
T409 20650-20660 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T410 20677-20679 http://purl.obolibrary.org/obo/CLO_0001302 denotes 34
T411 20700-20702 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T412 20703-20705 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T413 20707-20709 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T414 20720-20722 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T415 20750-20754 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T416 20793-20802 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T417 20821-20831 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T418 20837-20839 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T419 20840-20842 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T420 20857-20859 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T421 20957-20961 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T422 21006-21008 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T423 21070-21079 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T424 21080-21096 http://purl.obolibrary.org/obo/GO_0043235 denotes receptor complex
T425 21297-21301 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T426 21302-21312 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T427 21315-21317 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T428 21415-21417 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T429 21477-21479 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T430 21731-21736 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T431 21770-21771 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T432 21819-21821 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T433 21839-21840 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T434 21905-21907 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T435 21945-21947 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T436 21960-21961 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T437 22075-22077 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T438 22153-22155 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T439 22165-22167 http://purl.obolibrary.org/obo/CLO_0001000 denotes 35
T440 22208-22210 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T441 22268-22270 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T442 22284-22285 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T443 22499-22501 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T444 22508-22510 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T445 22584-22589 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T446 22755-22759 http://purl.obolibrary.org/obo/PR_000001307 denotes CD44
T447 22851-22853 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T448 22854-22856 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T449 22918-22922 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T450 22923-22933 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T451 23021-23023 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T452 23024-23026 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T453 23093-23099 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T454 23171-23175 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T455 23279-23281 http://purl.obolibrary.org/obo/CLO_0053794 denotes 41
T456 23305-23306 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T457 23440-23448 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T458 23582-23590 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T459 23724-23727 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T460 23851-23855 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T461 23856-23864 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T462 23891-23899 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T463 23959-23967 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T464 24217-24219 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T465 24223-24228 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T466 24260-24268 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T467 24326-24328 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T468 24428-24430 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T469 24480-24482 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T470 24485-24497 http://purl.obolibrary.org/obo/OBI_0000245 denotes organization
T471 24505-24509 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T472 24510-24518 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T473 24706-24708 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T474 24742-24743 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T475 24909-24911 http://purl.obolibrary.org/obo/CLO_0001302 denotes 34
T476 24924-24926 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T477 25032-25034 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T478 25078-25079 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T479 25128-25130 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T480 25140-25148 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T481 25166-25176 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T482 25237-25244 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T483 25389-25391 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T484 25401-25403 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T485 25407-25409 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T486 25607-25609 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T487 25637-25639 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T488 25649-25651 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T489 25688-25692 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T490 25813-25817 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T491 25818-25828 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T492 25832-25834 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T493 25840-25842 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T494 25942-25951 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T495 26007-26009 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T496 26044-26053 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T497 26070-26076 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T498 26077-26087 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T499 26228-26230 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T500 26249-26253 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T501 26281-26291 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T502 26307-26309 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T503 26314-26316 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T504 26323-26325 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T505 26332-26334 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T506 26377-26379 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T507 26406-26408 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T508 26468-26470 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T509 26563-26567 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T510 26568-26578 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T511 26606-26611 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T512 26640-26642 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T513 26690-26696 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T514 26697-26707 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T515 26856-26858 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T516 26877-26881 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T517 26965-26971 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T518 27032-27033 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T519 27052-27054 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T520 27068-27070 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T521 27071-27073 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T522 27078-27081 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T523 27174-27184 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T524 27190-27192 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T525 27225-27227 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T526 27256-27266 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T527 27283-27284 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T528 27385-27387 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T529 27392-27393 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T530 27465-27467 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T531 27509-27515 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T532 27569-27576 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T533 27770-27772 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T534 27876-27877 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T535 27962-27965 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T536 28014-28016 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T537 28092-28094 http://purl.obolibrary.org/obo/CLO_0001407 denotes 52
T538 28125-28127 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T539 28247-28253 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T540 28269-28271 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T541 28360-28362 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T542 28427-28429 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T543 28430-28432 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T544 28528-28531 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T545 28589-28594 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T546 28595-28597 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T547 28604-28609 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T548 28679-28681 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T549 28850-28855 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T550 28888-28903 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T551 28917-28918 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T552 28945-28946 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T553 29022-29024 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T554 29037-29043 http://purl.obolibrary.org/obo/UBERON_0003891 denotes stroma
T555 29063-29078 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T556 29155-29159 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T557 29206-29213 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T558 29248-29250 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T559 29392-29393 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T560 29456-29460 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T561 29475-29477 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T562 29481-29486 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T563 29487-29489 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T564 29503-29508 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T565 29592-29594 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T566 29652-29656 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T567 29668-29669 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T568 29677-29681 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T569 29721-29723 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T570 29746-29748 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T571 29749-29751 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T572 29787-29788 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T573 29796-29800 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T574 29860-29862 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T575 29903-29907 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T576 29984-29985 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T577 30009-30013 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T578 30069-30075 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T579 30104-30107 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T580 30104-30107 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T581 30123-30126 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T582 30123-30126 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T583 30194-30200 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T584 30207-30210 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T585 30207-30210 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T586 30222-30230 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T587 30231-30233 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T588 30248-30253 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T589 30271-30280 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T590 30296-30302 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T591 30356-30366 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T592 30370-30372 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T593 30386-30391 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T594 30408-30410 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T595 30622-30624 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T596 30682-30683 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T597 30691-30695 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T598 30799-30800 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T599 30808-30812 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T600 30924-30929 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T601 31014-31016 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T602 31024-31026 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T603 31027-31029 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T604 31118-31120 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T605 31300-31304 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T606 31339-31341 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T607 31441-31443 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T608 31479-31481 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T609 31525-31527 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T610 31528-31530 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T611 31776-31778 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T612 32041-32043 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T613 32095-32100 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T614 32208-32217 http://purl.obolibrary.org/obo/CLO_0053695 denotes human IgG
T615 32442-32444 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T616 32445-32447 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T617 32618-32620 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T618 32621-32623 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T619 32641-32643 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T620 32690-32692 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T621 32735-32736 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T622 32829-32831 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T623 32900-32902 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T624 33084-33086 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T625 33128-33130 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T626 33183-33185 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T627 33206-33209 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T628 33238-33242 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T629 33238-33242 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T630 33238-33242 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T631 33238-33242 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T632 33238-33242 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T633 33263-33265 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T634 33284-33285 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T635 33311-33313 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T636 33332-33336 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T637 33332-33336 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T638 33332-33336 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T639 33332-33336 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T640 33332-33336 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T641 33353-33354 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T642 33405-33413 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T643 33448-33450 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T644 33490-33494 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T645 33490-33494 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T646 33490-33494 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T647 33490-33494 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T648 33490-33494 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T649 33590-33592 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T650 33674-33677 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T651 33692-33700 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T652 33735-33737 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T653 33870-33872 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T654 33921-33923 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T655 33970-33972 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T656 33975-33978 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T657 34022-34024 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T658 34028-34031 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T659 34032-34033 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T660 34150-34152 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T661 34191-34196 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T662 34387-34389 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T663 34390-34392 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T664 34427-34432 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T665 34438-34440 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T666 34456-34458 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T667 34463-34465 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T668 34473-34475 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T669 34600-34602 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T670 34911-34913 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T671 35004-35006 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T672 35128-35130 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T673 35209-35211 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T674 35287-35289 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T675 35306-35308 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T676 35343-35345 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T677 35354-35356 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T678 35477-35479 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T679 36003-36004 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T680 36401-36404 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T681 36785-36788 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T682 36930-36933 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T683 36959-36960 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T684 37027-37028 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T685 37072-37075 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T686 37145-37147 http://purl.obolibrary.org/obo/CLO_0054055 denotes 71
T687 37213-37215 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T688 37260-37263 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T689 37384-37386 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T690 37476-37479 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T691 37883-37885 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T692 38082-38084 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T693 38124-38125 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T694 38130-38135 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T695 38252-38254 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T696 38505-38506 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T697 38635-38645 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T698 38716-38718 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T699 38734-38743 http://purl.obolibrary.org/obo/CLO_0053695 denotes human IgG
T700 38773-38774 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T701 38900-38902 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T702 38927-38928 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T703 38958-38964 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T704 39025-39026 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T705 39039-39041 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T706 39081-39082 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T707 39109-39111 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T708 39169-39179 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T709 39185-39187 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T710 39188-39190 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T711 39268-39270 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T712 39396-39398 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T713 39765-39767 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T714 39790-39792 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T715 39842-39844 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T716 40050-40052 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T717 40199-40209 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T718 40271-40273 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T719 40424-40428 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T720 40449-40453 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T721 40498-40507 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T722 40554-40556 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T723 40737-40738 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T724 40739-40744 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T725 40775-40785 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T726 40791-40793 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T727 40831-40839 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T728 40975-40985 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T729 40986-40988 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T730 40997-40999 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T731 41026-41028 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T732 41065-41075 http://purl.obolibrary.org/obo/GO_0005623 denotes cells will
T733 41086-41088 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T734 41108-41110 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T735 41115-41117 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T736 41127-41129 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T737 41152-41153 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T738 41218-41222 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T739 41279-41281 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T740 41301-41310 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T741 41318-41328 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T742 41329-41331 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T743 41400-41404 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T744 41436-41440 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T745 41529-41539 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T746 41541-41542 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T747 41563-41565 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T748 41599-41603 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T749 41609-41610 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T750 41694-41702 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T751 41738-41739 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T752 41852-41853 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T753 41994-41996 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T754 42068-42078 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T755 42129-42139 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T756 42145-42147 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T757 42164-42166 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T758 42237-42242 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T759 42302-42304 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T760 42344-42346 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T761 42349-42350 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T762 42473-42475 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T763 42498-42500 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T764 42516-42518 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T765 42765-42768 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T766 42862-42864 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T767 42885-42887 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T768 43015-43017 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T769 43323-43325 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T770 43373-43378 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T771 43416-43418 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T772 43518-43520 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T773 43564-43567 http://www.ebi.ac.uk/efo/EFO_0000826 denotes ear
T774 43568-43572 http://www.ebi.ac.uk/efo/EFO_0000828 denotes nose
T775 43655-43660 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T776 43740-43742 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T777 43897-43901 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T778 43943-43945 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T779 43964-43986 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T780 43964-43986 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T781 43964-43986 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T782 44214-44216 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T783 44348-44350 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T784 44369-44391 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T785 44369-44391 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T786 44369-44391 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T787 44444-44448 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T788 44490-44492 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T789 44682-44684 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T790 44794-44796 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T791 44982-44984 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T792 45097-45099 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T793 45163-45166 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T794 45163-45166 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T795 45195-45197 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T796 45374-45376 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T797 45399-45401 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T798 45602-45604 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T799 45623-45645 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T800 45623-45645 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T801 45623-45645 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T802 46039-46041 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T803 46130-46131 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T804 46227-46229 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T805 46240-46242 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T806 46321-46323 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T807 46426-46428 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T808 46634-46635 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T809 46688-46690 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T810 46799-46801 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T811 46851-46858 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T812 46927-46929 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T813 46943-46945 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T814 46997-46999 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T815 47436-47438 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T816 47504-47506 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T817 47568-47570 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T818 47614-47624 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T819 47625-47627 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T820 47628-47630 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T821 47641-47645 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T822 47798-47800 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T823 47847-47849 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T824 47891-47893 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T825 47937-47939 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T826 48017-48022 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T827 48069-48071 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T828 48271-48273 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T829 48357-48359 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T830 48392-48393 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T831 48399-48401 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T832 48524-48538 http://purl.obolibrary.org/obo/CL_0001034 denotes cells in vitro
T833 48659-48661 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T834 48733-48734 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T835 48817-48819 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T836 48824-48826 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T837 48933-48935 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T838 49027-49029 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T839 49060-49062 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T840 49080-49081 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T841 49186-49188 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T842 49257-49259 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T843 49306-49307 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T844 49400-49403 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T845 49431-49433 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T846 49575-49577 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T847 49745-49747 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T848 49780-49782 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T849 49846-49853 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T850 49889-49891 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T851 49965-49975 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T852 49976-49978 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T853 49981-49984 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T854 50036-50037 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T855 50074-50084 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T856 50085-50087 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T857 50222-50224 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T858 50422-50428 http://purl.obolibrary.org/obo/PR_000001852 denotes CTLA‐4
T859 50436-50441 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T860 50493-50500 http://purl.obolibrary.org/obo/SO_0000418 denotes signals
T861 50765-50766 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T862 50888-50894 http://purl.obolibrary.org/obo/PR_000001852 denotes CTLA‐4
T863 50976-50981 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T864 51074-51084 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T865 51095-51097 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T866 51112-51114 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T867 51194-51204 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T868 51321-51323 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T869 51340-51348 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T870 51404-51406 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T871 51741-51743 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T872 51747-51748 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T873 51855-51857 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T874 51897-51899 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T875 51913-51915 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T876 51926-51929 http://purl.obolibrary.org/obo/CLO_0054060 denotes 102
T877 51957-51962 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T878 52027-52029 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T879 52052-52062 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T880 52086-52088 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T881 52116-52118 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T882 52164-52166 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T883 52178-52179 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T884 52290-52294 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T885 52408-52410 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T886 52503-52504 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T887 52523-52526 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T888 52548-52567 http://purl.obolibrary.org/obo/CHEBI_33708 denotes amino acid residues
T889 52548-52567 http://purl.obolibrary.org/obo/PR_000036907 denotes amino acid residues
T890 52577-52579 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T891 52638-52640 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T892 52770-52775 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T893 52997-52999 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T894 53034-53036 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T895 53091-53101 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T896 53182-53184 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T897 53192-53194 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T898 53242-53245 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T899 53254-53256 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T900 53307-53311 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T901 53367-53368 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T902 53447-53448 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T903 53455-53457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T904 53484-53487 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T905 53735-53736 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T906 53757-53759 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T907 53785-53795 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T908 53805-53807 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T909 53850-53852 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T910 53949-53950 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T911 53981-53983 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T912 54073-54075 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T913 54119-54121 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T914 54136-54138 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T915 54153-54163 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T916 54164-54166 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T917 54289-54291 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T918 54420-54422 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T919 54463-54466 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T920 54509-54518 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T921 54590-54599 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T922 54637-54644 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T923 54654-54660 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T924 54698-54700 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T925 54726-54730 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T926 54759-54769 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T927 54775-54777 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T928 54783-54784 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T929 54883-54892 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T930 54893-54909 http://purl.obolibrary.org/obo/GO_0043235 denotes receptor complex
T931 54978-54982 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T932 55011-55013 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T933 55056-55065 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T934 55112-55114 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T935 55127-55129 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T936 55298-55305 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T937 55370-55374 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T938 55413-55415 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T939 55508-55510 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T940 55596-55605 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T941 55639-55646 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T942 55751-55752 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T943 55765-55767 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T944 55826-55833 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T945 55981-55983 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T946 56016-56020 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T947 56021-56031 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T948 56037-56040 http://purl.obolibrary.org/obo/CLO_0053001 denotes 114
T949 56158-56164 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T950 56225-56231 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T951 56262-56264 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T952 56296-56298 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T953 56374-56381 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T954 56694-56696 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T955 56800-56810 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T956 56833-56835 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T957 56920-56922 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T958 56942-56943 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T959 56974-56976 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T960 57145-57147 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T961 57237-57239 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T962 57272-57274 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T963 57369-57371 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T964 57455-57458 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T965 57510-57512 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T966 57559-57561 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T967 57759-57762 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T968 57804-57806 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T969 57827-57828 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T970 57968-57970 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T971 58057-58059 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T972 58116-58121 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T973 58137-58146 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T974 58288-58293 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T975 58297-58304 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T976 58389-58394 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T977 58416-58419 http://purl.obolibrary.org/obo/CLO_0001046 denotes 116
T978 58432-58434 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T979 58501-58502 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T980 58513-58515 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T981 58645-58647 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T982 58758-58766 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T983 58955-58957 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T984 59005-59007 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T985 59125-59133 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T986 59344-59346 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T987 59455-59457 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T988 59499-59501 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T989 59563-59571 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T990 59708-59709 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T991 59942-59944 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T992 60059-60061 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T993 60077-60080 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T994 60088-60089 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T995 60872-60874 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T996 61413-61414 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T997 61537-61538 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T998 61630-61632 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T999 61770-61772 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T1000 61869-61882 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T1001 61954-61956 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 228-235 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T2 267-274 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T3 356-364 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T4 597-605 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T5 822-836 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T6 1603-1610 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T7 2114-2122 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T8 2377-2385 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T9 2976-2981 Chemical denotes sales http://purl.obolibrary.org/obo/CHEBI_24866
T10 3011-3016 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T11 3429-3437 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T12 4217-4225 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T13 4393-4398 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T14 5042-5050 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T15 5351-5358 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T16 5394-5401 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T17 5411-5418 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T18 5794-5802 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T19 6163-6170 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T20 6176-6183 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T21 6209-6216 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T22 6307-6315 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T23 6369-6376 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T24 6649-6657 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T25 6910-6913 Chemical denotes APC http://purl.obolibrary.org/obo/CHEBI_80551
T26 7060-7068 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T27 7438-7440 Chemical denotes Ag http://purl.obolibrary.org/obo/CHEBI_30512|http://purl.obolibrary.org/obo/CHEBI_9141
T29 7442-7449 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T30 7646-7652 Chemical denotes Action http://purl.obolibrary.org/obo/CHEBI_5133
T31 7885-7887 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T33 7962-7964 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T35 8148-8150 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T37 8155-8157 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T39 8513-8515 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T41 8560-8568 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T42 9020-9028 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T43 9357-9366 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T44 9619-9621 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T46 9786-9791 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T47 10038-10047 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T48 10098-10106 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T49 10377-10385 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T50 10570-10578 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T51 10713-10721 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T52 11009-11017 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T53 11321-11323 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T55 11360-11370 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T56 11819-11822 Chemical denotes Phe http://purl.obolibrary.org/obo/CHEBI_17295|http://purl.obolibrary.org/obo/CHEBI_29997
T58 12661-12666 Chemical denotes Light http://purl.obolibrary.org/obo/CHEBI_30212
T59 12759-12764 Chemical denotes Light http://purl.obolibrary.org/obo/CHEBI_30212
T60 12960-12969 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T61 13138-13146 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T62 13199-13209 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T64 13220-13222 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T66 13355-13363 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T67 13900-13908 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T68 14448-14450 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T70 14573-14575 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T72 14705-14707 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T74 14768-14778 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T75 14906-14908 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T77 14912-14922 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T78 15344-15352 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T79 16007-16017 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976
T80 17122-17130 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T81 17576-17583 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T82 17809-17819 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T83 17809-17814 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T84 17815-17819 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T85 17905-17912 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T86 18665-18673 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T87 19795-19809 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T88 19950-19959 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T89 20224-20231 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T90 20263-20265 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T92 20286-20288 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T94 20487-20494 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T95 20577-20585 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T96 20910-20918 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T97 21041-21049 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T98 21134-21142 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T99 21160-21168 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T100 21218-21223 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059
T101 21227-21234 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T102 21235-21243 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T103 21482-21490 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T104 21613-21621 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T105 21722-21730 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T106 21863-21871 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T107 22015-22022 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T108 22080-22088 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T109 22314-22321 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T110 22364-22371 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T111 22387-22395 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T112 22575-22583 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T113 22659-22676 Chemical denotes glycosaminoglycan http://purl.obolibrary.org/obo/CHEBI_18085
T114 22732-22745 Chemical denotes glycoproteins http://purl.obolibrary.org/obo/CHEBI_17089
T115 22904-22911 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T116 23073-23079 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T117 23162-23170 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T118 23220-23227 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T119 23371-23378 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T120 23476-23484 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T121 23559-23567 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T122 23694-23702 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T123 23922-23929 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T124 24001-24008 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T125 24709-24720 Chemical denotes polypeptide http://purl.obolibrary.org/obo/CHEBI_15841
T126 24832-24843 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T127 24892-24900 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T128 25047-25055 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T129 25204-25212 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T130 25404-25406 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T132 25652-25654 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T134 26110-26117 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T135 26310-26312 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T137 26380-26382 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T139 26409-26411 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T141 26579-26588 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T142 26756-26763 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T143 27581-27587 Chemical denotes toxins http://purl.obolibrary.org/obo/CHEBI_27026
T144 27722-27736 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T145 27785-27792 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T146 28296-28303 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T147 28472-28480 Chemical denotes antigens http://purl.obolibrary.org/obo/CHEBI_59132
T148 28490-28497 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T149 28598-28600 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T151 28610-28617 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T152 28720-28727 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T153 28804-28812 Chemical denotes antigens http://purl.obolibrary.org/obo/CHEBI_59132
T154 28831-28838 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T155 29000-29007 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T156 29121-29128 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T157 29195-29202 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T158 29372-29379 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T159 29618-29627 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T160 30148-30156 Chemical denotes mitogens http://purl.obolibrary.org/obo/CHEBI_52290
T161 31209-31216 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T162 31291-31299 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T163 31344-31353 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T164 31779-31781 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T166 32044-32046 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T168 32112-32122 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T169 32283-32293 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T170 32283-32288 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T171 32289-32293 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T172 32407-32414 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T173 32492-32494 Chemical denotes KD http://purl.obolibrary.org/obo/CHEBI_73601
T174 33004-33017 Chemical denotes phenylalanine http://purl.obolibrary.org/obo/CHEBI_28044|http://purl.obolibrary.org/obo/CHEBI_58095
T176 33018-33024 Chemical denotes valine http://purl.obolibrary.org/obo/CHEBI_27266
T177 33300-33306 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T178 33314-33316 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T180 33534-33543 Chemical denotes histidine http://purl.obolibrary.org/obo/CHEBI_27570
T181 33764-33772 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016|http://purl.obolibrary.org/obo/CHEBI_32696
T184 34025-34027 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T186 34459-34461 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T188 34772-34774 Chemical denotes FG http://purl.obolibrary.org/obo/CHEBI_73635
T189 34817-34827 Chemical denotes asparagine http://purl.obolibrary.org/obo/CHEBI_22653
T190 35188-35194 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T191 35212-35227 Chemical denotes oligosaccharide http://purl.obolibrary.org/obo/CHEBI_50699
T192 35655-35664 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T193 35863-35865 Chemical denotes Eu http://purl.obolibrary.org/obo/CHEBI_32999
T194 36272-36281 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T195 36327-36338 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T196 36327-36332 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T197 36333-36338 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T198 36670-36679 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T199 36727-36735 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T200 36795-36804 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T201 37302-37309 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T202 37356-37365 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T203 37745-37752 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T204 38381-38388 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T205 38670-38678 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T206 38949-38957 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T207 39044-39050 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T208 39083-39089 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T209 39357-39365 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T210 39509-39517 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T211 40559-40567 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T212 40646-40655 Chemical denotes rituximab http://purl.obolibrary.org/obo/CHEBI_64357
T213 41056-41064 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T214 41111-41113 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T216 41391-41399 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T217 41590-41598 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T218 41999-42007 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T219 42823-42833 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T220 42823-42828 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T221 42829-42833 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T222 43222-43227 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T223 43228-43232 Chemical denotes beta http://purl.obolibrary.org/obo/CHEBI_10545
T224 43373-43375 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T225 43655-43657 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T226 43806-43813 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T227 44542-44544 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T228 44835-44848 Chemical denotes Pembrolizumab http://purl.obolibrary.org/obo/CHEBI_82976
T229 44850-44852 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T230 45062-45064 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T232 45236-45238 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T233 45253-45255 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T234 45482-45484 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T235 46137-46143 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T236 46173-46179 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T237 46815-46823 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T238 47296-47302 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T239 47314-47323 Chemical denotes rituximab http://purl.obolibrary.org/obo/CHEBI_64357
T240 47507-47518 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T241 47507-47512 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T242 47513-47518 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T243 47537-47548 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T244 47537-47542 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T245 47543-47548 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T246 48200-48211 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T247 48200-48205 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T248 48206-48211 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T249 49836-49840 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T3637 50387-50397 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T24725 50436-50438 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T35015 50442-50444 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T38212 50603-50616 Chemical denotes Pembrolizumab http://purl.obolibrary.org/obo/CHEBI_82976
T9178 50656-50658 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T92845 50854-50863 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T60873 51115-51117 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T66616 51156-51164 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T93768 51298-51300 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T92385 51324-51326 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T98482 51957-51959 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T9506 51974-51983 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T68471 52089-52099 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T62086 52089-52094 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T40175 52095-52099 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T80744 52236-52243 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T54623 52311-52318 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449
T5000 52548-52558 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T20266 52548-52553 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T44260 52554-52558 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T10443 52724-52735 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T57589 52724-52729 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T8912 52730-52735 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T75315 52770-52772 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T36188 52799-52809 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T28 53185-53187 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T85014 53215-53217 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T2607 53579-53589 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T70545 53855-53863 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T34 54042-54050 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T62570 54312-54320 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T36 54701-54703 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T38 55984-55986 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T40 56647-56655 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016|http://purl.obolibrary.org/obo/CHEBI_32696
T32821 57495-57506 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T86511 57569-57577 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T45 57630-57639 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T38447 58256-58265 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T65735 58269-58276 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T80667 58690-58697 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T94340 58837-58844 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T17986 58901-58911 Chemical denotes antagonist http://purl.obolibrary.org/obo/CHEBI_48706
T59829 61250-61258 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T54895 61351-61359 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T75881 61834-61842 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T1 246-260 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T2 262-264 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T3 2019-2033 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T4 2035-2037 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T5 3376-3390 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T6 3392-3394 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T7 5270-5293 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes neutralizing antibodies http://purl.bioontology.org/ontology/MEDDRA/10058063
T8 7473-7475 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T9 7477-7491 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T10 12162-12164 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T11 12166-12180 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T12 13373-13375 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T13 13377-13391 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T14 15914-15916 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T15 18919-18933 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigations http://purl.bioontology.org/ontology/MEDDRA/10062026
T16 21218-21223 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes lipid http://purl.bioontology.org/ontology/MEDDRA/10024587
T17 34210-34215 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes X‐ray http://purl.bioontology.org/ontology/MEDDRA/10048064
T18 45667-45669 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T19 45671-45685 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T98304 60961-60974 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigation http://purl.bioontology.org/ontology/MEDDRA/10062026

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T1 38-46 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T2 340-344 http://purl.obolibrary.org/obo/IDO_0000531 denotes host
T3 365-374 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T4 437-446 http://purl.obolibrary.org/obo/IDO_0000528 denotes pathogens
T5 687-692 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T6 1149-1157 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T7 1170-1180 http://purl.obolibrary.org/obo/IDO_0000586 denotes infections
T8 1390-1398 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T9 2098-2102 http://purl.obolibrary.org/obo/IDO_0000531 denotes host
T10 2123-2132 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T11 2176-2192 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T12 2386-2395 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T13 2736-2744 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T14 2809-2817 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T15 3313-3320 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T16 3354-3359 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T17 3363-3372 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T18 3438-3442 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T19 3903-3907 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T20 4164-4173 http://purl.obolibrary.org/obo/IDO_0000528 denotes pathogens
T21 4296-4300 http://purl.obolibrary.org/obo/IDO_0000531 denotes host
T22 4549-4557 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T23 4752-4756 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T24 4779-4783 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T25 4846-4850 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T26 5255-5260 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T27 5336-5341 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T28 5370-5375 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T29 5741-5745 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T30 5803-5812 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T31 5833-5837 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T32 5857-5861 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T33 5921-5925 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T34 6228-6233 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T35 6260-6264 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T36 6364-6368 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T37 6441-6446 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T38 6803-6807 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T39 6927-6943 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T40 7069-7073 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T41 7146-7150 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T42 7195-7199 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T43 7277-7282 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T44 7410-7414 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T45 7458-7462 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T46 7703-7707 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T47 7756-7760 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T48 7790-7794 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T49 7857-7861 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T50 7996-8000 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T51 8025-8029 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T52 8083-8087 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T53 8421-8425 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T54 8481-8485 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T55 8524-8528 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T56 9009-9013 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T57 9029-9038 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T58 9103-9112 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T59 9357-9366 http://purl.obolibrary.org/obo/IDO_0000559 denotes antiviral
T60 9511-9520 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T61 9545-9555 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T62 9961-9965 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T63 10210-10218 http://purl.obolibrary.org/obo/GO_0085030 denotes mutually
T64 10322-10326 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T65 10366-10370 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T66 10386-10398 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions in
T67 10674-10683 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T68 10722-10731 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T69 11018-11026 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T70 11300-11304 http://purl.obolibrary.org/obo/CL_0000000 denotes Cell
T71 11423-11427 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T72 11449-11454 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T73 11550-11560 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T74 11639-11644 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T75 11676-11681 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T76 11754-11759 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T77 12021-12026 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T78 12031-12036 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T79 12157-12161 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T80 12185-12189 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T81 12206-12210 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T82 13756-13761 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T83 13799-13808 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T84 13909-13918 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T85 14067-14071 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T86 14109-14119 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T87 14339-14344 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T88 14649-14658 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T89 14832-14837 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T90 14862-14867 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T91 14877-14882 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T92 15075-15091 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T93 15284-15294 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T94 15353-15362 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T95 15663-15671 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T96 15681-15691 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T97 15817-15826 http://purl.obolibrary.org/obo/OBI_0100026 denotes organisms
T98 16155-16160 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T99 16674-16682 http://purl.obolibrary.org/obo/IDO_0000607 denotes products
T100 16739-16744 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T101 16920-16928 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T102 17002-17006 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T103 17131-17139 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T104 17548-17552 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T105 17624-17632 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T106 17643-17648 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T107 17900-17904 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T108 18050-18055 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T109 18067-18072 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T110 18315-18320 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T111 18397-18402 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T112 18542-18547 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T113 18574-18579 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T114 18674-18682 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T115 18774-18779 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T116 18883-18887 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T117 18888-18896 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T118 18997-19002 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T119 19059-19067 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T120 19218-19222 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T121 19324-19329 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T122 19475-19483 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T123 19518-19523 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T124 19786-19791 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T125 19950-19959 http://purl.obolibrary.org/obo/IDO_0000559 denotes antiviral
T126 20047-20056 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T127 20219-20223 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T128 20543-20547 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T129 20750-20754 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T130 20866-20874 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T131 21297-21301 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T132 21585-21592 http://purl.obolibrary.org/obo/BFO_0000019 denotes quality
T133 21731-21736 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T134 22584-22589 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T135 22697-22705 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T136 22918-22922 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T137 23171-23175 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T138 23176-23184 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T139 23266-23274 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T140 23851-23855 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T141 24223-24228 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T142 24331-24339 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T143 24485-24497 http://purl.obolibrary.org/obo/OBI_0100026 denotes organization
T144 24505-24509 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T145 24749-24757 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T146 24951-24961 http://purl.obolibrary.org/obo/IDO_0000607 denotes productive
T147 25056-25065 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T148 25143-25148 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T149 25213-25222 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T150 25240-25244 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T151 25688-25692 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T152 25813-25817 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T153 25981-25989 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T154 26072-26076 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T155 26249-26253 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T156 26265-26275 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T157 26493-26501 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T158 26563-26567 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T159 26606-26611 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T160 26692-26696 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T161 26877-26881 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T162 27267-27275 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T163 27569-27576 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T164 27581-27587 http://purl.obolibrary.org/obo/IDO_0000549 denotes toxins
T165 27829-27844 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T166 28850-28855 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T167 28898-28903 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T168 29073-29078 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T169 29155-29159 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T170 29208-29213 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T171 29422-29438 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T172 29456-29460 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T173 29481-29486 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T174 29503-29508 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T175 29652-29656 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T176 29677-29681 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T177 29796-29800 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T178 29903-29907 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T179 30009-30013 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T180 30071-30075 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T181 30196-30200 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T182 30248-30253 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T183 30298-30302 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T184 30386-30391 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T185 30691-30695 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T186 30808-30812 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T187 30924-30929 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T188 31300-31304 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T189 32095-32100 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T190 32172-32177 http://purl.obolibrary.org/obo/BFO_0000029 denotes sites
T191 32354-32364 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T192 33070-33074 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T193 33394-33404 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T194 33579-33583 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T195 33681-33691 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T196 34268-34276 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T197 37616-37630 http://purl.obolibrary.org/obo/IDO_0000467 denotes susceptibility
T198 37716-37726 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T199 38679-38688 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T200 39366-39374 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T201 39518-39527 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T202 39855-39864 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T203 40328-40335 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T204 40424-40428 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T205 40449-40453 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T206 40568-40577 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T207 41065-41075 http://purl.obolibrary.org/obo/CL_0000000 denotes cells will
T208 41218-41222 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T209 41400-41404 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T210 41436-41440 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T211 41599-41603 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T212 42237-42242 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T213 43580-43589 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T214 43862-43871 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T215 44113-44122 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T216 44583-44601 http://purl.obolibrary.org/obo/IDO_0000436 denotes Infectious disease
T217 44594-44601 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T218 44891-44900 http://purl.obolibrary.org/obo/IDO_0000586 denotes Infection
T219 45017-45026 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T220 45219-45228 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T221 46854-46858 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T222 46983-46992 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T223 48007-48013 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T224 48524-48529 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T225 49199-49208 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T226 50976-50981 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T227 51165-51174 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T228 53864-53873 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T229 54051-54060 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T230 54359-54367 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T231 54408-54416 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T232 54639-54644 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T233 54726-54730 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T234 54731-54738 http://www.geneontology.org/formats/oboInOwl#Subset denotes subsets
T235 54803-54813 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T236 54978-54982 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T237 55333-55340 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T238 55641-55646 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T239 55732-55741 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T240 56016-56020 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T241 56160-56164 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T242 56169-56179 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T243 56227-56231 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T244 56355-56365 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T245 56376-56381 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T246 56686-56690 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T247 58116-58121 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T248 58288-58293 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T249 58299-58304 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T250 58389-58394 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T251 59043-59051 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T252 59222-59228 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T253 59746-59754 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T254 59947-59955 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T255 60163-60173 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T256 60978-60996 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T257 60989-60996 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T258 61104-61122 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T259 61115-61122 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T260 61192-61201 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T261 61259-61268 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T262 61360-61372 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions in
T263 61392-61400 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T264 61457-61475 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T265 61468-61475 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T266 62078-62086 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T20 57466-57468 RP denotes up
T21 57469-57472 JJ denotes new
T22 57473-57486 NNS denotes possibilities
T23 57487-57490 IN denotes for
T24 57491-57494 DT denotes the
T25 57495-57506 NN denotes application
T26 57507-57509 IN denotes of
T27 57510-57527 VBG denotes FcγRIIb‐enhancing
T28 57528-57544 NN denotes modifications.17
T29 57545-57555 NNS denotes Antibodies
T30 57556-57558 CC denotes or
T31 57559-57561 NN denotes Fc
T32 57562-57568 NN denotes fusion
T33 57569-57577 NNS denotes proteins
T34 57577-57578 -COMMA- denotes ,
T35 57579-57584 WP-DOLLAR- denotes whose
T36 57585-57592 JJ denotes primary
T37 57593-57596 NN denotes MOA
T38 57597-57599 VBZ denotes is
T39 57600-57603 DT denotes the
T40 57604-57618 NN denotes neutralization
T41 57619-57621 IN denotes of
T42 57622-57629 JJ denotes soluble
T43 57630-57639 NNS denotes molecules
T44 57640-57644 JJ denotes such
T45 57645-57647 IN denotes as
T46 57648-57651 NN denotes IgE
T47 57652-57654 CC denotes or
T48 57655-57664 NNS denotes cytokines
T49 57664-57665 -COMMA- denotes ,
T50 57666-57669 VBP denotes are
T51 57670-57682 RB denotes particularly
T52 57683-57693 JJ denotes attractive
T53 57694-57704 NNS denotes candidates
T54 57705-57708 IN denotes for
T55 57709-57713 DT denotes this
T56 57714-57722 NN denotes approach
T57 57724-57740 NN denotes Proof‐of‐concept
T58 57741-57744 IN denotes for
T59 57745-57749 DT denotes this
T60 57750-57758 NN denotes strategy
T61 57759-57762 VBZ denotes has
T62 57763-57767 VBN denotes been
T63 57768-57780 VBN denotes demonstrated
T64 57781-57783 IN denotes in
T65 57784-57796 JJ denotes experimental
T66 57797-57806 NN denotes models.48
T67 57807-57813 RB denotes Indeed
T68 57813-57814 -COMMA- denotes ,
T69 57815-57819 DT denotes this
T70 57820-57823 MD denotes may
T71 57824-57826 VB denotes be
T72 57827-57828 DT denotes a
T73 57829-57840 JJ denotes significant
T74 57841-57850 NN denotes component
T75 57851-57853 IN denotes of
T76 57854-57857 DT denotes the
T77 57858-57863 JJ denotes rapid
T78 57864-57877 NN denotes disappearance
T79 57878-57880 IN denotes of
T80 57881-57884 NN denotes IgE
T81 57885-57889 IN denotes from
T82 57890-57893 DT denotes the
T83 57894-57905 NN denotes circulation
T84 57906-57908 IN denotes of
T85 57909-57917 NNS denotes patients
T86 57918-57925 VBN denotes treated
T87 57926-57930 IN denotes with
T88 57931-57934 DT denotes the
T89 57935-57943 NN denotes anti‐IgE
T90 57944-57952 NN denotes XmAb7195
T91 57953-57963 VBG denotes containing
T92 57964-57967 DT denotes the
T93 57968-57975 NN denotes FcγRIIb
T94 57976-57985 VBG denotes enhancing
T95 57986-57992 NNP denotes “SELF”
T96 57993-58006 NNS denotes modifications
T97 58006-58007 -COMMA- denotes ,
T98 58008-58010 IN denotes as
T99 58011-58020 VBN denotes described
T100 58021-58031 RB denotes previously
T101 58034-58040 JJ denotes Immune
T102 58041-58048 NN denotes agonism
T103 58049-58056 IN denotes through
T104 58057-58061 NN denotes FcγR
T105 58062-58073 NN denotes scaffolding
T106 58074-58083 JJ denotes Agonistic
T107 58084-58088 NNS denotes mAbs
T108 58089-58095 VBP denotes induce
T109 58096-58105 NNS denotes responses
T110 58106-58108 IN denotes in
T111 58109-58115 NN denotes target
T112 58116-58121 NNS denotes cells
T113 58122-58124 IN denotes by
T114 58125-58136 VBG denotes stimulating
T115 58137-58146 NN denotes signaling
T116 58147-58149 IN denotes of
T117 58150-58155 PRP-DOLLAR- denotes their
T118 58156-58165 JJ denotes molecular
T119 58166-58172 NN denotes target
T120 58174-58183 RB denotes Typically
T121 58183-58184 -COMMA- denotes ,
T122 58185-58189 DT denotes this
T123 58190-58192 VBZ denotes is
T124 58193-58195 TO denotes to
T125 58196-58202 CC denotes either
T126 58203-58210 VB denotes enhance
T127 58211-58220 NN denotes antitumor
T128 58221-58229 NN denotes immunity
T129 58230-58232 IN denotes by
T130 58233-58241 VBG denotes engaging
T131 58242-58255 JJ denotes costimulatory
T132 58256-58265 NNS denotes molecules
T133 58266-58268 IN denotes on
T134 58269-58287 JJ denotes antigen‐presenting
T135 58288-58293 NNS denotes cells
T136 58294-58296 CC denotes or
T137 58297-58298 NN denotes T
T138 58299-58304 NNS denotes cells
T139 58305-58306 -LRB- denotes (
T140 58306-58310 FW denotes i.e.
T141 58311-58315 NN denotes CD40
T142 58315-58316 -COMMA- denotes ,
T143 58317-58322 NN denotes 4‐1BB
T144 58322-58323 -COMMA- denotes ,
T145 58324-58328 NN denotes OX40
T146 58328-58329 -RRB- denotes )
T147 58330-58332 CC denotes or
T148 58333-58340 VB denotes promote
T149 58341-58350 NN denotes apoptosis
T150 58351-58353 IN denotes by
T151 58354-58362 VBG denotes engaging
T152 58363-58368 NN denotes death
T153 58369-58378 NNS denotes receptors
T154 58379-58381 IN denotes on
T155 58382-58388 NN denotes cancer
T156 58389-58394 NNS denotes cells
T157 58395-58396 -LRB- denotes (
T158 58396-58400 FW denotes i.e.
T159 58401-58404 NN denotes DR4
T160 58404-58405 -COMMA- denotes ,
T161 58406-58409 NN denotes DR5
T162 58409-58410 -COMMA- denotes ,
T163 58411-58414 NN denotes Fas
T164 58414-58415 -RRB- denotes )
T165 58420-58423 DT denotes The
T166 58424-58428 NN denotes role
T167 58429-58431 IN denotes of
T168 58432-58436 NN denotes FcγR
T169 58437-58439 IN denotes in
T170 58440-58443 DT denotes the
T171 58444-58450 NN denotes action
T172 58451-58453 IN denotes of
T173 58454-58459 DT denotes these
T174 58460-58465 NNS denotes types
T175 58466-58468 IN denotes of
T176 58469-58473 NNS denotes mAbs
T177 58474-58481 VBZ denotes appears
T178 58482-58484 TO denotes to
T179 58485-58487 VB denotes be
T180 58488-58497 RB denotes primarily
T181 58498-58500 IN denotes as
T182 58501-58502 DT denotes a
T183 58503-58511 NN denotes scaffold
T184 58513-58520 NN denotes FcγRIIb
T185 58521-58523 VBZ denotes is
T186 58524-58529 RB denotes often
T187 58530-58533 DT denotes the
T188 58534-58545 JJ denotes predominate
T189 58546-58554 NN denotes receptor
T190 58555-58563 VBN denotes involved
T191 58564-58567 CC denotes and
T192 58568-58571 DT denotes the
T193 58572-58578 NN denotes extent
T194 58579-58581 IN denotes of
T195 58582-58585 PRP-DOLLAR- denotes its
T196 58586-58597 NN denotes involvement
T197 58598-58600 VBZ denotes is
T198 58601-58608 JJ denotes complex
T199 58610-58612 IN denotes In
T200 58613-58616 DT denotes the
T201 58617-58621 NN denotes case
T202 58622-58624 IN denotes of
T203 58625-58629 NN denotes CD40
T204 58629-58630 -COMMA- denotes ,
T205 58631-58634 DT denotes the
T206 58635-58641 NN denotes degree
T207 58642-58644 IN denotes of
T208 58645-58652 NN denotes FcγRIIb
T209 58653-58664 NN denotes scaffolding
T210 58665-58672 NN denotes potency
T211 58673-58675 VBZ denotes is
T212 58676-58682 VBN denotes linked
T213 58683-58685 TO denotes to
T214 58686-58689 DT denotes the
T215 58690-58697 NN denotes epitope
T216 58698-58706 NN denotes location
T217 58707-58709 IN denotes of
T218 58710-58713 DT denotes the
T219 58714-58723 VBG denotes targeting
T220 58724-58727 NN denotes mAb
T221 58728-58732 IN denotes with
T222 58733-58740 JJR denotes greater
T223 58741-58748 NN denotes potency
T224 58749-58753 VBN denotes seen
T225 58754-58757 IN denotes for
T226 58758-58766 NN denotes membrane
T227 58767-58775 JJ denotes proximal
T228 58776-58787 NN denotes epitopes.43
T229 58787-58788 -COMMA- denotes ,
T230 58789-58792 CD denotes 117
T231 58793-58795 PRP denotes It
T232 58796-58798 VBZ denotes is
T233 58799-58803 RB denotes also
T234 58804-58814 JJ denotes noteworthy
T235 58815-58819 IN denotes that
T236 58820-58829 VBG denotes depending
T237 58830-58832 IN denotes on
T238 58833-58836 DT denotes the
T239 58837-58844 NN denotes epitope
T240 58845-58853 NN denotes location
T241 58853-58854 -COMMA- denotes ,
T242 58855-58858 DT denotes the
T243 58859-58870 NN denotes scaffolding
T244 58871-58873 IN denotes of
T245 58874-58883 NN denotes anti‐CD40
T246 58884-58888 NNS denotes mAbs
T247 58889-58892 MD denotes may
T248 58893-58900 VB denotes convert
T249 58901-58911 NN denotes antagonist
T250 58912-58916 NNS denotes mAbs
T251 58917-58919 TO denotes to
T252 58920-58929 JJ denotes agonistic
T253 58931-58942 NN denotes Engineering
T254 58943-58945 IN denotes of
T255 58946-58949 DT denotes the
T256 58950-58954 NN denotes IgG1
T257 58955-58957 NN denotes Fc
T258 58958-58964 NN denotes region
T259 58965-58968 IN denotes for
T260 58969-58977 VBN denotes enhanced
T261 58978-58984 CC denotes and/or
T262 58985-58993 JJ denotes specific
T263 58994-59001 NN denotes binding
T264 59002-59004 TO denotes to
T265 59005-59012 NN denotes FcγRIIb
T266 59013-59016 MD denotes can
T267 59017-59024 RB denotes greatly
T268 59025-59032 VB denotes improve
T269 59033-59042 JJ denotes agonistic
T270 59043-59054 NN denotes function.72
T271 59054-59055 -COMMA- denotes ,
T272 59056-59059 CD denotes 118
T273 59059-59060 -COMMA- denotes ,
T274 59061-59064 CD denotes 119
T275 59064-59065 -COMMA- denotes ,
T276 59066-59069 CD denotes 120
T277 59070-59074 JJ denotes Such
T278 59075-59084 NNS denotes mutations
T279 59085-59092 VBD denotes induced
T280 59093-59106 RB denotes significantly
T281 59107-59114 JJR denotes greater
T282 59115-59124 JJ denotes agonistic
T283 59125-59133 NN denotes activity
T284 59134-59136 IN denotes in
T285 59137-59139 DT denotes an
T286 59140-59148 NN denotes anti‐DR5
T287 59149-59154 NN denotes model
T288 59155-59162 IN denotes through
T289 59163-59172 VBN denotes increased
T290 59173-59182 NN denotes induction
T291 59183-59185 IN denotes of
T292 59186-59195 JJ denotes apoptotic
T293 59196-59201 NN denotes death
T294 59202-59205 CC denotes and
T295 59206-59215 VBD denotes decreased
T296 59216-59221 NN denotes tumor
T297 59222-59228 NN denotes growth
T298 59229-59237 VBN denotes compared
T299 59238-59242 IN denotes with
T300 59243-59253 JJ denotes unmodified
T301 59254-59262 NN denotes IgG1.121
T302 59263-59266 DT denotes The
T303 59267-59273 NNP denotes “SELF”
T304 59274-59287 NNS denotes modifications
T305 59288-59292 WDT denotes that
T306 59293-59305 RB denotes dramatically
T307 59306-59309 CC denotes and
T308 59310-59321 RB denotes selectively
T309 59322-59330 VBP denotes increase
T310 59331-59339 NN denotes affinity
T311 59340-59343 IN denotes for
T312 59344-59351 NN denotes FcγRIIb
T313 59352-59356 VBP denotes have
T314 59357-59361 RB denotes also
T315 59362-59366 VBN denotes been
T316 59367-59371 VBN denotes used
T317 59372-59374 TO denotes to
T318 59375-59382 VB denotes enhance
T319 59383-59389 JJ denotes immune
T320 59390-59397 NN denotes agonism
T321 59398-59400 IN denotes in
T322 59401-59403 DT denotes an
T323 59404-59413 NN denotes anti‐OX40
T324 59414-59423 NN denotes model.122
T325 59424-59427 DT denotes The
T326 59428-59444 NN denotes incorporation of
T327 59445-59448 DT denotes the
T328 59449-59450 -DQS- denotes "
T329 59450-59453 NN denotes V12
T330 59453-59454 '' denotes "
T331 59455-59457 NN denotes Fc
T332 59458-59467 NNS denotes mutations
T333 59468-59472 IN denotes into
T334 59473-59477 NN denotes IgG1
T335 59478-59490 RB denotes specifically
T336 59491-59498 VBP denotes enhance
T337 59499-59506 NN denotes FcγRIIb
T338 59507-59518 NN denotes interaction
T339 59519-59527 RB denotes 200‐fold
T340 59527-59528 -COMMA- denotes ,
T341 59529-59539 VBG denotes conferring
T342 59540-59543 DT denotes the
T343 59544-59552 VBN denotes enhanced
T344 59553-59562 JJ denotes agonistic
T345 59563-59571 NN denotes activity
T346 59572-59574 IN denotes of
T347 59575-59577 DT denotes an
T348 59578-59588 NN denotes anti‐CD137
T349 59589-59597 NN denotes antibody
T350 59598-59601 CC denotes and
T351 59602-59604 DT denotes an
T352 59605-59614 NN denotes anti‐OX40
T353 59615-59622 NN denotes mAb.115
T354 59622-59623 -COMMA- denotes ,
T355 59624-59627 CD denotes 122
T356 59629-59635 NNP denotes Future
T357 59636-59647 NNP denotes Engineering
T358 59648-59658 NNPS denotes Strategies
T359 59659-59669 JJ denotes Monoclonal
T360 59670-59680 NNS denotes antibodies
T361 59681-59684 VBP denotes are
T362 59685-59691 JJ denotes potent
T363 59692-59704 NNS denotes therapeutics
T364 59705-59707 IN denotes in
T365 59708-59709 DT denotes a
T366 59710-59716 NN denotes number
T367 59717-59719 IN denotes of
T368 59720-59727 JJ denotes chronic
T369 59728-59730 CC denotes or
T370 59731-59735 RB denotes once
T371 59736-59745 JJ denotes incurable
T372 59746-59754 NNS denotes diseases
T373 59756-59763 RB denotes However
T374 59763-59764 -COMMA- denotes ,
T375 59765-59770 EX denotes there
T376 59771-59773 VBZ denotes is
T377 59774-59779 RB denotes still
T378 59780-59789 JJ denotes extensive
T379 59790-59795 JJ denotes unmet
T380 59796-59804 JJ denotes clinical
T381 59805-59809 NN denotes need
T382 59810-59812 RB denotes as
T383 59813-59817 RB denotes well
T384 59818-59820 IN denotes as
T385 59821-59833 JJ denotes considerable
T386 59834-59838 NN denotes room
T387 59839-59842 IN denotes for
T388 59843-59854 NN denotes improvement
T389 59855-59857 IN denotes in
T390 59858-59862 JJ denotes many
T391 59863-59871 VBG denotes existing
T392 59872-59884 NNS denotes therapeutics
T393 59886-59893 JJ denotes Further
T394 59894-59907 NN denotes understanding
T395 59908-59910 IN denotes of
T396 59911-59914 WRB denotes how
T397 59915-59923 NN denotes antibody
T398 59924-59933 NN denotes structure
T399 59934-59941 VBZ denotes affects
T400 59942-59946 NN denotes FcγR
T401 59947-59955 NN denotes function
T402 59956-59958 VBZ denotes is
T403 59959-59968 JJ denotes essential
T404 59969-59972 IN denotes for
T405 59973-59979 JJ denotes future
T406 59980-59991 NN denotes development
T407 59992-59994 IN denotes of
T408 59995-59999 RBR denotes more
T409 60000-60006 JJ denotes potent
T410 60007-60010 CC denotes and
T411 60011-60020 JJ denotes effective
T412 60021-60025 NNS denotes mAbs
T413 60027-60034 RB denotes Already
T414 60034-60035 -COMMA- denotes ,
T415 60036-60047 NN denotes engineering
T416 60048-60050 IN denotes of
T417 60051-60054 DT denotes the
T418 60055-60058 NN denotes IgG
T419 60059-60061 NN denotes Fc
T420 60062-60065 CC denotes and
T421 60066-60069 PRP-DOLLAR- denotes its
T422 60070-60076 NN denotes glycan
T423 60077-60080 VBZ denotes has
T424 60081-60087 VBN denotes proved
T425 60088-60089 DT denotes a
T426 60090-60096 JJ denotes potent
T427 60097-60100 CC denotes and
T428 60101-60110 JJ denotes effective
T429 60111-60119 NN denotes approach
T430 60120-60123 IN denotes for
T431 60124-60134 VBG denotes increasing
T432 60135-60138 DT denotes the
T433 60139-60147 JJ denotes clinical
T434 60148-60161 NN denotes effectiveness
T435 60161-60162 -COMMA- denotes ,
T436 60163-60173 JJ denotes functional
T437 60174-60185 NN denotes specificity
T438 60186-60189 CC denotes and
T439 60190-60196 NN denotes safety
T440 60197-60199 IN denotes of
T441 60200-60211 JJ denotes therapeutic
T442 60212-60216 NNS denotes mAbs
T443 60217-60220 CC denotes and
T444 60221-60223 VBZ denotes is
T445 60224-60226 DT denotes an
T446 60227-60235 VBG denotes emerging
T447 60236-60243 NN denotes pathway
T448 60244-60246 TO denotes to
T449 60247-60250 DT denotes the
T450 60251-60262 NN denotes development
T451 60263-60265 IN denotes of
T452 60266-60269 DT denotes the
T453 60270-60280 NN denotes “next‐gen”
T454 60281-60293 NNS denotes therapeutics
T455 60295-60301 JJ denotes Future
T456 60302-60312 NNS denotes directions
T457 60313-60315 IN denotes in
T458 60316-60319 DT denotes the
T459 60320-60331 NN denotes development
T460 60332-60335 CC denotes and
T461 60336-60339 NN denotes use
T462 60340-60342 IN denotes of
T463 60343-60354 JJ denotes therapeutic
T464 60355-60365 NNS denotes antibodies
T465 60366-60372 MD denotes should
T466 60373-60385 RB denotes increasingly
T467 60386-60391 VB denotes mimic
T468 60392-60398 JJ denotes normal
T469 60399-60409 JJ denotes protective
T470 60410-60418 NN denotes antibody
T471 60419-60428 NNS denotes responses
T472 60428-60429 -COMMA- denotes ,
T473 60430-60435 WDT denotes which
T474 60436-60439 VBP denotes are
T475 60440-60450 JJ denotes polyclonal
T476 60451-60454 CC denotes and
T477 60455-60463 VBN denotes elicited
T478 60464-60466 IN denotes in
T479 60467-60470 DT denotes the
T480 60471-60478 NN denotes context
T481 60479-60481 IN denotes of
T482 60482-60488 JJ denotes innate
T483 60489-60497 NN denotes receptor
T484 60498-60508 NN denotes engagement
T485 60509-60514 WDT denotes which
T486 60515-60523 VBZ denotes includes
T487 60524-60527 DT denotes the
T488 60528-60531 NNS denotes FcR
T489 60532-60534 RB denotes as
T490 60535-60539 RB denotes well
T491 60540-60542 IN denotes as
T492 60543-60548 JJ denotes other
T493 60549-60559 RB denotes powerfully
T494 60560-60570 JJ denotes responsive
T495 60571-60578 NNS denotes systems
T496 60579-60588 VBG denotes including
T497 60589-60592 DT denotes the
T498 60593-60602 JJ denotes Toll‐like
T499 60603-60612 NNS denotes receptors
T500 60613-60616 CC denotes and
T501 60617-60627 NN denotes complement
T502 60628-60637 NNS denotes receptors
T503 60639-60650 RB denotes Furthermore
T504 60650-60651 -COMMA- denotes ,
T505 60652-60655 DT denotes the
T506 60656-60661 JJ denotes mixed
T507 60662-60670 NN denotes subclass
T508 60671-60677 NN denotes nature
T509 60678-60680 IN denotes of
T510 60681-60686 DT denotes these
T511 60687-60693 JJ denotes normal
T512 60694-60702 NN denotes antibody
T513 60703-60712 NNS denotes responses
T514 60713-60721 VBZ denotes suggests
T515 60722-60726 IN denotes that
T516 60727-60740 NNS denotes circumstances
T517 60741-60744 MD denotes may
T518 60745-60750 VB denotes arise
T519 60751-60753 IN denotes in
T520 60754-60765 JJ denotes therapeutic
T521 60766-60776 NNS denotes strategies
T522 60777-60782 WRB denotes where
T523 60783-60788 EX denotes there
T524 60789-60791 VBZ denotes is
T525 60792-60797 NN denotes value
T526 60798-60800 IN denotes in
T527 60801-60807 VBG denotes having
T528 60808-60818 RB denotes distinctly
T529 60819-60827 VBN denotes modified
T530 60828-60831 NNS denotes Fcs
T531 60832-60835 IN denotes for
T532 60836-60839 DT denotes the
T533 60840-60847 JJ denotes nuanced
T534 60848-60858 NN denotes engagement
T535 60859-60861 IN denotes of
T536 60862-60871 JJ denotes different
T537 60872-60876 NN denotes FcγR
T538 60877-60883 NN denotes family
T539 60884-60891 NNS denotes members
T540 60893-60903 NNS denotes Treatments
T541 60904-60914 VBG denotes comprising
T542 60915-60923 JJ denotes multiple
T543 60924-60928 NNS denotes mAbs
T544 60929-60932 CC denotes and
T545 60933-60939 JJ denotes immune
T546 60940-60950 NNS denotes stimulants
T547 60951-60954 VBP denotes are
T548 60955-60960 IN denotes under
T549 60961-60974 NN denotes investigation
T550 60975-60977 IN denotes in
T551 60978-60988 JJ denotes infectious
T552 60989-60996 NN denotes disease
T0 57351-57354 DT denotes The
T1 57355-57365 NN denotes expression
T2 57366-57368 IN denotes of
T3 57369-57376 NN denotes FcγRIIb
T4 57377-57379 IN denotes on
T5 57380-57384 NNP denotes LSEC
T6 57385-57388 CC denotes and
T7 57389-57392 PRP-DOLLAR- denotes its
T8 57393-57399 NN denotes action
T9 57400-57402 IN denotes in
T10 57403-57406 DT denotes the
T11 57407-57417 NN denotes “sweeping”
T12 57418-57420 CC denotes or
T13 57421-57428 NN denotes removal
T14 57429-57431 IN denotes of
T15 57432-57437 JJ denotes small
T16 57438-57444 JJ denotes immune
T17 57445-57454 NNS denotes complexes
T18 57455-57458 VBZ denotes has
T19 57459-57465 VBN denotes opened
T553 60997-61000 IN denotes for
T554 61001-61015 NN denotes neutralization
T555 61016-61024 NN denotes coverage
T556 61025-61027 IN denotes of
T557 61028-61035 JJ denotes variant
T558 61036-61043 NNS denotes strains
T559 61045-61051 RB denotes Indeed
T560 61051-61052 -COMMA- denotes ,
T561 61053-61057 PDT denotes such
T562 61058-61060 DT denotes an
T563 61061-61069 NN denotes approach
T564 61070-61073 MD denotes may
T565 61074-61076 VB denotes be
T566 61077-61081 RBS denotes most
T567 61082-61091 JJ denotes effective
T568 61092-61094 IN denotes in
T569 61095-61103 VBG denotes emerging
T570 61104-61114 JJ denotes infectious
T571 61115-61122 NN denotes disease
T572 61123-61127 JJ denotes such
T573 61128-61130 IN denotes as
T574 61131-61137 JJ denotes severe
T575 61138-61143 JJ denotes acute
T576 61144-61155 JJ denotes respiratory
T577 61156-61164 NN denotes syndrome
T578 61165-61176 NN denotes coronavirus
T579 61177-61178 CD denotes 2
T580 61179-61180 -LRB- denotes (
T581 61180-61190 NN denotes SARS‐CoV‐2
T582 61190-61191 -RRB- denotes )
T583 61192-61201 NN denotes infection
T584 61203-61206 DT denotes The
T585 61207-61210 NN denotes use
T586 61211-61213 IN denotes of
T587 61214-61222 JJ denotes multiple
T588 61223-61227 NNS denotes mAbs
T589 61228-61236 VBN denotes tailored
T590 61237-61240 IN denotes for
T591 61241-61249 JJ denotes distinct
T592 61250-61258 NN denotes effector
T593 61259-61268 NNS denotes functions
T594 61269-61272 CC denotes and
T595 61273-61282 VBG denotes targeting
T596 61283-61292 JJ denotes different
T597 61293-61301 NNS denotes epitopes
T598 61302-61306 MD denotes will
T599 61307-61315 VB denotes maximize
T600 61316-61319 DT denotes the
T601 61320-61331 NN denotes opportunity
T602 61332-61335 IN denotes for
T603 61336-61347 NN denotes cocktailing
T604 61348-61350 IN denotes of
T605 61351-61359 NN denotes effector
T606 61360-61369 NNS denotes functions
T607 61370-61372 IN denotes in
T608 61373-61382 JJ denotes different
T609 61383-61388 NNS denotes types
T610 61389-61391 IN denotes of
T611 61392-61400 NNS denotes diseases
T612 61402-61408 RB denotes Indeed
T613 61408-61409 -COMMA- denotes ,
T614 61410-61412 IN denotes in
T615 61413-61414 DT denotes a
T616 61415-61420 JJ denotes small
T617 61421-61424 CC denotes but
T618 61425-61437 JJ denotes contemporary
T619 61438-61445 NN denotes example
T620 61446-61453 IN denotes outside
T621 61454-61456 IN denotes of
T622 61457-61467 JJ denotes infectious
T623 61468-61475 NN denotes disease
T624 61475-61476 -COMMA- denotes ,
T625 61477-61480 DT denotes the
T626 61481-61493 NNP denotes FDA‐approved
T627 61494-61505 NN denotes combination
T628 61506-61508 IN denotes in
T629 61509-61523 NN denotes adenocarcinoma
T630 61524-61531 NN denotes therapy
T631 61532-61536 VBZ denotes uses
T632 61537-61538 DT denotes a
T633 61539-61547 NN denotes cocktail
T634 61548-61550 IN denotes of
T635 61551-61554 CD denotes two
T636 61555-61559 NNS denotes mAbs
T637 61559-61560 -COMMA- denotes ,
T638 61561-61571 NN denotes pertuzumab
T639 61572-61575 CC denotes and
T640 61576-61587 NN denotes trastuzumab
T641 61587-61588 -COMMA- denotes ,
T642 61589-61596 IN denotes against
T643 61597-61605 NN denotes Her2.123
T644 61606-61612 RB denotes Rather
T645 61613-61617 IN denotes than
T646 61618-61621 CD denotes one
T647 61622-61626 NN denotes type
T648 61627-61629 IN denotes of
T649 61630-61632 NN denotes Fc
T650 61633-61635 TO denotes to
T651 61636-61643 VB denotes conquer
T652 61644-61647 DT denotes all
T653 61647-61648 -COMMA- denotes ,
T654 61649-61652 DT denotes the
T655 61653-61661 JJ denotes combined
T656 61662-61665 NN denotes use
T657 61666-61668 IN denotes of
T658 61669-61682 RB denotes appropriately
T659 61683-61691 VBN denotes selected
T660 61692-61696 NNS denotes mAbs
T661 61697-61702 WP-DOLLAR- denotes whose
T662 61703-61713 JJ denotes individual
T663 61714-61724 NNS denotes components
T664 61725-61728 VBP denotes are
T665 61729-61737 VBN denotes enhanced
T666 61738-61741 IN denotes for
T667 61742-61745 DT denotes the
T668 61746-61756 NN denotes engagement
T669 61757-61759 IN denotes of
T670 61760-61769 JJ denotes different
T671 61770-61774 NN denotes FcγR
T672 61775-61782 NNS denotes members
T673 61783-61786 MD denotes may
T674 61787-61794 VB denotes utilize
T675 61795-61803 JJ denotes multiple
T676 61804-61814 NNS denotes components
T677 61815-61817 IN denotes of
T678 61818-61821 DT denotes the
T679 61822-61830 NN denotes spectrum
T680 61831-61833 IN denotes of
T681 61834-61842 NN denotes effector
T682 61843-61852 NNS denotes responses
T683 61853-61855 IN denotes on
T684 61856-61861 NN denotes offer
T685 61862-61864 IN denotes by
T686 61865-61868 DT denotes the
T687 61869-61875 JJ denotes immune
T688 61876-61882 NN denotes system
T689 61884-61888 JJ denotes Such
T690 61889-61899 NN denotes “next‐gen”
T691 61900-61909 NNS denotes biologics
T692 61910-61914 MD denotes will
T693 61915-61920 VB denotes begin
T694 61921-61923 TO denotes to
T695 61924-61931 VB denotes realize
T696 61932-61935 DT denotes the
T697 61936-61940 JJ denotes full
T698 61941-61950 NN denotes potential
T699 61951-61953 IN denotes of
T700 61954-61967 JJ denotes FcγR‐mediated
T701 61968-61976 NN denotes antibody
T702 61977-61983 JJ denotes immune
T703 61984-61996 NNS denotes therapeutics
T704 61997-62000 CC denotes and
T705 62001-62006 VB denotes offer
T706 62007-62023 JJ denotes transformational
T707 62024-62030 NN denotes change
T708 62031-62034 IN denotes for
T709 62035-62038 DT denotes the
T710 62039-62048 NN denotes treatment
T711 62049-62051 IN denotes of
T712 62052-62063 JJ denotes intractable
T713 62064-62067 CC denotes and
T714 62068-62077 JJ denotes incurable
T715 62078-62086 NNS denotes diseases
T716 62089-62097 NN denotes Conflict
T717 62098-62100 IN denotes of
T718 62101-62109 NN denotes Interest
T719 62110-62114 NN denotes None
T720 62117-62132 NNS denotes Acknowledgments
T721 62133-62135 PRP denotes We
T722 62136-62141 VBP denotes thank
T723 62142-62148 NNP denotes Halina
T724 62149-62154 NNP denotes Trist
T725 62155-62158 IN denotes for
T726 62159-62169 NN denotes assistance
T727 62170-62174 IN denotes with
T728 62175-62178 DT denotes the
T729 62179-62189 NN denotes manuscript
T730 62191-62193 PRP denotes We
T731 62194-62198 RB denotes also
T732 62199-62204 VBP denotes thank
T733 62205-62210 NNP denotes NHMRC
T734 62210-62211 -COMMA- denotes ,
T735 62212-62218 NNP denotes Janina
T736 62219-62222 CC denotes and
T737 62223-62227 NNP denotes Bill
T738 62228-62233 NNP denotes Amiet
T739 62234-62239 NNP denotes Trust
T740 62239-62240 -COMMA- denotes ,
T741 62241-62249 NNP denotes Margaret
T742 62250-62256 NNP denotes Walkom
T743 62257-62262 NNP denotes Trust
T744 62263-62266 CC denotes and
T745 62267-62272 NNP denotes Nancy
T746 62273-62274 NNP denotes E
T747 62275-62285 NNP denotes Pendergast
T748 62286-62291 NNP denotes Trust
T749 62291-62292 -COMMA- denotes ,
T750 62293-62299 NNP denotes Genmab
T751 62299-62300 -COMMA- denotes ,
T752 62301-62304 IN denotes for
T753 62305-62310 PRP-DOLLAR- denotes their
T754 62311-62318 NN denotes support
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R2 T3 T2 arg2Of FcγRIIb,of
R3 T1 T4 arg1Of expression,on
R4 T5 T4 arg2Of LSEC,on
R5 T1 T6 arg1Of expression,and
R6 T8 T6 arg2Of action,and
R7 T8 T7 arg1Of action,its
R8 T8 T9 arg1Of action,in
R9 T12 T9 arg2Of or,in
R10 T12 T10 arg1Of or,the
R11 T11 T12 arg1Of “sweeping”,or
R12 T13 T12 arg2Of removal,or
R13 T12 T14 arg1Of or,of
R14 T17 T14 arg2Of complexes,of
R15 T17 T15 arg1Of complexes,small
R16 T17 T16 arg1Of complexes,immune
R17 T6 T18 arg1Of and,has
R18 T19 T18 arg2Of opened,has
R19 T6 T19 arg1Of and,opened
R20 T22 T19 arg2Of possibilities,opened
R21 T19 T20 arg1Of opened,up
R22 T22 T21 arg1Of possibilities,new
R23 T22 T23 arg1Of possibilities,for
R24 T25 T23 arg2Of application,for
R25 T25 T24 arg1Of application,the
R26 T25 T26 arg1Of application,of
R27 T30 T26 arg2Of or,of
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R29 T29 T28 arg1Of Antibodies,modifications.17
R30 T29 T30 arg1Of Antibodies,or
R31 T33 T30 arg2Of proteins,or
R32 T33 T31 arg1Of proteins,Fc
R33 T33 T32 arg1Of proteins,fusion
R34 T22 T34 arg1Of possibilities,","
R35 T37 T35 arg1Of MOA,whose
R36 T22 T35 arg2Of possibilities,whose
R37 T37 T36 arg1Of MOA,primary
R38 T37 T38 arg1Of MOA,is
R39 T40 T38 arg2Of neutralization,is
R40 T40 T39 arg1Of neutralization,the
R41 T40 T41 arg1Of neutralization,of
R42 T43 T41 arg2Of molecules,of
R43 T43 T42 arg1Of molecules,soluble
R44 T45 T44 arg1Of as,such
R45 T43 T45 arg1Of molecules,as
R46 T47 T45 arg2Of or,as
R47 T46 T47 arg1Of IgE,or
R48 T48 T47 arg2Of cytokines,or
R49 T38 T49 arg1Of is,","
R50 T50 T49 arg2Of are,","
R51 T37 T50 arg1Of MOA,are
R52 T53 T50 arg2Of candidates,are
R53 T52 T51 arg1Of attractive,particularly
R54 T53 T52 arg1Of candidates,attractive
R55 T53 T54 arg1Of candidates,for
R56 T56 T54 arg2Of approach,for
R57 T56 T55 arg1Of approach,this
R58 T57 T58 arg1Of Proof‐of‐concept,for
R59 T60 T58 arg2Of strategy,for
R60 T60 T59 arg1Of strategy,this
R61 T57 T61 arg1Of Proof‐of‐concept,has
R62 T63 T61 arg2Of demonstrated,has
R63 T57 T62 arg1Of Proof‐of‐concept,been
R64 T63 T62 arg2Of demonstrated,been
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R66 T63 T64 arg1Of demonstrated,in
R67 T66 T64 arg2Of models.48,in
R68 T66 T65 arg1Of models.48,experimental
R69 T66 T67 arg1Of models.48,Indeed
R70 T63 T68 arg1Of demonstrated,","
R71 T71 T68 arg2Of be,","
R72 T69 T70 arg1Of this,may
R73 T71 T70 arg2Of be,may
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R367 T358 T356 arg1Of Strategies,Future
R368 T358 T357 arg1Of Strategies,Engineering
R369 T360 T359 arg1Of antibodies,Monoclonal
R370 T360 T361 arg1Of antibodies,are
R371 T363 T361 arg2Of therapeutics,are
R372 T363 T362 arg1Of therapeutics,potent
R373 T361 T364 arg1Of are,in
R374 T366 T364 arg2Of number,in
R375 T366 T365 arg1Of number,a
R376 T366 T367 arg1Of number,of
R377 T372 T367 arg2Of diseases,of
R378 T372 T368 arg1Of diseases,chronic
R379 T368 T369 arg1Of chronic,or
R380 T371 T369 arg2Of incurable,or
R381 T371 T370 arg1Of incurable,once
R382 T372 T371 arg1Of diseases,incurable
R383 T376 T373 arg1Of is,However
R384 T376 T374 arg1Of is,","
R385 T375 T376 arg1Of there,is
R386 T384 T376 arg2Of as,is
R387 T376 T377 arg1Of is,still
R388 T380 T378 arg1Of clinical,extensive
R389 T380 T379 arg1Of clinical,unmet
R390 T381 T380 arg1Of need,clinical
R391 T384 T382 arg1Of as,as
R392 T384 T383 arg1Of as,well
R393 T381 T384 arg1Of need,as
R394 T386 T384 arg2Of room,as
R395 T386 T385 arg1Of room,considerable
R396 T386 T387 arg1Of room,for
R397 T388 T387 arg2Of improvement,for
R398 T388 T389 arg1Of improvement,in
R399 T392 T389 arg2Of therapeutics,in
R400 T392 T390 arg1Of therapeutics,many
R401 T392 T391 arg1Of therapeutics,existing
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable
R736 T716 T717 arg1Of Conflict,of
R737 T718 T717 arg2Of Interest,of
R738 T721 T722 arg1Of We,thank
R739 T724 T722 arg2Of Trist,thank
R740 T724 T723 arg1Of Trist,Halina
R741 T722 T725 arg1Of thank,for
R742 T726 T725 arg2Of assistance,for
R743 T726 T727 arg1Of assistance,with
R744 T729 T727 arg2Of manuscript,with
R745 T729 T728 arg1Of manuscript,the
R746 T732 T731 arg1Of thank,also
R747 T730 T732 arg1Of We,thank
R748 T749 T732 arg2Of ",",thank
R749 T733 T734 arg1Of NHMRC,","
R750 T735 T734 arg2Of Janina,","
R751 T734 T736 arg1Of ",",and
R752 T739 T736 arg2Of Trust,and
R753 T739 T737 arg1Of Trust,Bill
R754 T739 T738 arg1Of Trust,Amiet
R755 T736 T740 arg1Of and,","
R756 T743 T740 arg2Of Trust,","
R757 T743 T741 arg1Of Trust,Margaret
R758 T743 T742 arg1Of Trust,Walkom
R759 T740 T744 arg1Of ",",and
R760 T748 T744 arg2Of Trust,and
R761 T748 T745 arg1Of Trust,Nancy
R762 T748 T746 arg1Of Trust,E
R763 T748 T747 arg1Of Trust,Pendergast
R764 T744 T749 arg1Of and,","
R765 T750 T749 arg2Of Genmab,","
R766 T732 T751 arg1Of thank,","
R767 T732 T752 arg1Of thank,for
R768 T754 T752 arg2Of support,for
R769 T754 T753 arg1Of support,their

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 822-836 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T2 1603-1610 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T3 5042-5050 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T4 6307-6315 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T5 6649-6657 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T6 8560-8568 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T7 11819-11822 Chemical denotes Phe http://purl.obolibrary.org/obo/CHEBI_17295|http://purl.obolibrary.org/obo/CHEBI_29997
T9 12960-12969 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T10 13199-13209 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T12 16007-16017 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976
T13 17809-17819 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T14 19795-19809 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T15 20577-20585 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T16 20910-20918 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T17 21041-21049 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T18 21134-21142 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T19 21160-21168 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T20 21218-21223 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059
T21 21227-21234 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T22 21235-21243 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T23 22659-22676 Chemical denotes glycosaminoglycan http://purl.obolibrary.org/obo/CHEBI_18085
T24 22732-22745 Chemical denotes glycoproteins http://purl.obolibrary.org/obo/CHEBI_17089
T25 23559-23567 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T26 23694-23702 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T27 24709-24720 Chemical denotes polypeptide http://purl.obolibrary.org/obo/CHEBI_15841
T28 27722-27736 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T29 32283-32293 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T30 33004-33017 Chemical denotes phenylalanine http://purl.obolibrary.org/obo/CHEBI_28044|http://purl.obolibrary.org/obo/CHEBI_58095
T32 33018-33024 Chemical denotes valine http://purl.obolibrary.org/obo/CHEBI_27266
T33 33534-33543 Chemical denotes histidine http://purl.obolibrary.org/obo/CHEBI_27570
T34 33764-33772 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_32696|http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016
T37 34817-34827 Chemical denotes asparagine http://purl.obolibrary.org/obo/CHEBI_22653
T38 35188-35194 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T39 35212-35227 Chemical denotes oligosaccharide http://purl.obolibrary.org/obo/CHEBI_50699
T40 35655-35664 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T41 36272-36281 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T42 36327-36338 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T43 36670-36679 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T44 36795-36804 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T45 37745-37752 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T46 42823-42833 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T47 43806-43813 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T48 46137-46143 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T49 46173-46179 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T50 47296-47302 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T51 47507-47518 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T52 47537-47548 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T53 48200-48211 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T54 52089-52099 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T55 52236-52243 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T56 52311-52318 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449
T57 52548-52558 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T58 52724-52735 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T59 53579-53589 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T61 54312-54320 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T62 56647-56655 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_32696|http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016
T65 57569-57577 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
1 33-37 Gene denotes FcγR Gene:2213
100 6910-6913 Disease denotes APC MESH:D011125
1003 50422-50428 Gene denotes CTLA‐4 Gene:1493
1004 50436-50441 Gene denotes PD‐L1 Gene:29126
1005 50442-50446 Gene denotes PD‐1 Gene:5133
1006 50656-50660 Gene denotes PD‐1 Gene:5133
1007 50888-50894 Gene denotes CTLA‐4 Gene:1493
1008 50222-50226 Gene denotes FcγR Gene:2213
1009 50085-50089 Gene denotes FcγR Gene:2213
101 7424-7436 Disease denotes cytotoxicity MESH:D064420
1010 49976-49980 Gene denotes FcγR Gene:2213
1011 50603-50616 Chemical denotes Pembrolizumab MESH:C582435
1012 50618-50627 Chemical denotes nivolumab MESH:D000077594
1013 50632-50642 Chemical denotes cemiplimab MESH:C000627974
1014 50864-50876 Chemical denotes tremelimumab MESH:C520704
1015 50544-50549 Disease denotes tumor MESH:D009369
1016 50691-50697 Disease denotes cancer MESH:D009369
1017 50790-50795 Mutation denotes S228P rs1469294455
1022 51112-51117 Gene denotes FcγRI Gene:2214
1023 51321-51326 Gene denotes FcγRI Gene:2214
1024 51404-51411 Gene denotes FcγRIIb Gene:2213
1025 51298-51302 Gene denotes PD‐1 Gene:5133
1031 51957-51962 Gene denotes PD‐L1 Gene:29126
1032 52027-52031 Gene denotes FcγR Gene:2213
1033 51855-51859 Gene denotes FcγR Gene:2213
1034 51811-51826 Chemical denotes N‐linked glycan
1035 51930-51942 Chemical denotes Atezolizumab MESH:C000594389
1044 52408-52412 Gene denotes FcγR Gene:2213
1045 52164-52168 Gene denotes FcγR Gene:2213
1046 52116-52120 Gene denotes FcγR Gene:2213
1047 52236-52243 Chemical denotes leucine MESH:D007930
1048 52311-52318 Chemical denotes alanine MESH:D000409
1049 52466-52476 Chemical denotes teplizumab MESH:C502540
1050 52481-52491 Chemical denotes spesolimab
1051 52320-52331 Mutation denotes L234A L235A p.L234,235A,A
1063 52770-52775 Gene denotes PD‐L1 Gene:29126
1064 53087-53090 Gene denotes C1q Gene:712
1065 53034-53038 Gene denotes FcγR Gene:2213
1066 52638-52642 Gene denotes FcγR Gene:2213
1067 52997-53001 Gene denotes FcγR Gene:2213
1068 52577-52581 Gene denotes FcγR Gene:2213
1069 52753-52763 Chemical denotes durvalumab MESH:C000613593
1070 52781-52792 Chemical denotes anifrolumab MESH:C582345
1071 52879-52884 Mutation denotes L234F p.L234F
1072 52918-52923 Mutation denotes L235E p.L235E
1073 52947-52952 Mutation denotes P331S p.P331S
1088 53182-53187 Gene denotes FcγRI Gene:2214
1089 53192-53199 Gene denotes FcγRIIb Gene:2213
1090 53455-53459 Gene denotes FcγR Gene:2213
1091 53254-53258 Gene denotes FcγR Gene:2213
1092 53757-53761 Gene denotes FcγR Gene:2213
1093 53579-53589 Chemical denotes disulfides MESH:D004220
1094 53215-53241 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 53370-53375 Mutation denotes E233P p.E233P
1096 53377-53382 Mutation denotes F234V rs755807976
1097 53384-53389 Mutation denotes L235A p.L235A
1098 53417-53422 Mutation denotes D265A p.D265A
1099 53520-53525 Mutation denotes S228P rs1469294455
1100 53538-53543 Mutation denotes L309V p.L309V
1101 53548-53553 Mutation denotes R409K p.R409K
1104 53981-53985 Gene denotes FcγR Gene:2213
1105 53850-53854 Gene denotes FcγR Gene:2213
1110 54136-54143 Gene denotes FcγRIIb Gene:2213
1111 54164-54168 Gene denotes FcγR Gene:2213
1113 54312-54320 Chemical denotes tyrosine MESH:D014443
1122 54420-54427 Gene denotes FcγRIIb Gene:2213
1123 54622-54625 Gene denotes BCR Gene:613
1124 55011-55018 Gene denotes FcγRIIb Gene:2213
1125 55112-55119 Gene denotes FcγRIIb Gene:2213
1126 54775-54779 Gene denotes FcγR Gene:2213
1127 55127-55129 Chemical denotes Fc
1128 54664-54692 Disease denotes systemic lupus erythematosus MESH:D008180
1129 54742-54751 Disease denotes allergies MESH:D004342
1136 55382-55385 Gene denotes BCR Gene:613
1137 55508-55515 Gene denotes FcγRIIb Gene:2213
1138 55592-55595 Gene denotes BCR Gene:613
1139 55322-55340 Disease denotes autoimmune disease MESH:D001327
1140 55431-55436 Mutation denotes S267E p.S267E
1141 55441-55446 Mutation denotes L328F p.L328F
1147 56262-56269 Gene denotes FcγRIIb Gene:2213
1148 56214-56217 Gene denotes BCR Gene:613
1149 55659-55677 Disease denotes IgE mAb omalizumab MESH:D007589
1150 55723-55741 Disease denotes allergic disorders MESH:D004342
1151 56484-56491 Disease denotes allergy MESH:D004342
1162 56694-56701 Gene denotes FcγRIIb Gene:2213
1163 57237-57244 Gene denotes FcγRIIb Gene:2213
1164 56974-56981 Gene denotes FcγRIIa Gene:2212
1165 57009-57017 Species denotes patients Tax:9606
1166 56647-56655 Chemical denotes arginine MESH:D001120
1167 57173-57178 Mutation denotes P238D p.P238D
1168 57180-57185 Mutation denotes E233D p.E233D
1169 57187-57192 Mutation denotes G237D p.G237D
1170 57201-57206 Mutation denotes P271G p.P271G
1171 57211-57216 Mutation denotes A330R p.A330R
1176 57369-57376 Gene denotes FcγRIIb Gene:2213
1177 57510-57517 Gene denotes FcγRIIb Gene:2213
1178 57968-57975 Gene denotes FcγRIIb Gene:2213
1179 57909-57917 Species denotes patients Tax:9606
1181 58057-58061 Gene denotes FcγR Gene:2213
1188 58324-58328 Gene denotes OX40 Gene:7293
1189 58401-58404 Gene denotes DR4 Gene:3126
119 7762-7770 Gene denotes FcγRIIIa Gene:2214
1190 58406-58409 Gene denotes DR5 Gene:8795
1191 58317-58322 Gene denotes 4‐1BB Gene:3604
1192 58363-58368 Disease denotes death MESH:D003643
1193 58382-58388 Disease denotes cancer MESH:D009369
1197 58513-58520 Gene denotes FcγRIIb Gene:2213
1198 58645-58652 Gene denotes FcγRIIb Gene:2213
1199 58432-58436 Gene denotes FcγR Gene:2213
120 7863-7871 Gene denotes FcγRIIIa Gene:2214
1206 59005-59012 Gene denotes FcγRIIb Gene:2213
1207 59145-59148 Gene denotes DR5 Gene:8795
1208 59344-59351 Gene denotes FcγRIIb Gene:2213
1209 59409-59413 Gene denotes OX40 Gene:7293
121 7873-7880 Gene denotes FcγRIIa Gene:2212
1210 59196-59201 Disease denotes death MESH:D003643
1211 59206-59228 Disease denotes decreased tumor growth MESH:D006130
1215 59499-59506 Gene denotes FcγRIIb Gene:2213
1216 59583-59588 Gene denotes CD137 Gene:3604
1217 59610-59614 Gene denotes OX40 Gene:7293
122 7882-7887 Gene denotes FcγRI Gene:2214
1220 59942-59946 Gene denotes FcγR Gene:2213
1221 60070-60076 Chemical denotes glycan MESH:D011134
123 7959-7964 Gene denotes FcγRI Gene:2214
1233 60872-60876 Gene denotes FcγR Gene:2213
1234 61597-61601 Gene denotes Her2 Gene:2064
1235 61131-61178 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
1236 61180-61190 Species denotes SARS‐CoV‐2 Tax:2697049
1237 61561-61571 Chemical denotes pertuzumab MESH:C485206
1238 61576-61587 Chemical denotes trastuzumab MESH:D000068878
1239 60978-60996 Disease denotes infectious disease MESH:D003141
124 7966-7974 Gene denotes FcγRIIIa Gene:2214
1240 61104-61122 Disease denotes infectious disease MESH:D003141
1241 61192-61201 Disease denotes infection MESH:D007239
1242 61457-61475 Disease denotes infectious disease MESH:D003141
1243 61509-61523 Disease denotes adenocarcinoma MESH:D000230
1246 61770-61774 Gene denotes FcγR Gene:2213
1247 61954-61958 Gene denotes FcγR Gene:2213
125 8105-8108 Gene denotes BCR Gene:613
126 8174-8181 Gene denotes FcγRIIb Gene:2213
127 8242-8249 Gene denotes FcγRIIb Gene:2213
128 8487-8494 Gene denotes FcγRIIb Gene:2213
129 8501-8508 Gene denotes FcγRIIa Gene:2212
131 8461-8465 Gene denotes FcγR Gene:2213
132 8139-8143 Gene denotes FcγR Gene:2213
134 7950-7957 Gene denotes FcγRIIa Gene:2212
135 7717-7729 Disease denotes cytotoxicity MESH:D064420
141 8560-8568 Chemical denotes tyrosine MESH:D014443
145 8756-8764 Disease denotes COVID-19 MESH:C000657245
150 9314-9318 Gene denotes FcRn Gene:2217
151 9443-9459 Gene denotes Fc receptor‐like Gene:84824
152 9113-9117 Gene denotes FcγR Gene:2213
153 9097-9102 Species denotes human Tax:9606
16 1754-1761 Gene denotes FcγRIIb Gene:2213
17 1870-1874 Gene denotes FcγR Gene:2213
170 9616-9621 Gene denotes FcγRI Gene:2214
171 9632-9639 Gene denotes FcγRIIc Gene:9103
172 9641-9649 Gene denotes FcγRIIIa Gene:2214
173 9694-9699 Gene denotes CD32a Gene:2212
174 9701-9706 Gene denotes CD32c Gene:9103
175 9708-9713 Gene denotes CD16a Gene:2214
176 9718-9723 Gene denotes CD16b Gene:2215
177 9793-9800 Gene denotes FcγRIIb Gene:2213
178 9813-9818 Gene denotes CD32b Gene:2213
179 9623-9630 Gene denotes FcγRIIa Gene:2212
18 1800-1804 Gene denotes FcγR Gene:2213
180 9505-9510 Species denotes human Tax:9606
181 9654-9662 Gene denotes FcγRIIIb Gene:2215
189 10684-10688 Gene denotes FcγR Gene:2213
19 1385-1389 Gene denotes FcγR Gene:2213
190 11168-11172 Gene denotes FcγR Gene:2213
191 10946-10950 Gene denotes FcγR Gene:2213
192 10788-10792 Gene denotes FcγR Gene:2213
193 10455-10459 Gene denotes FcγR Gene:2213
194 10668-10673 Species denotes human Tax:9606
195 10940-10945 Species denotes human Tax:9606
20 940-944 Gene denotes FcγR Gene:2213
21 583-587 Gene denotes FcγR Gene:2213
213 11318-11323 Gene denotes FcγRI Gene:2214
214 11337-11341 Gene denotes IgG3 Gene:3502
215 11360-11372 Gene denotes interferon‐γ Gene:3458
216 11475-11479 Gene denotes IgG3 Gene:3502
217 11624-11628 Gene denotes IgG3 Gene:3502
218 11645-11653 Gene denotes FcγRIIIa Gene:2214
219 11666-11670 Gene denotes IgG3 Gene:3502
22 164-169 Species denotes human Tax:9606
220 11860-11864 Gene denotes IgG3 Gene:3502
221 11878-11885 Gene denotes FcγRIIb Gene:2213
222 11898-11902 Gene denotes IgG3 Gene:3502
223 12062-12070 Gene denotes FcγRIIIb Gene:2215
224 11537-11543 Species denotes people Tax:9606
225 11839-11847 Gene denotes FcγRIIIb Gene:2215
226 11455-11462 Gene denotes FcγRIIa Gene:2212
227 11819-11822 Chemical denotes Phe MESH:D010649
228 11736-11753 Disease denotes myeloid dendritic MESH:D007635
229 12003-12020 Disease denotes myeloid dendritic MESH:D007635
23 1189-1236 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
233 12235-12241 Species denotes people Tax:9606
235 8756-8764 Disease denotes COVID-19 MESH:C000657245
24 1238-1248 Species denotes SARS‐CoV‐2 Tax:2697049
246 13217-13222 Gene denotes FcγRI Gene:2214
247 13224-13231 Gene denotes FcγRIIb Gene:2213
248 13242-13245 Gene denotes CH1 Gene:51430
249 12881-12884 Gene denotes CH1 Gene:51430
25 1593-1599 Chemical denotes glycan MESH:D011134
250 12740-12744 Gene denotes FcγR Gene:2213
252 13233-13240 Gene denotes FcγRIIc Gene:9103
253 12865-12872 Gene denotes FcγRIIa Gene:2212
254 12960-12969 Chemical denotes disulfide MESH:D004220
255 13199-13209 Chemical denotes disulfides MESH:D004220
257 8756-8764 Disease denotes COVID-19 MESH:C000657245
26 680-686 Disease denotes cancer MESH:D009369
262 13809-13813 Gene denotes FcγR Gene:2213
263 13793-13798 Species denotes human Tax:9606
27 1127-1134 Disease denotes cancers MESH:D009369
275 14445-14450 Gene denotes FcγRI Gene:2214
276 14455-14462 Gene denotes FcγRIIb Gene:2213
277 14570-14575 Gene denotes FcγRI Gene:2214
278 14577-14584 Gene denotes FcγRIIa Gene:2212
279 14589-14597 Gene denotes FcγRIIIa Gene:2214
28 1136-1157 Disease denotes inflammatory diseases MESH:D007249
280 14605-14612 Gene denotes FcγRIIb Gene:2213
281 14528-14535 Gene denotes FcγRIIa Gene:2212
282 14411-14415 Gene denotes FcγR Gene:2213
283 14157-14161 Gene denotes FcγR Gene:2213
285 14103-14108 Species denotes human Tax:9606
287 14659-14663 Gene denotes FcγR Gene:2213
29 1170-1180 Disease denotes infections MESH:D007239
294 14768-14780 Gene denotes interferon‐γ Gene:3458
295 14903-14908 Gene denotes FcγRI Gene:14129
296 14912-14924 Gene denotes interferon‐γ Gene:15978
297 15009-15014 Species denotes mouse Tax:10090
306 15487-15492 Species denotes human Tax:9606
307 15675-15680 Species denotes human Tax:9606
308 15506-15511 Species denotes human Tax:9606
309 15420-15437 Disease denotes thrombocytopenias MESH:D013921
31 2372-2376 Gene denotes FcγR Gene:2213
310 15756-15784 Disease denotes systemic lupus erythematosus MESH:D008180
311 15838-15854 Disease denotes hyper‐responsive MESH:D012130
318 16264-16271 Gene denotes FcγRIIb Gene:2213
319 16385-16392 Gene denotes FcγRIIc Gene:9103
320 15965-15969 Gene denotes FcγR Gene:2213
322 16079-16085 Species denotes humans Tax:9606
323 16371-16378 Gene denotes FcγRIIa Gene:2212
335 16632-16639 Gene denotes FcγRIII Gene:2214
336 16684-16692 Gene denotes FcγRIIIa Gene:2214
337 16697-16705 Gene denotes FcγRIIIb Gene:2215
338 16711-16719 Gene denotes FcγRIIIa Gene:2214
339 16834-16842 Gene denotes FcγRIIIa Gene:2214
340 17282-17289 Gene denotes FcγRIIa Gene:2212
341 16954-16960 Species denotes humans Tax:9606
342 17098-17103 Species denotes human Tax:9606
343 17202-17210 Gene denotes FcγRIIIb Gene:2215
344 16932-16940 Gene denotes FcγRIIIb Gene:2215
345 17181-17188 Gene denotes FcγRIIa Gene:2212
35 2796-2817 Disease denotes inflammatory diseases MESH:D007249
354 17684-17691 Gene denotes FcγRIIb Gene:2213
355 17744-17752 Gene denotes FcγRIIb1 Gene:1555
356 17898-17921 Gene denotes B‐cell antigen receptor Gene:613
357 17923-17926 Gene denotes BCR Gene:613
358 18149-18157 Gene denotes FcγRIIb1 Gene:1555
359 17619-17623 Gene denotes FcγR Gene:2213
36 2830-2837 Disease denotes cancers MESH:D009369
360 17337-17341 Gene denotes FcγR Gene:2213
361 18307-18312 Species denotes human Tax:9606
369 18556-18564 Gene denotes FcγRIIIa Gene:2214
37 2868-2880 Disease denotes malignancies MESH:D009369
370 18599-18606 Gene denotes FcγRIIa Gene:2212
371 18608-18615 Gene denotes FcγRIIb Gene:2213
372 18619-18627 Gene denotes FcγRIIIa Gene:2214
373 18376-18380 Gene denotes FcγR Gene:2213
374 18526-18530 Gene denotes FcγR Gene:2213
375 18569-18573 Disease denotes αβ T MESH:D001260
382 18963-18967 Gene denotes FcγR Gene:2213
383 19167-19174 Gene denotes FcγRIIb Gene:2213
384 19388-19395 Gene denotes FcγRIIb Gene:2213
385 19425-19432 Gene denotes FcγRIIb Gene:2213
386 19837-19844 Gene denotes FcγRIIb Gene:2213
395 20514-20517 Gene denotes BCR Gene:613
396 20209-20212 Gene denotes BCR Gene:613
397 20455-20459 Gene denotes FcγR Gene:2213
398 20100-20104 Gene denotes FcγR Gene:2213
399 20577-20585 Chemical denotes tyrosine MESH:D014443
403 20810-20813 Gene denotes BCR Gene:613
405 21477-21481 Gene denotes FcγR Gene:2213
410 21819-21823 Gene denotes FcγR Gene:2213
411 22508-22512 Gene denotes FcγR Gene:2213
412 22075-22079 Gene denotes FcγR Gene:2213
413 21945-21949 Gene denotes FcγR Gene:2213
418 23408-23413 Disease denotes flush MESH:D005483
419 23648-23660 Disease denotes cytotoxicity MESH:D064420
42 3934-3938 Gene denotes FcγR Gene:2213
420 23711-23723 Disease denotes cytotoxicity MESH:D064420
421 23830-23835 Disease denotes flush MESH:D005483
426 24326-24330 Gene denotes FcγR Gene:2213
427 24217-24221 Gene denotes FcγR Gene:2213
428 24167-24171 Chemical denotes ADCP
429 24150-24162 Disease denotes cytotoxicity MESH:D064420
43 3302-3320 Disease denotes autoimmune disease MESH:D001327
432 24480-24484 Gene denotes FcγR Gene:2213
433 24728-24734 Chemical denotes glycan MESH:D011134
44 3363-3372 Disease denotes infection MESH:D007239
443 25128-25136 Gene denotes FcγRIIIa Gene:2214
444 25389-25396 Gene denotes FcγRIIa Gene:2212
445 25401-25406 Gene denotes FcγRI Gene:2214
446 25607-25614 Gene denotes FcγRIII Gene:2214
447 25637-25644 Gene denotes FcγRIIa Gene:2212
448 25649-25654 Gene denotes FcγRI Gene:2214
449 25032-25036 Gene denotes FcγR Gene:2213
45 3400-3407 Disease denotes allergy MESH:D004342
450 25505-25513 Species denotes patients Tax:9606
451 25336-25342 Disease denotes cancer MESH:D009369
464 26007-26014 Gene denotes FcγRIIb Gene:2213
465 26147-26150 Gene denotes BCR Gene:613
466 26228-26236 Gene denotes FcγRIIb1 Gene:1555
467 26307-26312 Gene denotes FcγRI Gene:2214
468 26314-26321 Gene denotes FcγRIIa Gene:2212
469 26332-26339 Gene denotes FcγRIII Gene:2214
470 26661-26664 Gene denotes BCR Gene:613
471 26793-26796 Gene denotes BCR Gene:613
472 26856-26864 Gene denotes FcγRIIB1 Gene:1555
473 26323-26330 Gene denotes FcγRIIc Gene:9103
48 4471-4475 Gene denotes FcγR Gene:2213
481 27225-27232 Gene denotes FcγRIIb Gene:14130
482 27465-27472 Gene denotes FcγRIIb Gene:14130
483 27190-27194 Gene denotes FcγR Gene:2213
484 27052-27056 Gene denotes FcγR Gene:2213
485 26965-26971 Species denotes humans Tax:9606
486 27500-27504 Species denotes mice Tax:10090
487 27509-27515 Species denotes humans Tax:9606
49 4259-4263 Gene denotes FcγR Gene:2213
493 28125-28129 Gene denotes FcγR Gene:2213
494 28005-28009 Species denotes mice Tax:10090
495 28083-28091 Species denotes patients Tax:9606
682 40687-40691 Gene denotes HER2 Gene:2064
496 28041-28054 Disease denotes recall memory MESH:D008569
497 28183-28188 Disease denotes tumor MESH:D009369
504 28595-28600 Gene denotes FcγRI Gene:2214
505 28360-28364 Gene denotes FcγR Gene:2213
506 28269-28273 Gene denotes FcγR Gene:2213
507 28589-28594 Species denotes human Tax:9606
508 28644-28648 Species denotes mice Tax:10090
509 28604-28609 Species denotes human Tax:9606
511 29022-29029 Gene denotes FcγRIIb Gene:2213
513 29248-29255 Gene denotes FcγRIIb Gene:2213
515 29475-29479 Gene denotes FcγR Gene:2213
524 30571-30576 Gene denotes CD357 Gene:8784
525 30408-30412 Gene denotes FcγR Gene:2213
526 30370-30374 Gene denotes FcγR Gene:2213
527 30231-30235 Gene denotes FcγR Gene:2213
528 29860-29864 Gene denotes FcγR Gene:2213
529 29592-29596 Gene denotes FcγR Gene:2213
530 29463-29479 Gene denotes und mAbs by FcγR Gene:2213
531 29539-29551 Species denotes participants Tax:9606
535 30622-30626 Gene denotes FcγR Gene:2213
536 30849-30860 Chemical denotes daratumumab MESH:C556306
537 30790-30795 Disease denotes death MESH:D003643
544 31776-31781 Gene denotes FcγRI Gene:2214
545 32041-32046 Gene denotes FcγRI Gene:2214
546 32112-32124 Gene denotes interferon‐γ Gene:3458
547 31479-31483 Gene denotes FcγR Gene:2213
548 31339-31343 Gene denotes FcγR Gene:2213
549 32181-32193 Disease denotes inflammation MESH:D007249
554 32386-32390 Gene denotes IgG3 Gene:3502
555 32641-32648 Gene denotes FcγRIIb Gene:2213
556 32690-32697 Gene denotes FcγRIII Gene:2214
557 32208-32213 Species denotes human Tax:9606
562 32900-32908 Gene denotes FcγRIIIa Gene:2214
563 32829-32833 Gene denotes FcγR Gene:2213
564 33004-33017 Chemical denotes phenylalanine MESH:D010649
565 33018-33024 Chemical denotes valine MESH:D014633
572 33263-33270 Gene denotes FcγRIIb Gene:2213
573 33311-33316 Gene denotes FcγRI Gene:2214
574 33448-33455 Gene denotes FcγRIIa Gene:2212
575 33183-33187 Gene denotes FcγR Gene:2213
576 33534-33543 Chemical denotes histidine MESH:D006639
577 33764-33772 Chemical denotes arginine MESH:D001120
579 33870-33874 Gene denotes FcγR Gene:2213
58 4974-4981 Gene denotes FcγRIIb Gene:2213
583 34022-34027 Gene denotes FcγRI Gene:2214
584 33970-33974 Gene denotes FcγR Gene:2213
585 33921-33925 Gene denotes FcγR Gene:2213
588 34150-34154 Gene denotes FcγR Gene:2213
589 34191-34196 Species denotes human Tax:9606
59 5487-5494 Gene denotes FcγRIIb Gene:2213
60 5143-5147 Gene denotes FcγR Gene:2213
602 34456-34461 Gene denotes FcγRI Gene:2214
603 34473-34480 Gene denotes FcγRIII Gene:2214
604 35128-35136 Gene denotes FcγRIIIa Gene:2214
605 34463-34469 Gene denotes FcγRII Gene:2214
606 35004-35008 Gene denotes FcγR Gene:2213
607 34600-34604 Gene denotes FcγR Gene:2213
608 34427-34432 Species denotes human Tax:9606
609 34798-34813 Chemical denotes N‐linked glycan
61 4686-4690 Gene denotes FcγR Gene:2213
610 34817-34827 Chemical denotes asparagine MESH:D001216
611 34833-34837 Chemical denotes N297
612 35188-35194 Chemical denotes fucose MESH:D005643
613 35212-35227 Chemical denotes oligosaccharide MESH:D009844
617 35306-35310 Gene denotes FcγR Gene:2213
618 35477-35481 Gene denotes FcγR Gene:2213
619 35354-35358 Gene denotes FcγR Gene:2213
62 4544-4548 Gene denotes FcγR Gene:2213
621 35655-35664 Chemical denotes disulfide MESH:D004220
624 36272-36281 Chemical denotes disulfide MESH:D004220
625 36670-36679 Chemical denotes disulfide MESH:D004220
63 5521-5533 Species denotes participants Tax:9606
630 36930-36933 Gene denotes CH1 Gene:51430
631 37072-37075 Gene denotes CH1 Gene:51430
632 37384-37388 Gene denotes FcγR Gene:2213
633 36795-36804 Chemical denotes disulfide MESH:D004220
635 37471-37475 Gene denotes IgG3 Gene:3502
639 37883-37887 Gene denotes FcγR Gene:2213
64 5042-5050 Chemical denotes tyrosine MESH:D014443
641 38082-38086 Gene denotes FcγR Gene:2213
645 39109-39116 Gene denotes FcγRIIb Gene:2213
646 39039-39043 Gene denotes FcγR Gene:2213
647 38734-38739 Species denotes human Tax:9606
65 4793-4805 Disease denotes cytotoxicity MESH:D064420
652 39268-39272 Gene denotes FcγR Gene:2213
653 39842-39846 Gene denotes FcγR Gene:2213
654 39790-39794 Gene denotes FcγR Gene:2213
655 39499-39507 Species denotes patients Tax:9606
680 40514-40518 Gene denotes HER2 Gene:2064
681 40525-40529 Gene denotes EGFR Gene:1956
683 40713-40717 Gene denotes EGFR Gene:1956
684 40997-41005 Gene denotes FcγRIIIa Gene:2214
685 41026-41033 Gene denotes FcγRIIb Gene:2213
686 41086-41093 Gene denotes FcγRIIb Gene:2213
687 41108-41113 Gene denotes FcγRI Gene:2214
688 41115-41122 Gene denotes FcγRIIa Gene:2212
689 41279-41286 Gene denotes FcγRIIb Gene:2213
690 41563-41567 Gene denotes FcγR Gene:2213
691 41329-41333 Gene denotes FcγR Gene:2213
692 40986-40990 Gene denotes FcγR Gene:2213
693 40791-40795 Gene denotes FcγR Gene:2213
694 40554-40558 Gene denotes FcγR Gene:2213
695 40739-40744 Species denotes human Tax:9606
696 40646-40655 Chemical denotes rituximab MESH:D000069283
697 40669-40680 Chemical denotes trastuzumab MESH:D000068878
698 40697-40706 Chemical denotes cetuximab MESH:D000068818
699 40282-40302 Disease denotes Cytotoxic mAb cancer MESH:D064420
700 40429-40448 Disease denotes death of the cancer MESH:D009369
701 40601-40606 Disease denotes tumor MESH:D009369
702 41154-41159 Disease denotes tumor MESH:D009369
703 41211-41217 Disease denotes cancer MESH:D009369
714 42164-42172 Gene denotes FcγRIIIa Gene:2214
715 42302-42309 Gene denotes FcγRIIb Gene:2213
716 42473-42480 Gene denotes FcγRIII Gene:2214
717 42516-42524 Gene denotes FcγRIIIa Gene:2214
718 42344-42348 Gene denotes FcγR Gene:2213
719 42145-42149 Gene denotes FcγR Gene:2213
720 41994-41998 Gene denotes FcγR Gene:2213
721 42584-42591 Species denotes patient Tax:9606
722 42231-42236 Disease denotes tumor MESH:D009369
723 42649-42655 Disease denotes cancer MESH:D009369
725 42800-42815 Chemical denotes N‐linked glycan
793 43108-43134 Gene denotes Matrix Metalloproteinase 9 Gene:4318
794 43136-43140 Gene denotes MMP9 Gene:4318
795 43518-43525 Gene denotes FcγRIII Gene:2214
796 43943-43950 Gene denotes FcγRIII Gene:2214
798 44214-44221 Gene denotes FcγRIII Gene:2214
799 44270-44299 Gene denotes C–C chemokine receptor type 4 Gene:1233
800 44301-44305 Gene denotes CCR4 Gene:1233
801 44348-44355 Gene denotes FcγRIII Gene:2214
802 44490-44497 Gene denotes FcγRIII Gene:2214
803 44542-44546 Gene denotes PD‐1 Gene:5133
804 44682-44689 Gene denotes FcγRIII Gene:2214
805 44794-44801 Gene denotes FcγRIII Gene:2214
806 44850-44854 Gene denotes PD‐1 Gene:5133
807 44982-44989 Gene denotes FcγRIII Gene:2214
808 45602-45609 Gene denotes FcγRIII Gene:2214
809 45399-45403 Gene denotes FcγR Gene:2213
810 45374-45378 Gene denotes FcγR Gene:2213
811 45195-45199 Gene denotes FcγR Gene:2213
812 45097-45101 Gene denotes FcγR Gene:2213
813 43740-43744 Gene denotes FcγR Gene:2213
814 43416-43420 Gene denotes FcγR Gene:2213
815 43323-43327 Gene denotes FcγR Gene:2213
816 45482-45486 Gene denotes PD‐1 Gene:5133
817 45253-45257 Gene denotes PD‐1 Gene:5133
818 43655-43660 Gene denotes PD‐L1 Gene:29126
819 43373-43378 Gene denotes PD‐L1 Gene:29126
820 43564-43589 Disease denotes ear nose throat disorders MESH:D004427
821 43852-43871 Disease denotes Metabolic disorders MESH:D008659
822 44097-44122 Disease denotes musculoskeletal disorders MESH:D009140
823 44583-44601 Disease denotes Infectious disease MESH:D003141
824 44891-44900 Disease denotes Infection MESH:D007239
825 45003-45026 Disease denotes Hematological disorders MESH:D006402
826 45209-45228 Disease denotes Metabolic disorders MESH:D008659
827 45494-45499 Mutation denotes S228P rs1469294455
828 43668-43673 Mutation denotes L234F p.L234F
829 43675-43680 Mutation denotes L235E p.L235E
830 43682-43687 Mutation denotes P331S p.P331S
831 43401-43406 Mutation denotes N297A p.N297A
832 43251-43256 Mutation denotes L234F p.L234F
833 43258-43263 Mutation denotes L235E p.L235E
834 43265-43270 Mutation denotes P331S p.P331S
835 45265-45270 Mutation denotes S228P rs1469294455
836 44862-44867 Mutation denotes S228P rs1469294455
837 44159-44164 Mutation denotes F243L p.F243L
838 44166-44171 Mutation denotes L235V p.L235V
839 44173-44178 Mutation denotes R292P p.R292P
84 5888-5896 Gene denotes FcγRIIIa Gene:2214
840 44180-44185 Mutation denotes Y300L p.Y300L
841 44187-44192 Mutation denotes P396L p.P396L
842 44456-44461 Mutation denotes S239D p.S239D
843 44463-44468 Mutation denotes I332E p.I332E
844 44554-44559 Mutation denotes S228P rs1469294455
845 44760-44765 Mutation denotes P247I p.P247I
846 44767-44772 Mutation denotes A339Q p.A339Q
848 45174-45179 Mutation denotes L234A p.L234A
849 45286-45291 Mutation denotes L235A p.L235A
85 6051-6059 Gene denotes FcγRIIIa Gene:2214
850 45076-45081 Mutation denotes L234A p.L234A
851 45181-45186 Mutation denotes L235A p.L235A
853 45272-45277 Mutation denotes E233P p.E233P
854 45279-45284 Mutation denotes F234V rs755807976
855 45083-45088 Mutation denotes L235A p.L235A
856 45293-45298 Mutation denotes D265A p.D265A
857 45300-45305 Mutation denotes L309V p.L309V
858 45307-45312 Mutation denotes R409K p.R409K
86 6279-6286 Gene denotes FcγRIIb Gene:2213
861 8756-8764 Disease denotes COVID-19 MESH:C000657245
863 46042-46048 Chemical denotes glycan MESH:D011134
87 6580-6587 Gene denotes FcγRIIb Gene:2213
879 46227-46235 Gene denotes FcγRIIIa Gene:2214
88 7021-7028 Gene denotes FcγRIIb Gene:2213
880 46240-46248 Gene denotes FcγRIIIb Gene:2215
881 46321-46328 Gene denotes FcγRIIb Gene:2213
882 46426-46434 Gene denotes FcγRIIIa Gene:2214
883 46531-46535 Gene denotes HER2 Gene:2064
884 46542-46546 Gene denotes EGFR Gene:1956
885 46688-46695 Gene denotes FcγRIII Gene:2214
886 46799-46806 Gene denotes FcγRIII Gene:2214
887 46943-46951 Gene denotes FcγRIIIa Gene:2214
888 46997-47004 Gene denotes FcγRIIa Gene:2212
889 46927-46935 Gene denotes FcγRIIIb Gene:2215
89 6411-6415 Gene denotes FcγR Gene:2213
890 46069-46084 Chemical denotes N‐linked glycan
891 46137-46143 Chemical denotes fucose MESH:D005643
892 46173-46179 Chemical denotes fucose MESH:D005643
893 46497-46502 Disease denotes tumor MESH:D009369
90 6038-6042 Gene denotes FcγR Gene:2213
900 47266-47274 Species denotes patients Tax:9606
901 47147-47159 Chemical denotes obinutuzumab MESH:C543332
902 47296-47302 Chemical denotes fucose MESH:D005643
903 47314-47323 Chemical denotes rituximab MESH:D000069283
904 47397-47403 Chemical denotes glycan MESH:D011134
905 47237-47265 Disease denotes chronic lymphocytic leukemia MESH:D015451
91 5789-5793 Gene denotes FcγR Gene:2213
914 47847-47855 Gene denotes FcγRIIIa Gene:2214
915 47891-47899 Gene denotes FcγRIIIa Gene:2214
916 47937-47944 Gene denotes FcγRIII Gene:14131
917 48017-48022 Species denotes mouse Tax:10090
918 47728-47756 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 47990-48013 Disease denotes reduced lymphoma growth MESH:D006130
92 7134-7138 Gene denotes FcγR Gene:2213
920 47802-47807 Mutation denotes S329D p.S329D
921 47812-47817 Mutation denotes I332E p.I332E
93 6626-6633 Gene denotes FcγRIIb Gene:2213
94 7451-7454 Gene denotes BCR Gene:613
941 48112-48116 Gene denotes HER2 Gene:2064
942 48150-48154 Gene denotes HER2 Gene:2064
943 48271-48279 Gene denotes FcγRIIIa Gene:2214
944 48357-48364 Gene denotes FcγRIIb Gene:2213
945 48518-48522 Gene denotes HER2 Gene:13866
946 48589-48593 Gene denotes HER2 Gene:13866
947 48399-48403 Gene denotes FcγR Gene:2213
948 48620-48624 Species denotes mice Tax:10090
949 48031-48043 Chemical denotes Margetuximab MESH:C000617981
95 6064-6071 Gene denotes FcγRIIa Gene:2212
950 48121-48132 Chemical denotes trastuzumab MESH:D000068878
951 48459-48470 Chemical denotes trastuzumab MESH:D000068878
952 48476-48488 Chemical denotes margetuximab MESH:C000617981
953 48166-48173 Disease denotes cancers MESH:D009369
954 48605-48610 Disease denotes tumor MESH:D009369
955 48213-48218 Mutation denotes L235V p.L235V
956 48220-48225 Mutation denotes F243L p.F243L
957 48227-48232 Mutation denotes R292P p.R292P
958 48234-48239 Mutation denotes Y300L p.Y300L
959 48244-48249 Mutation denotes P396L p.P396L
96 6307-6315 Chemical denotes tyrosine MESH:D014443
967 48933-48941 Gene denotes FcγRIIIa Gene:2214
968 48640-48652 Chemical denotes ocaratuzumab MESH:C550337
969 48744-48751 Disease denotes cancers MESH:D009369
97 6649-6657 Chemical denotes tyrosine MESH:D014443
970 48763-48783 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 48788-48816 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 48838-48843 Mutation denotes P247I p.P247I
973 48848-48853 Mutation denotes A339Q p.A339Q
976 49060-49068 Gene denotes FcγRIIIa Gene:2214
977 49040-49046 Chemical denotes glycan MESH:D011134
979 39842-39846 Gene denotes FcγR Gene:2213
98 6749-6753 Chemical denotes ITAM
984 49889-49893 Gene denotes FcγR Gene:2213
985 49575-49579 Gene denotes FcγR Gene:2213
986 49431-49435 Gene denotes FcγR Gene:2213
987 49257-49261 Gene denotes FcγR Gene:2213
99 5871-5883 Disease denotes cytotoxicity MESH:D064420

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T1 164-169 Species denotes human NCBItxid:9606
T2 1189-1236 Species denotes severe acute respiratory syndrome coronavirus 2 NCBItxid:2697049
T3 1238-1248 Species denotes SARS‐CoV‐2 NCBItxid:2697049
T4 8756-8764 Species denotes COVID-19 NCBItxid:2697049
T5 9097-9102 Species denotes human NCBItxid:9606
T6 9471-9476 Species denotes Human NCBItxid:9606
T7 9505-9510 Species denotes human NCBItxid:9606
T8 10668-10673 Species denotes human NCBItxid:9606
T9 10940-10945 Species denotes human NCBItxid:9606
T10 10958-10965 Species denotes rodents NCBItxid:9989
T11 10978-10986 Species denotes primates NCBItxid:9443
T12 12348-12356 Species denotes COVID-19 NCBItxid:2697049
T13 13498-13506 Species denotes COVID-19 NCBItxid:2697049
T14 13793-13798 Species denotes human NCBItxid:9606
T15 14103-14108 Species denotes human NCBItxid:9606
T16 15009-15014 Species denotes mouse NCBItxid:10090|NCBItxid:10088
T18 15199-15207 Species denotes primates NCBItxid:9443
T19 15487-15492 Species denotes human NCBItxid:9606
T20 15506-15511 Species denotes human NCBItxid:9606
T21 15675-15680 Species denotes human NCBItxid:9606
T22 16079-16085 Species denotes humans NCBItxid:9605
T23 16954-16960 Species denotes humans NCBItxid:9605
T24 17098-17103 Species denotes human NCBItxid:9606
T25 17214-17221 Species denotes macaque NCBItxid:9539
T26 18307-18312 Species denotes human NCBItxid:9606
T27 26965-26971 Species denotes humans NCBItxid:9605
T28 27500-27504 Species denotes mice NCBItxid:10095|NCBItxid:10088
T30 27509-27515 Species denotes humans NCBItxid:9605
T31 27569-27576 Species denotes viruses NCBItxid:10239
T32 28005-28009 Species denotes mice NCBItxid:10095|NCBItxid:10088
T34 28589-28594 Species denotes human NCBItxid:9606
T35 28604-28609 Species denotes human NCBItxid:9606
T36 28644-28648 Species denotes mice NCBItxid:10095|NCBItxid:10088
T38 32208-32213 Species denotes human NCBItxid:9606
T39 34191-34196 Species denotes human NCBItxid:9606
T40 34427-34432 Species denotes human NCBItxid:9606
T41 38734-38739 Species denotes human NCBItxid:9606
T42 40739-40744 Species denotes human NCBItxid:9606
T43 45792-45800 Species denotes COVID-19 NCBItxid:2697049
T44 48017-48022 Species denotes mouse NCBItxid:10090|NCBItxid:10088
T46 48620-48624 Species denotes mice NCBItxid:10095|NCBItxid:10088
T48 61131-61178 Species denotes severe acute respiratory syndrome coronavirus 2 NCBItxid:2697049
T49 61180-61190 Species denotes SARS‐CoV‐2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T1 0-92 Sentence denotes Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
T2 93-120 Sentence denotes FcγR and mAb immune therapy
T3 121-140 Sentence denotes AM Chenoweth et al.
T4 142-150 Sentence denotes Abstract
T5 151-159 Sentence denotes Abstract
T6 160-447 Sentence denotes The human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens.
T7 448-633 Sentence denotes More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees.
T8 634-868 Sentence denotes This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs.
T9 869-1085 Sentence denotes The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects.
T10 1086-1322 Sentence denotes The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) requires increased effort on the development of improved and novel mAbs.
T11 1323-1544 Sentence denotes A more mature appreciation of the immunobiology of individual FcγR function and the complexity of the relationships between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies.
T12 1545-1828 Sentence denotes Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcγRs or the inhibitory FcγRIIb or alternatively, for the ablation of FcγR interaction altogether.
T13 1829-1974 Sentence denotes This review touches on recent aspects of FcγR and IgG immunobiology and its relationship with the present and future actions of therapeutic mAbs.
T14 1976-2193 Sentence denotes Fragment crystallizable (Fc) receptors for immunoglobulin (Ig)G activate and modulate a powerful network of inflammatory, host‐protective effector functions that are central to effective and balanced immune responses.
T15 2194-2277 Sentence denotes These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies.
T16 2278-2469 Sentence denotes The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "next‐gen" antibody therapeutics.
T17 2471-2483 Sentence denotes Introduction
T18 2484-2619 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 2620-2745 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 2746-3199 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1
T21 3200-3574 Sentence denotes The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity.
T22 3575-3967 Sentence denotes Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review.
T23 3968-4301 Sentence denotes In normal homeostatic immunity, there is a balance between IgG immune complex activation of proinflammatory responses through the activating‐type FcγRs—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host.
T24 4302-4490 Sentence denotes Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7
T25 4491-4654 Sentence denotes Many therapeutic mAbs depend, to varying degrees, on FcγR function (Figure 1, Table 1) for their mechanism of action (MOA) and/or their pharmacokinetic properties.
T26 4655-4907 Sentence denotes For some mAbs interaction with FcγR is central to their MOA, such as the destruction of a target cell by antibody‐dependent cell‐mediated cytotoxicity (ADCC; Figure 1a) or antibody‐dependent cell‐mediated phagocytosis (phagocytosis or ADCP; Figure 1b).
T27 4908-5126 Sentence denotes This also includes mAbs that may harness the inhibitory action of FcγRIIb to modulate the proinflammatory responses of immunoreceptor tyrosine activation motif (ITAM)‐dependent receptor signaling complexes (Figure 1c).
T28 5127-5453 Sentence denotes For other mAbs, FcγR may play a secondary role, such as the removal or “sweeping” of all immune complexes formed by cytokine or virus‐specific neutralizing antibodies or of opsonized fragments of lysed target cells which in antigen‐presenting cells may also feed the antigen into the antigen‐presentation pathways (Figure 1d).
T29 5454-5746 Sentence denotes In addition, FcγRs, particularly FcγRIIb (Figure 1e), are also key participants in the MOA of immune‐stimulating agonistic mAbs or apoptotic mAbs by acting as a scaffold for the additional cross‐linking of mAbs already bound to a cellular target, thereby inducing a signal in the target cell.
T30 5747-6072 Sentence denotes Figure 1 Graphical representation of the FcγR effector functions. (a) Natural killer cell antibody‐dependent cell‐mediated cytotoxicity via FcγRIIIa. (b) Antibody‐dependent cell‐mediated phagocytosis, and/or trogocytosis of large immune complexes, by professional phagocytes via activating FcγR such as FcγRIIIa and FcγRIIa.
T31 6073-6287 Sentence denotes Biological sequelae include the destruction of the ingested complexes which may also feed antigen into antigen‐presentation pathways of antigen‐presenting cells (APCs). (c) Inhibition of cell activation by FcγRIIb.
T32 6288-6588 Sentence denotes The immunoreceptor tyrosine activation motif (ITAM)‐mediated signaling of B‐cell antigen receptors (left) or of activating FcγR (right) on innate immune cells such as macrophages and basophils is inhibited by IgG Fc‐mediated co‐cross‐linking of these activating receptors with the inhibitory FcγRIIb.
T33 6589-7000 Sentence denotes This leads to phosphorylation of the FcγRIIb immunoreceptor tyrosine‐based inhibitory motif (ITIM) and consequently recruits the phosphatases that modulate the ITAM‐driven signaling responses leading to diminished cell responses. (d) Sweeping or internalization of small immune complexes leading to their removal and, in APC, to enhanced immune responses. (e) Scaffolding in which the FcγRs play a passive role.
T34 7001-7319 Sentence denotes Typically involving FcγRIIb, no signal is generated in the effector cell but “super‐cross‐linking” of the opsonizing antibody by the FcγR on one cell generates a signal in the conjugated target cell, for example, induction of apoptosis or activation in agonistic expansion of cells and/or their secretion of cytokines.
T35 7320-7384 Sentence denotes In extreme cases, this leads to life‐threatening cytokine storm.
T36 7385-7512 Sentence denotes ADCC, antibody‐dependent cell‐mediated cytotoxicity; Ag, antigen; BCR, B‐cell receptor; Ig, immunoglobulin; NK, natural killer.
T37 7513-7590 Sentence denotes Table 1 FcγR responses relevant to therapeutic monoclonal antibodies (mAbs).
T38 7591-7671 Sentence denotes FcγR‐mediated mechanism of action Effector responses Action Dominant receptor
T39 7672-7770 Sentence denotes Activation Antibody‐dependent cell‐mediated cytotoxicity Direct killing of target cell FcγRIIIa
T40 7771-7887 Sentence denotes Antibody‐dependent cell‐mediated phagocytosis, trogocytosis Direct killing of target cell FcγRIIIa, FcγRIIa, FcγRI
T41 7888-7974 Sentence denotes Antigen presentation Vaccine‐like immunity post‐mAb therapy FcγRIIa, FcγRI, FcγRIIIa
T42 7975-8159 Sentence denotes Inhibition Reduce B‐cell proliferation or innate cell activation by antibody complexes Inhibition of ITAM cell activation (i.e. BCR) or activating‐type FcR (i.e. FcγR, FcεRI, FcαRI).
T43 8160-8240 Sentence denotes Note that the FcγRIIb must be co‐cross‐linked with the ITAM activating receptor.
T44 8242-8249 Sentence denotes FcγRIIb
T45 8250-8321 Sentence denotes Sweeping Internalization Removal of small immune complexes FcγRIIb a
T46 8322-8516 Sentence denotes Scaffolding Target agonism or apoptosis Passive “super‐cross‐linking” of mAb on opsonized target cell, for example, CD40, CD28, CD20, by FcγR on an adjacent cell FcγRIIb; also FcγRIIa, FcγRI?
T47 8517-8586 Sentence denotes BCR, B‐cell receptor; ITAM, immunoreceptor tyrosine activation motif.
T48 8587-8650 Sentence denotes a Activating FcγR can also contribute to removal of complexes.
T49 8651-8798 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T50 8799-8981 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T51 8982-9469 Sentence denotes This review focuses on the cell‐based effector functions that arise from the interaction of IgG with the classical human leukocyte FcγR.7 Although beyond the scope of this review, it should be noted that the IgG‐Fc portion dictates other aspects of an antibody’s biology, including its serum half‐life mediated by the neonatal FcR (FcRn), 3 the activation of complement C1,8 antiviral protection via the intracellular receptor TRIM219 and interactions with the Fc receptor‐like family.10
T52 9471-9500 Sentence denotes Human FcγR General Properties
T53 9501-9868 Sentence denotes The human leukocyte receptors fall into two functional groups, namely, proinflammatory, activating‐type receptors (FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb, which are also known as CD64, CD32a, CD32c, CD16a and CD16b, respectively) and the anti‐inflammatory, inhibitory‐receptor group (FcγRIIb also called CD32b) which was the first immune checkpoint described.
T54 9869-9976 Sentence denotes These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses.
T55 9977-10185 Sentence denotes In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1).
T56 10186-10333 Sentence denotes These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types.
T57 10334-10589 Sentence denotes Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses.
T58 10590-10732 Sentence denotes In this review, we address only key aspects of the extensive knowledge of the human leukocyte FcγR family as it relates to effector functions.
T59 10733-11233 Sentence denotes A number of other reviews more comprehensively explore FcγR biology physiology, biochemistry, genetics and structure.7, 11, 12, 13, 14 Notwithstanding the recognized differences between the immunobiology of human FcγR and of rodents or nonhuman primates, animal models of FcR effector function in vivo have helped shape the strategies for the development of current therapeutic mAbs and are well reviewed.12, 15 Furthermore, humanized FcγR models will provide even greater insights into the future.16
T60 11234-11262 Sentence denotes Table 2 Properties of FcγR.
T61 11263-11317 Sentence denotes Receptor Affinity IgG specificity Cell distribution
T62 11318-11454 Sentence denotes FcγRI High IgG1, IgG3, IgG4 Induced by interferon‐γ on monocytes, neutrophils, macrophages, dendritic cell subpopulations; mast cells
T63 11455-11601 Sentence denotes FcγRIIa Low IgG1, IgG3, but IgG2 binding limited to the FcγRIIa‐H131 form, ~70% people) All leukocytes and platelets except T and B lymphocytes
T64 11602-11644 Sentence denotes FcγRIIc a Low IgG1, IgG3, IgG4 NK cells
T65 11645-11671 Sentence denotes FcγRIIIa Low IgG1, IgG3.
T66 11673-11791 Sentence denotes NK cells, macrophages, subpopulation of circulating monocytes, myeloid dendritic cells, neutrophils at very low levels
T67 11792-11838 Sentence denotes Binding avidity reduced by Phe at position 158
T68 11839-11877 Sentence denotes FcγRIIIb Low IgG1, IgG3 Neutrophils
T69 11878-11985 Sentence denotes FcγRIIb Low IgG1, IgG3, IgG4 B lymphocytes, some monocytes (can be upregulated); basophils; eosinophils?
T70 11986-12097 Sentence denotes Plasmacytoid and myeloid dendritic cells; NK cells only of individuals with FcγRIIIb gene copy number variation
T71 12098-12161 Sentence denotes Airway smooth muscle, LSEC, placenta, follicular dendritic cell
T72 12162-12211 Sentence denotes Ig, immunoglobulin; NK cell, natural killer cell.
T73 12212-12242 Sentence denotes a Expressed in 20% of people.
T74 12243-12390 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T75 12391-12573 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T76 12574-12628 Sentence denotes Table 3 Unique features of IgG subclass Fc and hinge.
T77 12629-12729 Sentence denotes IgG subclass FcγR specificity Light‐chain attachment Hinge characteristics Fc stability Comment
T78 12730-12840 Sentence denotes IgG1 All FcγR Upper hinge Light‐chain attachment Stable Fc is >100× times more stable than IgG4 and IgG2.
T79 12841-12858 Sentence denotes Stable core hinge
T80 12859-12995 Sentence denotes IgG2 FcγRIIa His131 CH1 of Fab and/or upper hinge Stable core hinge with additional inter H‐chain disulfide bonds in the upper hinge.
T81 12997-13078 Sentence denotes Unstable CH3:CH3 Alternative light‐chain attachment creates distinct conformers.
T82 13079-13210 Sentence denotes Unlike IgG4, the CH3:CH3 instability does not lead to half‐molecule exchange as a result of stable core and upper hinge disulfides.
T83 13211-13372 Sentence denotes IgG4 FcγRI, FcγRIIb, FcγRIIc CH1 of Fab Labile core hinge Unstable CH3:CH3 Combined instability of core hinge and CH3:CH3 permits half‐IgG molecule exchange
T84 13373-13392 Sentence denotes Ig, immunoglobulin.
T85 13393-13540 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T86 13541-13723 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T87 13725-13761 Sentence denotes FcγR expression on hemopoietic cells
T88 13762-14026 Sentence denotes The tissue distribution of the human leukocyte FcγR is well documented and reviewed comprehensively elsewhere.7, 11, 17 In the context of effector functions harnessed by therapeutic mAbs, several aspects of the cellular distribution (Table 2) should be emphasized.
T89 14027-14172 Sentence denotes FcγR expression profiles differ between cell lineages but almost all mature human leukocytes, and platelets, express at least one FcγR (Table 2).
T90 14173-14614 Sentence denotes It should also be appreciated that the cellular expression levels and receptor diversity as will be described later is also influenced by the activation state of the cells, anatomical location and the cytokine environment which modulates FcγR expression, particularly for FcγRI and FcγRIIb.18 For example, resting monocyte subpopulations may express only FcγRIIa but activated macrophages express FcγRI, FcγRIIa and FcγRIIIa and/or FcγRIIb.7
T91 14615-14701 Sentence denotes Thus, specific characteristics of leukocyte FcγR expression are summarized as follows:
T92 14702-14883 Sentence denotes FcγRI is not usually expressed until induced by cytokines such as interferon‐γ on monocytes, neutrophils, macrophages, microglial cells in the brain, dendritic cells and mast cells.
T93 14884-15169 Sentence denotes The sensitivity of FcγRI to interferon‐γ suggests that its in vivo activity is closely tied to immune activation events, and mouse studies have suggested that it has a critical role early in immune responses.19, 20 Its role in the MOA of antibodies may vary with anatomical location.21
T94 15170-15295 Sentence denotes FcγRIIa is expressed only in primates and shows the broadest expression of all FcγRs, being present on all innate leukocytes.
T95 15296-15438 Sentence denotes It is also present on platelets but its role in effector functions is not established but it is important in certain immune thrombocytopenias.
T96 15439-15517 Sentence denotes A polymorphic form of this receptor is the only human receptor for human IgG2.
T97 15518-15692 Sentence denotes This, together with its limited species expression and unique ITAM‐containing cytoplasmic tail (reviewed by Anania et al. 11), suggests a unique function in human leukocytes.
T98 15693-15939 Sentence denotes Interestingly, polymorphism of the receptor is associated with systemic lupus erythematosus and resistance to Gram‐negative organisms.11 A rare, hyper‐responsive form is a risk factor for neutrophil‐driven anaphylaxis in Ig replacement therapy.22
T99 15940-16379 Sentence denotes FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa.
T100 16380-16498 Sentence denotes Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals.
T101 16499-16631 Sentence denotes Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this.
T102 16632-16706 Sentence denotes FcγRIII forms are two highly related gene products, FcγRIIIa and FcγRIIIb.
T103 16707-16799 Sentence denotes The FcγRIIIa is expressed on NK cells and professional phagocytes, particularly macrophages.
T104 16800-17047 Sentence denotes It is only recently apparent that FcγRIIIa is expressed on neutrophils, albeit at low levels, but plays a role in their function.23 FcγRIIIb is unique to humans and unlike other FcγRs it is attached to cell membrane via a glycophosphatidyl anchor.
T105 17048-17189 Sentence denotes It is expressed, predominantly and abundantly, on human neutrophils.7 Its effector function depends in part on its coexpression with FcγRIIa.
T106 17190-17303 Sentence denotes The lack of FcγRIIIb on macaque neutrophils appears to be compensated for by an increase in FcγRIIa expression.15
T107 17304-17371 Sentence denotes FcγRIIbs are the inhibitory‐type FcγR and arise from a single gene.
T108 17372-17453 Sentence denotes They lack intrinsic proinflammatory signaling and are instead immune checkpoints.
T109 17454-17584 Sentence denotes They provide feedback regulation by antibodies, in the form of immune complexes, to inhibit B‐cell activation by specific antigen.
T110 17585-17649 Sentence denotes They also control activating‐type FcγR function on innate cells.
T111 17650-17743 Sentence denotes Two major splice variant forms of FcγRIIb exist with differential tissue expression profiles.
T112 17744-17928 Sentence denotes FcγRIIb1 preferentially expressed on B lymphocytes contains a 20‐amino acid cytoplasmic insertion necessary for membrane retention and cocapping with the B‐cell antigen receptor (BCR).
T113 17929-18104 Sentence denotes FcγRIIb2 is the predominant inhibitory receptor found on basophils and neutrophils, as well as on subpopulations of mast cells, dendritic cells and some monocytes/macrophages.
T114 18105-18321 Sentence denotes FcγRIIb2 lacks the cytoplasmic insertion of FcγRIIb1 and consequently can internalize rapidly including with the activating FcR when they are co‐cross‐linked.11 It is not clear which form is present on human T cells.
T115 18322-18449 Sentence denotes One additional comment on tissue distribution is that FcγR expression on T cells has been difficult to establish unequivocally.
T116 18450-18531 Sentence denotes However, there is increasing evidence that T‐lymphocyte populations express FcγR.
T117 18532-18743 Sentence denotes Some γδ T cells express FcγRIIIa and αβ T cells reportedly express FcγRIIa, FcγRIIb or FcγRIIIa but the significance with respect to effector function mediated by antibody is presently unclear.24, 25, 26, 27, 28
T118 18745-18779 Sentence denotes Expression on nonhemopoietic cells
T119 18780-19003 Sentence denotes The immunobiology of FcγR is studied and understood almost exclusively in the context of hematopoietic cell function but relatively recent investigations have identified and explored FcγR expression on nonhemopoietic cells.
T120 19004-19108 Sentence denotes These studies suggest important roles in normal immune function and in the MOA of some therapeutic mAbs.
T121 19109-19267 Sentence denotes The most extensively characterized receptor expression is FcγRIIb which is expressed on follicular dendritic cell, airway smooth muscle and liver endothelium.
T122 19268-19658 Sentence denotes Its abundant expression on liver sinusoidal endothelial cells (LSECs) is estimated to represent the majority of in vivo FcγRIIb expression.17, 29, 30, 31 As FcγRIIb lacks intrinsic proinflammatory signaling function, its role on these nonhemopoietic cells involves immune complex handling without the danger of, or the need for, induction of local tissue destructive inflammatory responses.
T123 19659-19996 Sentence denotes On LSEC its major role appears to be immune complex sweeping, a process of removal of small immune complexes such as opsonized virus or macromolecules.17 This scavenging role by FcγRIIb on LSEC can be exploited in principle by mAbs forming small soluble complexes with their targets such as antiviral, anticytokine or similar antibodies.
T124 19998-20037 Sentence denotes FcγR activating or inhibitory signaling
T125 20038-20165 Sentence denotes Effector functions that are initiated via the activating‐type FcγR occur by signaling via the ITAM pathway of immune receptors.
T126 20166-20350 Sentence denotes This well‐characterized pathway is used by BCR and T‐cell antigen receptors, the IgE receptor FcεRI and IgA receptor FcαRI (reviewed extensively by Hogarth and Pietersz 7 Anania et al.
T127 20351-20518 Sentence denotes 11 and Getahun and Cambier 32) Induction of an activating signal requires the aggregation of activating FcγR by immune complexes, or by antigen in the case of the BCR.
T128 20519-20679 Sentence denotes This aggregation at the cell membrane results in specific tyrosine phosphorylation of the ITAM by Src kinases, thus initiating the activation cascade.32, 33, 34
T129 20680-21313 Sentence denotes The inhibitory‐type FcγRs, FcγRIIb1 and FcγRIIb2, whose expression is cell lineage restricted, modulate the ITAM signaling of the BCR or the activating‐type FcγRs, respectively.11 Their function is dependent on the immunoreceptor tyrosine inhibition motif in their cytoplasmic tail.32, 33 This checkpoint action requires that FcγRIIbs are coaggregated with the tyrosine‐phosphorylated ITAM‐signaling receptor complex which results also in immunoreceptor tyrosine inhibition motif tyrosine phosphorylation and consequential recruitment of lipid or protein tyrosine phosphatases that powerfully dampen the ITAM‐induced cell activation.
T130 21315-21348 Sentence denotes FcγR‐Dependent Effector Responses
T131 21350-21441 Sentence denotes Not all opsonized targets are equal: size, distance, valency and Fc geometry affect potency
T132 21442-21737 Sentence denotes To understand the immunobiology of FcγR effector responses particularly in the therapeutic mAb context, it is important to appreciate that the quality and potency of such effector responses is greatly affected by the nature of the IgG immune complex and/or the state of potential effector cells.
T133 21738-21881 Sentence denotes First, opsonization, per se, of a target is not necessarily sufficient to ensure FcγR interaction in a way that initiates an effector response.
T134 21882-22556 Sentence denotes Although it is the IgG Fc that interacts with and clusters the FcγR to induce a response, the nature of the Fab interaction with its epitope can strongly influence the likelihood or potency of FcγR effector responses by influencing the density of appropriately presented Fc portions.35 and also the size of the immune complex.36 Furthermore, the display/orientation and geometry of the Fc portions, as a consequence of the fragment antigen‐binding (Fab) interaction with the target epitope, can result in effector responses such as ADCC that differ substantially in potency, presumably because the orientation of the Fc makes FcγR engagement more, or less, accessible.37, 38
T135 22557-22912 Sentence denotes Second, in innate effector cells at rest, the largely linear actin cytoskeleton and the extracellular glycosaminoglycan glycocalyx regulate function by interacting with large glycoproteins, such as CD44, arranging these into ordered “picket” fences.39, 40 These corral receptors, including the FcγRs, and sterically inhibit their interaction with ligands.
T136 22913-23611 Sentence denotes Upon cell activation, cytoskeletal remodeling is associated with the loss of the receptor corrals, allowing FcγRs and other receptors to freely diffuse, engage ligand, cluster and signal.39 The influence of such surface constraints on receptors and effector cell function helps explain some of the observed epitope distance requirements for optimal mAb function,39, 41 which were apparent in a comparative study of ADCC and ADCP.42 ADCC was optimal when the epitope was displayed close, 0.3 nm “flush” or 1.5 nm, to the target membrane where close conjugation of effector and target by the mAb presumably facilitates the delivery of pore‐forming proteins to the target membrane as required by ADCC.
T137 23612-23757 Sentence denotes Interestingly, complement‐dependent cytotoxicity which also utilizes pore‐forming proteins for its cytotoxicity has similar distance constraints.
T138 23758-24051 Sentence denotes By contrast, ADCP was poor  when targeting epitopes displayed close or "flush" to the target cell membrane (within ~0.3 nm) but ADCP activity was restored when the epitope was displayed 1.5 nm off the membrane, demonstrating different optimal epitope distance requirements for ADCC and ADCP.42
T139 24052-24247 Sentence denotes Although the action of agonistic/antagonistic mAbs is mechanistically distinct to those eliciting cytotoxicity and ADCP, the distance segregation between target and FcγR+ cells is also important.
T140 24248-24379 Sentence denotes Indeed, the membrane proximal epitopes of CD28 and CD40 are important for the FcγR function in the complex MOA of these mAbs.43, 44
T141 24380-24624 Sentence denotes Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use.
T142 24625-24741 Sentence denotes Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone.
T143 24742-24962 Sentence denotes A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive.
T144 24964-24985 Sentence denotes ADCC and phagocytosis
T145 24986-25197 Sentence denotes ADCC and ADCP are the most widely appreciated FcγR‐dependent effector functions (Figure 1a, b) and are, respectively, mediated primarily via  FcγRIIIa on NK cells and professional phagocytes such as macrophages.
T146 25198-25351 Sentence denotes These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy.
T147 25352-25525 Sentence denotes In addition, ADCP can also occur via FcγRIIa and FcγRI,45 but the extent to which cytotoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear.
T148 25526-25797 Sentence denotes The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later.
T149 25799-25839 Sentence denotes Inhibition of cell activation by FcγRIIb
T150 25840-25964 Sentence denotes FcγRIIb is an immune checkpoint46, 47 and its splice variants are potent modulators of ITAM‐dependent signaling (Figure 1c).
T151 25965-26063 Sentence denotes This modulatory function occurs only when FcγRIIb is coaggregated with an ITAM signaling receptor.
T152 26064-26477 Sentence denotes Thus, B‐cell activation by the binding of the antigen in the immune complex to the BCR is regulated by the simultaneous binding of the Fcs of the immune complex to FcγRIIb1 on the same cell. In innate leukocytes, the activating‐type FcR (i.e. FcγRI, FcγRIIa, FcγRIIc, FcγRIII) and the high‐affinity IgE receptor, FcεRI, and the IgA receptor, FcαRI, are all modulated by immune complex co‐engagement with FcγRIIb2.
T153 26478-26683 Sentence denotes The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later).
T154 26684-26882 Sentence denotes Thus, B‐cell activation is modulated by the simulatenous binding of the antigen in the immune complex to the BCR and the binding of the Fcs, also in the immune complex, to FcγRIIB1 on the same cell.
T155 26884-26929 Sentence denotes Sweeping: clearance of small immune complexes
T156 26930-27057 Sentence denotes The removal of immune complexes in humans depends primarily on the complement receptor pathway and to a lesser degree the FcγR.
T157 27058-27195 Sentence denotes Among the FcγRs, it has been widely believed that immune complex removal only occurs by phagocytosis/endocytosis of activating‐type FcγR.
T158 27196-27516 Sentence denotes Surprisingly, the inhibitory FcγRIIb, which lacks intrinsic activating function, plays a major role in clearance, and rapidly “sweeps” away small complexes from the circulation (Figure 1d).48, 49 A major tissue involved in the clearance is likely to be the LSEC, where FcγRIIb is expressed abundantly in mice and humans.
T159 27517-27768 Sentence denotes This role is potentially important in resistance to viruses and toxins but may also be key to optimal performance of therapeutic IgG mAbs whose primary MOA is believed to be only neutralization of soluble macromolecules, for example, cytokines or IgE.
T160 27770-27844 Sentence denotes FcγR uptake of antigen: antibody complexes and shaping the immune response
T161 27845-27907 Sentence denotes Monoclonal antibody therapy is a form of passive immunization.
T162 27908-28229 Sentence denotes Indeed, longer‐term vaccine‐like or vaccinal immunity has been demonstrated in anti‐CD20‐treated mice via FcγRIIa50, 51 and in vitro recall memory responses from CD20‐treated patients.52 Although this is dependent on FcγR and anti‐CD20, the mechanism by which long‐term anti‐tumor response is established remains unclear.
T163 28230-28931 Sentence denotes Nonetheless, the active involvement of FcγR in the enhancement of antigen‐specific immunity by uptake of immune complexes through FcγR is historically well documented in experimental systems where FcγRs bind immune complexes and thereby feed antigens into the antigen‐presentation pathways.53 This has been demonstrated in vivo for small immune complexes via human FcγRI on human antigen‐presenting cells54 and in mice.19 Similarly, the capacity of FcγRIIbs to bind and rapidly internalize antigen–antibody complexes suggests that it too may significantly influence feeding antigens into professional antigen‐presenting cells of hematopoietic origin such as dendritic cells and possibly B lymphocytes.
T164 28932-29216 Sentence denotes Although not a classical major histocompatibility complex‐dependent antigen presentation, FcγRIIb on the stroma‐derived follicular dendritic cells influences antibody immunity by recycling antigen–antibody complexes to the cell surface for presentation of intact antigen to B cells.55
T165 29217-29439 Sentence denotes Although somewhat speculative, FcγRIIb’s rapid internalization/sweeping of complexes by the abundant LSEC, which interact with lymphocytes and can present antigen,56 may have a significant role in shaping immune responses.
T166 29441-29486 Sentence denotes Scaffolding of cell‐bound mAbs by FcγR+ cells
T167 29487-29588 Sentence denotes FcγR‐expressing cells can be critical, but passive, participants in the MOA of some mAbs (Figure 1e).
T168 29589-29801 Sentence denotes In FcγR scaffolding, IgG mAb molecules that have opsonized the cell surface of a target cell are additionally cross‐linked by their Fc portions engaging the FcγRs that are arrayed on the surface of a second cell.
T169 29802-30014 Sentence denotes This “super‐cross‐linking” of the target‐bound mAb by the FcγR lattice or “scaffold” on the adjacent cell greatly exceeds the target cross‐linking by the mAb alone, thereby inducing a response in the target cell.
T170 30015-30608 Sentence denotes Scaffolding was originally identified as the basis of T‐cell mitogenesis induced by anti‐CD3 mAb.57, 58 The CD3 mAbs alone were poor mitogens but the “super‐cross‐linking” of the T‐cell‐bound CD3 mAb by the membrane FcγR on adjacent cells, particularly by monocytes, induced rapid T‐cell expansion and cytokine secretion but did not require activation of FcγR‐expressing cells.57 Regrettably, FcγR scaffolding came to prominence and clinical relevance because of its causal role in the catastrophic adverse events resulting from the administration of anti‐CD357 and anti‐CD28 (TGN1412)59 mAbs.
T171 30609-30744 Sentence denotes Nonetheless, FcγR scaffold‐based induction of intracellular responses in a target cell can also lead to beneficial therapeutic effects.
T172 30745-30967 Sentence denotes Such examples are the induction of apoptotic death in a target cell, which is likely part of the MOA of daratumumab in multiple myeloma60 or the controlled agonistic expansion of cells, for example, via CD40 mAb agonism.43
T173 30969-31018 Sentence denotes IgG subclasses: specificity and affinity for FcγR
T174 31019-31242 Sentence denotes Most FcγRs (Table 2) are weak, low‐affinity receptors (affinities in the micromolar range) for IgG‐Fc, irrespective of whether the IgG is uncomplexed, monomeric or when it is complexed with antigen (i.e. an immune complex).
T175 31243-31484 Sentence denotes The very avid binding of immune complexes to an effector cell surface that displays an array of FcγR molecules is the result of the collective contributions of the low‐affinity interactions of each Fc of the IgGs in the complex with an FcγR.
T176 31485-31637 Sentence denotes This avidity effect is necessary as the FcγRs operate in vivo in environments of high concentrations of uncomplexed monomeric IgG (normally 3–12 g L–1).
T177 31638-31728 Sentence denotes Thus, the avid multivalent binding of the complex out competes uncomplexed, monomeric IgG.
T178 31729-31782 Sentence denotes The notable exception to this is the enigmatic FcγRI.
T179 31783-31959 Sentence denotes This receptor shows high, nanomolar affinity for uncomplexed monomeric IgG and thus would be expected to be constantly occupied in vivo by the normal circulating monomeric IgG.
T180 31960-32027 Sentence denotes However, IgG dissociation permits engagement with immune complexes.
T181 32028-32194 Sentence denotes Furthermore, FcγRI is not expressed or expressed poorly on resting cells, requiring interferon‐γ for induction of its expression, presumably at sites of inflammation.
T182 32195-32376 Sentence denotes Although the human IgG heavy‐chain constant domains have greater than 90% identity, key amino acid differences confer each subclass with unique structural and functional properties.
T183 32377-32448 Sentence denotes IgG1 and IgG3 are “universal” ligands, that is, they bind to all FcγRs.
T184 32449-32771 Sentence denotes Formal measurement of the weak, micromolar KD interactions of the low‐affinity receptors with monomeric IgG1 also revealed differing affinities between the low‐affinity FcγRs, with inhibitory FcγRIIb generally having the lowest affinity and FcγRIII the higher, sometimes referred to as a “moderate” affinity receptor.7, 61
T185 32772-32935 Sentence denotes The strength of IgG1 interaction can also be affected by FcγR polymorphism and in the context of therapeutic mAbs, variation in FcγRIIIa is particularly important.
T186 32936-33147 Sentence denotes The most common and possibly clinically significant polymorphism is phenylalanine/valine variation at position 158 in the IgG‐binding site, wherein FcγRIIIa‐F158 binds IgG1 less well than the FcγRIIIa‐V158 form.
T187 33148-33200 Sentence denotes IgG4 and IgG2 have more restricted FcγR specificity.
T188 33201-33338 Sentence denotes IgG4 has low affinity (KA = ~2 × 105 m –1) for the inhibitory FcγRIIb, but is also a high‐affinity ligand for FcγRI (KA = ~4 × 108 m –1).
T189 33339-33584 Sentence denotes IgG2 exhibits a highly restricted specificity, showing functional activity with only one polymorphic form of FcγRIIa (binding affinity KA = ~4.5 × 105 m –1) which is permitted by the presence of histidine at position 131 of its IgG‐binding site.
T190 33585-33795 Sentence denotes This FcγRIIa–H131 form is expressed in approximately 70% of the population, whereas IgG2 has no functional activity on the other common allelic form, FcγRIIa‐R131, which contains arginine at position 131.11, 61
T191 33797-33812 Sentence denotes IgG Subclasses:
T192 33813-33837 Sentence denotes Structure and Properties
T193 33839-33887 Sentence denotes The molecular basis of IgG and FcγR interactions
T194 33888-33951 Sentence denotes The extracellular regions of the FcγR are structurally similar.
T195 33952-34098 Sentence denotes Each low‐affinity FcγR has two ectodomains, whereas the high‐affinity FcγRI has a third domain but this is not directly involved in IgG binding.62
T196 34099-34393 Sentence denotes The interaction between the IgG subclasses and the FcγR is most comprehensively defined for human IgG1 by both X‐ray crystallographic7, 62, 63 and mutagenesis structure/function analyses.64, 65, 66 These studies defined key regions of the IgG sequence required for interaction with their FcγRs.
T197 34394-34560 Sentence denotes Crystallographic analyses of the human IgG1‐Fc complexed with FcγRI, FcγRII or FcγRIII show that these interactions are similar in topology, and asymmetric in nature.
T198 34561-34642 Sentence denotes The second extracellular domain of the FcγR inserts between the two heavy chains.
T199 34643-34793 Sentence denotes Here it makes contacts with the lower hinge of both H chains and with residues of the adjacent BC loop of one CH2 domain and the FG loop of the other.
T200 34794-34975 Sentence denotes The N‐linked glycan at asparagine 297 (N297) of the heavy chain is essential for the structural integrity of the IgG‐Fc by affecting the spacing and conformation of the CH2 domains.
T201 34976-35230 Sentence denotes Indeed, its removal ablates FcγR binding.67 Of particular relevance to therapeutic mAb development is that the normal low‐affinity IgG interaction with FcγRIIIa is profoundly increased by the removal of the core fucose from the N297 Fc oligosaccharide.68
T202 35231-35482 Sentence denotes No crystallographic data are available for IgG2 or IgG4 Fc in complex with FcγR, but mutagenesis studies of the Fc and the FcγR revealed general similarity, but with critical differences, in the interaction of these subclasses with their cognate FcγR.
T203 35484-35531 Sentence denotes Unique features of the IgG2 and IgG4 subclasses
T204 35532-35739 Sentence denotes In IgG1, the stable interaction of the two heavy chains results from the combined effects of stable covalent inter H‐chain disulfide bonds and strong noncovalent interaction of the two CH3 domains (Table 3).
T205 35740-35835 Sentence denotes In stark contrast, in IgG2 and IgG4 the interaction of the CH3 domains of each H‐chain is weak.
T206 35836-35931 Sentence denotes Residues 392, 397 and 409 (Eu numbering) profoundly affect the stability of these interactions.
T207 35932-36128 Sentence denotes The difference at position 409 (R409 in IgG4 and K409 in IgG1) confers a 100‐fold decrease in stability of the interface between the two CH3 domains of IgG4 compared with that of IgG1 (Table 3).69
T208 36129-36288 Sentence denotes Furthermore, the core hinge of IgG4 differs from IgG1 at position 228 (P228 in IgG1 and S228 in IgG4), resulting in unstable inter‐heavy‐chain disulfide bonds.
T209 36289-36757 Sentence denotes This, together with the destabilizing amino acids in the CH3, confers the unique property of half‐antibody (Fab arm) exchange between different IgG4 antibodies,69 thereby creating monovalent, bispecific IgG4 antibodies in vivo.69, 70 The similarly unstable interactions between the CH3 domains in IgG2 are conferred by the interface residue M397; however, the stable inter‐H‐chain disulfide bonds of the core and upper hinge prevent half‐molecule exchange (Table 3).69
T210 36758-36831 Sentence denotes In addition, IgG2 uniquely has three disulfide bond conformers (Table 3).
T211 36832-37441 Sentence denotes The distinct conformers are formed when (1) each light chain is attached to the Cys131 residue of CH1 in the heavy chain (IgG2‐A conformer), (2) both light chains attach to the upper hinge (IgG2‐B) or (3) one light chain is attached to the CH1 Cys131 and one to the upper hinge of the other heavy chain (IgG2‐AB).71 This results in distinct positioning of the Fabs relative to the Fc portions in the different conformers, which has implications for the interaction with antigen and the capacity of IgG2 to cross‐link target molecules in the absence of FcγR binding, for example, in an agonistic mAb setting.72
T212 37442-37541 Sentence denotes It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology.
T213 37542-37807 Sentence denotes The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73
T214 37809-37859 Sentence denotes Therapeutic antibody design: improving mAb potency
T215 37860-37950 Sentence denotes Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy.
T216 37951-38257 Sentence denotes The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.
T217 38258-38556 Sentence denotes Therapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical.
T218 38558-38587 Sentence denotes The nature of the IgG isotype
T219 38588-38755 Sentence denotes Different capabilities for the recruitment and activation of the different immune effector functions are naturally found in the Fc regions of the human IgG subclasses.
T220 38756-38903 Sentence denotes Thus, to achieve a desired MOA, the different IgG subclasses are important starting points for the selection and engineering of the optimal mAb Fc.
T221 38904-39234 Sentence denotes IgG1 is, in many ways, a proinflammatory or “effector‐active” subclass, as it can initiate the complement cascade and is a “universal” FcγR ligand.74 Notwithstanding it is also a ligand for the inhibitory FcγRIIb, IgG1 elicits proinflammatory responses through all activating‐type FcγRs, including ADCC, ADCP and cytokine release.
T222 39235-39411 Sentence denotes Because of their more restricted FcγR‐binding profile, IgG2 and IgG4 have offered some choice in potentially avoiding FcR effector function without the need for Fc engineering.
T223 39412-39881 Sentence denotes They have been used as the backbone for therapeutic mAbs either because recruitment of patients’ effector functions was unlikely to be necessary for the primary MOA of the mAb or is possibly detrimental to the desired therapeutic effect.75 However, the use of these unmodified “inert” subclasses is not without consequences and underscores the need for Fc engineering to modify FcγR interactions—See the “Attenuating and ablating FcγR related functions of IgG” section.
T224 39882-40048 Sentence denotes Thus, the choice of IgG subclass for therapeutic mAb engineering is an important first step for engineering of novel mAbs of improved specificity, potency and safety.
T225 40050-40101 Sentence denotes Fc engineering for enhanced anticancer therapeutics
T226 40102-40281 Sentence denotes IgG1 is the predominant subclass used in the development of cytotoxic mAbs where induction of an activation‐type response, ADCC or phagocytosis, is considered desirable.45, 76, 77
T227 40282-40374 Sentence denotes Cytotoxic mAb cancer therapeutics can control disease progression by one or more mechanisms.
T228 40375-40531 Sentence denotes Their MOAs include direct induction of apoptotic cell death of the cancer cell (anti‐CD20, anti‐CD52) or blocking receptor signaling (anti‐HER2, anti‐EGFR).
T229 40532-40944 Sentence denotes They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design.
T230 40945-41034 Sentence denotes IgG1 antibodies bind both the activating FcγR (e.g. FcγRIIIa) and the inhibitory FcγRIIb.
T231 41035-41184 Sentence denotes In some environments effector cells will coexpress FcγRIIb together with FcγRI, FcγRIIa and FcγIIIa, as may occur on a tumor‐infiltrating macrophage.
T232 41185-41441 Sentence denotes Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell.
T233 41442-41488 Sentence denotes This leads to reduced therapeutic mAb potency.
T234 41489-41938 Sentence denotes Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response.
T235 41939-42050 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 42051-42243 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 42244-42310 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 42311-42385 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 42386-42656 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.
T240 42657-42742 Sentence denotes At the time of writing, some mAbs with improved potency are coming into clinical use.
T241 42743-42875 Sentence denotes Their improved action has been achieved by modifying the N‐linked glycan or the amino acid sequence of the heavy‐chain Fc (Table 4).
T242 42876-42982 Sentence denotes Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development.
T243 42983-43092 Sentence denotes mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage
T244 43093-43197 Sentence denotes Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III
T245 43198-43358 Sentence denotes Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III
T246 43359-43448 Sentence denotes Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed
T247 43449-43642 Sentence denotes Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed
T248 43643-43772 Sentence denotes Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed
T249 43773-43882 Sentence denotes Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III
T250 43883-44007 Sentence denotes Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T251 44008-44132 Sentence denotes Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed
T252 44133-44254 Sentence denotes Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III
T253 44255-44411 Sentence denotes Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed
T254 44412-44530 Sentence denotes Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III
T255 44531-44621 Sentence denotes Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed
T256 44622-44733 Sentence denotes Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed
T257 44734-44834 Sentence denotes Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III
T258 44835-44920 Sentence denotes Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed
T259 44921-45037 Sentence denotes Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III
T260 45038-45150 Sentence denotes Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III
T261 45151-45238 Sentence denotes Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II
T262 45239-45459 Sentence denotes Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III
T263 45460-45542 Sentence denotes Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III
T264 45543-45666 Sentence denotes Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T265 45667-45686 Sentence denotes Ig, immunoglobulin.
T266 45687-45834 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T267 45835-46017 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T268 46019-46048 Sentence denotes Modification of the Fc glycan
T269 46049-46329 Sentence denotes The typical complex N‐linked glycan attached to N297 of the heavy chain includes a core fucose.85 Antibodies that lack this fucose have approximately 50‐fold improved binding to FcγRIIIa and FcγRIIIb and importantly retain the weak, low‐affinity binding to the inhibitory FcγRIIb.
T270 46330-46704 Sentence denotes Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding.
T271 46705-47030 Sentence denotes Compared with their unmodified counterparts, the afucosyl mAbs showed dramatic improvement of FcγRIII‐related effector responses such as stronger NK cell‐mediated ADCC, or enhanced neutrophil‐mediated phagocytosis through FcγRIIIb and/or FcγRIIIa.23 However, certain neutrophil functions via FcγRIIa may be compromised.90, 91
T272 47031-47135 Sentence denotes There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4).
T273 47136-47486 Sentence denotes Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments.
T274 47488-47518 Sentence denotes Mutation of the Fc amino acids
T275 47519-47631 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 47632-47912 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 47913-48030 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 48031-48410 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 48411-48625 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 48626-48997 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 48998-49159 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.
T282 49161-49215 Sentence denotes Attenuating and ablating FcγR‐related functions of IgG
T283 49216-49324 Sentence denotes There are circumstances where binding to FcγR is unnecessary or undesirable in the MOA of a therapeutic mAb.
T284 49325-49662 Sentence denotes Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FcγR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.57, 59 Clearly reducing or eliminating FcγR interactions, when they are not required for therapeutic effect, may be desirable.
T285 49663-49755 Sentence denotes Indeed, this had been addressed by the choice of IgG subclass or by modifying the Fc region.
T286 49756-49917 Sentence denotes Indeed, most efforts in Fc engineering mAbs that have translated to an approved drug have focused on the reduction or elimination of FcγR interactions (Table 4).
T287 49918-50185 Sentence denotes One approach to minimize interactions with the activating FcγR has been the use of IgG4 or IgG2 backbones, which show a more restricted specificity for the activating FcγR and consequently have been traditionally, and simplistically, viewed as “inert” IgG subclasses.
T288 50186-50367 Sentence denotes Notwithstanding the unexpected, and FcγR‐dependent, severe adverse reaction induced by the IgG4 TGN1412 mAb, the IgG4 or IgG2 backbones have been successfully used in many settings.
T289 50368-50602 Sentence denotes Indeed, checkpoint inhibitors, such as mAbs targeting CTLA‐4 or the PD‐L1/PD‐1 interaction for the suppression of inhibitory signals that contribute to immune tolerance in the tumor microenvironment, are formatted on an IgG4 backbone.
T290 50603-50827 Sentence denotes Pembrolizumab, nivolumab and cemiplimab are all anti‐PD‐1 antibodies currently used for cancer therapy and have been formatted on an IgG4 backbone95, 96, 97 with a stabilized core hinge (S228P) to prevent half‐IgG4 exchange.
T291 50828-50984 Sentence denotes Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98
T292 50985-51056 Sentence denotes However, the use of IgG2 and IgG4 as “inert” subclasses is problematic.
T293 51057-51452 Sentence denotes Both bind to the activating receptors FcγRIIa‐H131 and FcγRI, respectively (Table 2), and initiate effector functions such as neutrophil activation and apoptosis induction.75, 99 Interestingly, in experimental systems, cross‐linking of anti‐PD‐1 IgG4‐based mAb by FcγRI switched its activity from blocking to activatory.10 Moreover, IgG4 binds to FcγRIIb, which may scaffold the therapeutic mAb.
T294 51453-51770 Sentence denotes Although scaffolding may be beneficial in some contexts, for example, in immune agonism,43 it can be disastrous and unexpected in others as it was for the anti‐CD28 TGN1412 mAb.59 Thus, the IgG2 and IgG4 subclasses are not the optimum choice for “FcR‐inactive” mAbs, and so modifying the Fc is a more direct approach.
T295 51771-52065 Sentence denotes The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13
T296 52066-52177 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 52178-52333 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 52334-52502 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).
T299 52503-52707 Sentence denotes A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations.
T300 52708-52886 Sentence denotes The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F).
T301 52887-53104 Sentence denotes They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16
T302 53105-53200 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 53201-53475 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 53476-53693 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 53694-53798 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 53799-54061 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 54063-54093 Sentence denotes Improving FcγRIIb interactions
T308 54094-54263 Sentence denotes Preferential or specific Fc engagement of FcγRIIb over the activating FcγR offers several potential therapeutic advantages for new mAbs in distinct therapeutic settings.
T309 54265-54367 Sentence denotes Improved recruitment of FcγRIIb immunoreceptor tyrosine inhibition motif‐dependent inhibitory function
T310 54368-54854 Sentence denotes Harnessing the physiological inhibitory function of FcγRIIb by mAbs that target ITAM receptors has the potential to shut down ITAM‐dependent signaling pathways of major importance in antibody pathologies.32, 108 Such ITAM signaling receptors include the BCR complex on B cells which is active in systemic lupus erythematosus, the FcεRI on basophils and mast cell subsets in allergies or the activating‐type FcγR on a variety of innate leukocytes in antibody‐mediated tissue destruction.
T311 54855-55019 Sentence denotes In such scenarios, the ITAM signaling receptor complex that is targeted by the therapeutic mAb must be co‐expressed on the cell surface with the inhibitory FcγRIIb.
T312 55020-55223 Sentence denotes This permits coengagement with ITAM signaling receptor by the Fab of the mAb and inhibitory FcγRIIb by its Fc which is the critical requirement in the inhibitory MOA for such therapeutic mAbs (Figure 1).
T313 55224-55649 Sentence denotes Obexelimab (also known as XmAb5871; Table 4), currently in early clinical testing in inflammatory autoimmune disease, is an IgG1 mAb that targets CD19 of the BCR complex.19 It contains two Fc modifications, S267E and L328F (also known as “SELF” mutations), that selectively increased FcγRIIb binding by 400‐fold to about 1 nm, which results in powerful suppression of BCR signaling and the proliferation of primary B cells.19
T314 55650-56614 Sentence denotes The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later).
T315 56615-56846 Sentence denotes One cautionary note is that the arginine 131 (R131) of the IgG‐binding site in FcγRIIb is critical for the enhanced affinity binding of “SELF”‐mutated Fcs but it is also present in the activating‐type “high responder” FcγRIIa‐R131.
T316 56847-57109 Sentence denotes Thus, antibodies modified with “SELF” have very‐high‐affinity binding to FcγRIIa‐R131 115 with a potentially increased risk of FcγRIIa‐dependent complications in patients expressing this allelic form, although, so far, none have been reported in clinical trials.
T317 57110-57300 Sentence denotes However, an alternative set of six Fc mutations, termed “V12” (P238D, E233D, G237D, H268D, P271G and A330R), potently enhanced FcγRIIb binding without increasing FcγRIIa–R131 interaction.115
T318 57302-57350 Sentence denotes Enhancing the sweeping of small immune complexes
T319 57351-57723 Sentence denotes The expression of FcγRIIb on LSEC and its action in the “sweeping” or removal of small immune complexes has opened up new possibilities for the application of FcγRIIb‐enhancing modifications.17 Antibodies or Fc fusion proteins, whose primary MOA is the neutralization of soluble molecules such as IgE or cytokines, are particularly attractive candidates for this approach.
T320 57724-58032 Sentence denotes Proof‐of‐concept for this strategy has been demonstrated in experimental models.48 Indeed, this may be a significant component of the rapid disappearance of IgE from the circulation of patients treated with the anti‐IgE XmAb7195 containing the FcγRIIb enhancing “SELF” modifications, as described previously.
T321 58034-58073 Sentence denotes Immune agonism through FcγR scaffolding
T322 58074-58173 Sentence denotes Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target.
T323 58174-58419 Sentence denotes Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116
T324 58420-58512 Sentence denotes The role of FcγR in the action of these types of mAbs appears to be primarily as a scaffold.
T325 58513-58609 Sentence denotes FcγRIIb is often the predominate receptor involved and the extent of its involvement is complex.
T326 58610-58930 Sentence denotes In the case of CD40, the degree of FcγRIIb scaffolding potency is linked to the epitope location of the targeting mAb with greater potency seen for membrane proximal epitopes.43, 117 It is also noteworthy that depending on the epitope location, the scaffolding of anti‐CD40 mAbs may convert antagonist mAbs to agonistic.
T327 58931-59423 Sentence denotes Engineering of the IgG1 Fc region for enhanced and/or specific binding to FcγRIIb can greatly improve agonistic function.72, 118, 119, 120 Such mutations induced significantly greater agonistic activity in an anti‐DR5 model through increased induction of apoptotic death and decreased tumor growth compared with unmodified IgG1.121 The “SELF” modifications that dramatically and selectively increase affinity for FcγRIIb have also been used to enhance immune agonism in an anti‐OX40 model.122
T328 59424-59627 Sentence denotes The incorporation of the "V12" Fc mutations into IgG1 specifically enhance FcγRIIb interaction 200‐fold, conferring the enhanced agonistic activity of an anti‐CD137 antibody and an anti‐OX40 mAb.115, 122
T329 59629-59658 Sentence denotes Future Engineering Strategies
T330 59659-59755 Sentence denotes Monoclonal antibodies are potent therapeutics in a number of chronic or once incurable diseases.
T331 59756-59885 Sentence denotes However, there is still extensive unmet clinical need as well as considerable room for improvement in many existing therapeutics.
T332 59886-60026 Sentence denotes Further understanding of how antibody structure affects FcγR function is essential for future development of more potent and effective mAbs.
T333 60027-60294 Sentence denotes Already, engineering of the IgG Fc and its glycan has proved a potent and effective approach for increasing the clinical effectiveness, functional specificity and safety of therapeutic mAbs and is an emerging pathway to the development of the “next‐gen” therapeutics.
T334 60295-60638 Sentence denotes Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors.
T335 60639-60892 Sentence denotes Furthermore, the mixed subclass nature of these normal antibody responses suggests that circumstances may arise in therapeutic strategies where there is value in having distinctly modified Fcs for the nuanced engagement of different FcγR family members.
T336 60893-61044 Sentence denotes Treatments comprising multiple mAbs and immune stimulants are under investigation in infectious disease for neutralization coverage of variant strains.
T337 61045-61202 Sentence denotes Indeed, such an approach may be most effective in emerging infectious disease such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection.
T338 61203-61401 Sentence denotes The use of multiple mAbs tailored for distinct effector functions and targeting different epitopes will maximize the opportunity for cocktailing of effector functions in different types of diseases.
T339 61402-61605 Sentence denotes Indeed, in a small but contemporary example outside of infectious disease, the FDA‐approved combination in adenocarcinoma therapy uses a cocktail of two mAbs, pertuzumab and trastuzumab, against Her2.123
T340 61606-61883 Sentence denotes Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system.
T341 61884-62087 Sentence denotes Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases.
T342 62089-62109 Sentence denotes Conflict of Interest
T343 62110-62115 Sentence denotes None.
T344 62117-62132 Sentence denotes Acknowledgments
T345 62133-62190 Sentence denotes We thank Halina Trist for assistance with the manuscript.
T346 62191-62319 Sentence denotes We also thank NHMRC, Janina and Bill Amiet Trust, Margaret Walkom Trust and Nancy E Pendergast Trust, Genmab, for their support.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 15-28 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T2 9268-9273 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T3 12126-12134 Body_part denotes placenta http://purl.obolibrary.org/obo/UBERON_0001987
T4 13766-13772 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T5 14845-14850 Body_part denotes brain http://purl.obolibrary.org/obo/UBERON_0000955
T6 15608-15612 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T7 16331-16335 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T8 17716-17722 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T9 18348-18354 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T10 19249-19254 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T11 19255-19266 Body_part denotes endothelium http://purl.obolibrary.org/obo/UBERON_0001986
T12 19295-19300 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T13 19616-19622 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T14 20957-20961 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T15 23546-23550 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T16 23681-23685 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T17 27400-27406 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T18 29037-29043 Body_part denotes stroma http://purl.obolibrary.org/obo/UBERON_0003891
T19 36401-36404 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T20 37710-37715 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T21 38130-38135 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T22 43564-43567 Body_part denotes ear http://purl.obolibrary.org/obo/UBERON_0001690
T23 43568-43572 Body_part denotes nose http://purl.obolibrary.org/obo/UBERON_0000004
T24 43573-43579 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T25 43964-43986 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T26 44369-44391 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T27 45623-45645 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T28 54835-54841 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T29 61869-61882 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1 6910-6913 Protein denotes APC https://www.uniprot.org/uniprot/P0C1F2|https://www.uniprot.org/uniprot/P01532
T3 8440-8444 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T29 8446-8450 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T45 8452-8456 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4|https://www.uniprot.org/uniprot/P11836
T52 9314-9318 Protein denotes FcRn https://www.uniprot.org/uniprot/Q9R2A5|https://www.uniprot.org/uniprot/Q9QUR0|https://www.uniprot.org/uniprot/Q9NZ19|https://www.uniprot.org/uniprot/Q9HBV7|https://www.uniprot.org/uniprot/Q8SPV9|https://www.uniprot.org/uniprot/Q61559|https://www.uniprot.org/uniprot/Q5HYM5|https://www.uniprot.org/uniprot/Q2KN22|https://www.uniprot.org/uniprot/P55899|https://www.uniprot.org/uniprot/P13599
T62 9688-9692 Protein denotes CD64 https://www.uniprot.org/uniprot/Q92663|https://www.uniprot.org/uniprot/Q92495|https://www.uniprot.org/uniprot/Q5QNW7|https://www.uniprot.org/uniprot/P26151|https://www.uniprot.org/uniprot/P12315|https://www.uniprot.org/uniprot/P12314
T68 9708-9713 Protein denotes CD16a https://www.uniprot.org/uniprot/Q6PIJ0|https://www.uniprot.org/uniprot/Q65ZM6|https://www.uniprot.org/uniprot/Q5EBR4|https://www.uniprot.org/uniprot/Q53FL6|https://www.uniprot.org/uniprot/Q53FJ0|https://www.uniprot.org/uniprot/P08637|https://www.uniprot.org/uniprot/A2N6W9
T75 9718-9723 Protein denotes CD16b https://www.uniprot.org/uniprot/O75015
T76 11360-11370 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T78 11444-11448 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T81 12105-12111 Protein denotes smooth https://www.uniprot.org/uniprot/Q9VPM8|https://www.uniprot.org/uniprot/P91682|https://www.uniprot.org/uniprot/B7FNK1
T84 14768-14778 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T86 14872-14876 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T89 14912-14922 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T91 18045-18049 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T94 19231-19237 Protein denotes smooth https://www.uniprot.org/uniprot/Q9VPM8|https://www.uniprot.org/uniprot/P91682|https://www.uniprot.org/uniprot/B7FNK1
T97 22618-22623 Protein denotes actin https://www.uniprot.org/uniprot/Q92193|https://www.uniprot.org/uniprot/Q92192|https://www.uniprot.org/uniprot/Q24733|https://www.uniprot.org/uniprot/Q11212|https://www.uniprot.org/uniprot/P91754|https://www.uniprot.org/uniprot/P90689|https://www.uniprot.org/uniprot/P80709|https://www.uniprot.org/uniprot/P68555|https://www.uniprot.org/uniprot/P45521|https://www.uniprot.org/uniprot/P38136|https://www.uniprot.org/uniprot/P14227|https://www.uniprot.org/uniprot/O17320|https://www.uniprot.org/uniprot/O16808
T110 22732-22745 Protein denotes glycoproteins https://www.uniprot.org/uniprot/Q9QSP1|https://www.uniprot.org/uniprot/Q9QJT6|https://www.uniprot.org/uniprot/Q9JGT4|https://www.uniprot.org/uniprot/Q9IPJ6|https://www.uniprot.org/uniprot/Q9DIC6|https://www.uniprot.org/uniprot/Q91DS0|https://www.uniprot.org/uniprot/Q91C28|https://www.uniprot.org/uniprot/Q8QQA2|https://www.uniprot.org/uniprot/Q8QPE5|https://www.uniprot.org/uniprot/Q8QPE4|https://www.uniprot.org/uniprot/Q8QPE3|https://www.uniprot.org/uniprot/Q8JTH0|https://www.uniprot.org/uniprot/Q8BDV6|https://www.uniprot.org/uniprot/Q8B6J6|https://www.uniprot.org/uniprot/Q8B0I1|https://www.uniprot.org/uniprot/Q8B0H6|https://www.uniprot.org/uniprot/Q8B0H1|https://www.uniprot.org/uniprot/Q89669|https://www.uniprot.org/uniprot/Q85213|https://www.uniprot.org/uniprot/Q82706|https://www.uniprot.org/uniprot/Q82683|https://www.uniprot.org/uniprot/Q82020|https://www.uniprot.org/uniprot/Q787B5|https://www.uniprot.org/uniprot/Q77SK0|https://www.uniprot.org/uniprot/Q77N36|https://www.uniprot.org/uniprot/Q76G52|https://www.uniprot.org/uniprot/Q75T09|https://www.uniprot.org/uniprot/Q6X1D5|https://www.uniprot.org/uniprot/Q6X1D1|https://www.uniprot.org/uniprot/Q6TYA0|https://www.uniprot.org/uniprot/Q6E0W7|https://www.uniprot.org/uniprot/Q66T62|https://www.uniprot.org/uniprot/Q5VKP3|https://www.uniprot.org/uniprot/Q5VKN9|https://www.uniprot.org/uniprot/Q5K2K4|https://www.uniprot.org/uniprot/Q5IX93|https://www.uniprot.org/uniprot/Q5IX92|https://www.uniprot.org/uniprot/Q5IX91|https://www.uniprot.org/uniprot/Q5IX90|https://www.uniprot.org/uniprot/Q5IX89|https://www.uniprot.org/uniprot/Q5IX88|https://www.uniprot.org/uniprot/Q5IX87|https://www.uniprot.org/uniprot/Q5GA86|https://www.uniprot.org/uniprot/Q58FH1|https://www.uniprot.org/uniprot/Q4VKV3|https://www.uniprot.org/uniprot/Q4F900|https://www.uniprot.org/uniprot/Q49LL3|https://www.uniprot.org/uniprot/Q49IU2|https://www.uniprot.org/uniprot/Q49IU1|https://www.uniprot.org/uniprot/Q49IT9|https://www.uniprot.org/uniprot/Q49IT8|https://www.uniprot.org/uniprot/Q49AV0|https://www.uniprot.org/uniprot/Q0GBY1|https://www.uniprot.org/uniprot/Q0GBX6|https://www.uniprot.org/uniprot/Q08089|https://www.uniprot.org/uniprot/P32595|https://www.uniprot.org/uniprot/P32550|https://www.uniprot.org/uniprot/P19462|https://www.uniprot.org/uniprot/P16288|https://www.uniprot.org/uniprot/P15199|https://www.uniprot.org/uniprot/P13180|https://www.uniprot.org/uniprot/P0C572|https://www.uniprot.org/uniprot/P08667|https://www.uniprot.org/uniprot/P08163|https://www.uniprot.org/uniprot/P07923|https://www.uniprot.org/uniprot/P04884|https://www.uniprot.org/uniprot/P04883|https://www.uniprot.org/uniprot/P04882|https://www.uniprot.org/uniprot/P03524|https://www.uniprot.org/uniprot/P03522|https://www.uniprot.org/uniprot/O92284|https://www.uniprot.org/uniprot/O56677|https://www.uniprot.org/uniprot/O10236|https://www.uniprot.org/uniprot/J7HBH4|https://www.uniprot.org/uniprot/D8V075|https://www.uniprot.org/uniprot/A7WNB3|https://www.uniprot.org/uniprot/A4UHQ6|https://www.uniprot.org/uniprot/A4UHQ1|https://www.uniprot.org/uniprot/A3RM22|https://www.uniprot.org/uniprot/A3F5R8|https://www.uniprot.org/uniprot/A3F5R3|https://www.uniprot.org/uniprot/A3F5Q8|https://www.uniprot.org/uniprot/A3F5N3|https://www.uniprot.org/uniprot/A3F5M3|https://www.uniprot.org/uniprot/A3F5L8
T195 22755-22759 Protein denotes CD44 https://www.uniprot.org/uniprot/Q9UJ36|https://www.uniprot.org/uniprot/Q9UCB0|https://www.uniprot.org/uniprot/Q9UC30|https://www.uniprot.org/uniprot/Q9UC29|https://www.uniprot.org/uniprot/Q9UC28|https://www.uniprot.org/uniprot/Q9QYX8|https://www.uniprot.org/uniprot/Q9H5A5|https://www.uniprot.org/uniprot/Q99J14|https://www.uniprot.org/uniprot/Q99021|https://www.uniprot.org/uniprot/Q96J24|https://www.uniprot.org/uniprot/Q92493|https://www.uniprot.org/uniprot/Q8N694|https://www.uniprot.org/uniprot/Q86Z27|https://www.uniprot.org/uniprot/Q86T72|https://www.uniprot.org/uniprot/Q64296|https://www.uniprot.org/uniprot/Q62409|https://www.uniprot.org/uniprot/Q62408|https://www.uniprot.org/uniprot/Q62063|https://www.uniprot.org/uniprot/Q62062|https://www.uniprot.org/uniprot/Q62061|https://www.uniprot.org/uniprot/Q62060|https://www.uniprot.org/uniprot/Q61395|https://www.uniprot.org/uniprot/Q60523|https://www.uniprot.org/uniprot/Q60522|https://www.uniprot.org/uniprot/Q29423|https://www.uniprot.org/uniprot/Q28284|https://www.uniprot.org/uniprot/Q16522|https://www.uniprot.org/uniprot/Q16208|https://www.uniprot.org/uniprot/Q16066|https://www.uniprot.org/uniprot/Q16065|https://www.uniprot.org/uniprot/Q16064|https://www.uniprot.org/uniprot/Q15861|https://www.uniprot.org/uniprot/Q13980|https://www.uniprot.org/uniprot/Q13968|https://www.uniprot.org/uniprot/Q13967|https://www.uniprot.org/uniprot/Q13961|https://www.uniprot.org/uniprot/Q13960|https://www.uniprot.org/uniprot/Q13959|https://www.uniprot.org/uniprot/Q13958|https://www.uniprot.org/uniprot/Q13957|https://www.uniprot.org/uniprot/Q13419|https://www.uniprot.org/uniprot/Q05732|https://www.uniprot.org/uniprot/Q05078|https://www.uniprot.org/uniprot/Q04858|https://www.uniprot.org/uniprot/P26051|https://www.uniprot.org/uniprot/P22511|https://www.uniprot.org/uniprot/P20944|https://www.uniprot.org/uniprot/P16070|https://www.uniprot.org/uniprot/P15379|https://www.uniprot.org/uniprot/P14745|https://www.uniprot.org/uniprot/O95370|https://www.uniprot.org/uniprot/D3DR13|https://www.uniprot.org/uniprot/D3DR12|https://www.uniprot.org/uniprot/B6EAT9|https://www.uniprot.org/uniprot/A5YRN9
T250 24290-24294 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T266 24299-24303 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T292 27992-27996 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T299 28070-28074 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T306 28139-28143 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T313 30571-30576 Protein denotes CD357 https://www.uniprot.org/uniprot/Q9Y5U5|https://www.uniprot.org/uniprot/Q9NYJ9|https://www.uniprot.org/uniprot/Q9JKR3|https://www.uniprot.org/uniprot/Q9JKR2|https://www.uniprot.org/uniprot/Q9JKR1|https://www.uniprot.org/uniprot/Q5U0I4|https://www.uniprot.org/uniprot/O95851|https://www.uniprot.org/uniprot/O35714|https://www.uniprot.org/uniprot/B1AME1
T322 30586-30590 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T338 30948-30952 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T364 32112-32122 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T366 33224-33231 Protein denotes KA = ~2 https://www.uniprot.org/uniprot/Q8WWG8|https://www.uniprot.org/uniprot/Q63273|https://www.uniprot.org/uniprot/Q62643|https://www.uniprot.org/uniprot/Q61626|https://www.uniprot.org/uniprot/Q16478|https://www.uniprot.org/uniprot/G5E822
T372 40460-40464 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T379 40471-40475 Protein denotes CD52 https://www.uniprot.org/uniprot/Q9BW46|https://www.uniprot.org/uniprot/Q64389|https://www.uniprot.org/uniprot/Q63064|https://www.uniprot.org/uniprot/Q5T138|https://www.uniprot.org/uniprot/Q28896|https://www.uniprot.org/uniprot/P32763|https://www.uniprot.org/uniprot/P31358
T386 40662-40666 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T393 43108-43134 Protein denotes Matrix Metalloproteinase 9 https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8
T411 43136-43140 Protein denotes MMP9 https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8
T429 43211-43243 Protein denotes Interferon alpha/beta receptor 1 https://www.uniprot.org/uniprot/Q95206|https://www.uniprot.org/uniprot/Q8WTZ2|https://www.uniprot.org/uniprot/Q80UJ3|https://www.uniprot.org/uniprot/Q7M4L2|https://www.uniprot.org/uniprot/Q764M8|https://www.uniprot.org/uniprot/Q6PKD7|https://www.uniprot.org/uniprot/Q53H11|https://www.uniprot.org/uniprot/Q53GW9|https://www.uniprot.org/uniprot/Q28589|https://www.uniprot.org/uniprot/Q04790|https://www.uniprot.org/uniprot/P33896|https://www.uniprot.org/uniprot/P17181|https://www.uniprot.org/uniprot/D3DSF0|https://www.uniprot.org/uniprot/B4DNT3|https://www.uniprot.org/uniprot/B2R6L9
T444 43373-43378 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T453 43463-43476 Protein denotes Interleukin 5 https://www.uniprot.org/uniprot/Q9XT91|https://www.uniprot.org/uniprot/Q9MYM5|https://www.uniprot.org/uniprot/Q9ESI9|https://www.uniprot.org/uniprot/Q95J76|https://www.uniprot.org/uniprot/Q62575|https://www.uniprot.org/uniprot/Q28586|https://www.uniprot.org/uniprot/Q13840|https://www.uniprot.org/uniprot/Q08125|https://www.uniprot.org/uniprot/P52173|https://www.uniprot.org/uniprot/P48093|https://www.uniprot.org/uniprot/P46685|https://www.uniprot.org/uniprot/P05113|https://www.uniprot.org/uniprot/P04401|https://www.uniprot.org/uniprot/O77515|https://www.uniprot.org/uniprot/O62740|https://www.uniprot.org/uniprot/O08987|https://www.uniprot.org/uniprot/O02699|https://www.uniprot.org/uniprot/A9QWQ8
T471 43655-43660 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T480 43785-43815 Protein denotes Angiopoietin‐related protein 3 https://www.uniprot.org/uniprot/Q9Y5C1|https://www.uniprot.org/uniprot/Q9R182|https://www.uniprot.org/uniprot/B2RCW1|https://www.uniprot.org/uniprot/B1ALJ0|https://www.uniprot.org/uniprot/A0JLS0
T485 43897-43901 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T494 44020-44035 Protein denotes Interleukin 17A https://www.uniprot.org/uniprot/Q95L56|https://www.uniprot.org/uniprot/Q687Y7|https://www.uniprot.org/uniprot/Q62386|https://www.uniprot.org/uniprot/Q61453|https://www.uniprot.org/uniprot/Q60I29|https://www.uniprot.org/uniprot/Q60971|https://www.uniprot.org/uniprot/Q5T2P0|https://www.uniprot.org/uniprot/Q16552
T502 44272-44299 Protein denotes C chemokine receptor type 4 https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679
T508 44301-44305 Protein denotes CCR4 https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679
T514 44444-44448 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T523 44542-44546 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T531 44636-44640 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T538 44748-44752 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T545 44850-44854 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T553 45062-45068 Protein denotes IL‐36R https://www.uniprot.org/uniprot/Q9HB29|https://www.uniprot.org/uniprot/Q587I8|https://www.uniprot.org/uniprot/Q53TU8|https://www.uniprot.org/uniprot/Q45H74|https://www.uniprot.org/uniprot/Q13525|https://www.uniprot.org/uniprot/A4FU63
T559 45253-45257 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T567 45482-45486 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T575 45556-45560 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T582 46556-46560 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T589 47178-47182 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T596 47641-47645 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T605 48635-48639 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T612 50422-50428 Protein denotes CTLA‐4 https://www.uniprot.org/uniprot/Q9XSI1|https://www.uniprot.org/uniprot/Q9UKN9|https://www.uniprot.org/uniprot/Q9TT02|https://www.uniprot.org/uniprot/Q9QZZ7|https://www.uniprot.org/uniprot/Q9MYX7|https://www.uniprot.org/uniprot/Q96P43|https://www.uniprot.org/uniprot/Q8WXJ1|https://www.uniprot.org/uniprot/Q5S005|https://www.uniprot.org/uniprot/Q53TD5|https://www.uniprot.org/uniprot/Q52MC1|https://www.uniprot.org/uniprot/Q0PP65|https://www.uniprot.org/uniprot/P42072|https://www.uniprot.org/uniprot/P16410|https://www.uniprot.org/uniprot/P09793|https://www.uniprot.org/uniprot/O95653|https://www.uniprot.org/uniprot/E9PDH0|https://www.uniprot.org/uniprot/A0N1S0
T629 50436-50441 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T638 50442-50446 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T646 50656-50660 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T654 50888-50894 Protein denotes CTLA‐4 https://www.uniprot.org/uniprot/Q9XSI1|https://www.uniprot.org/uniprot/Q9UKN9|https://www.uniprot.org/uniprot/Q9TT02|https://www.uniprot.org/uniprot/Q9QZZ7|https://www.uniprot.org/uniprot/Q9MYX7|https://www.uniprot.org/uniprot/Q96P43|https://www.uniprot.org/uniprot/Q8WXJ1|https://www.uniprot.org/uniprot/Q5S005|https://www.uniprot.org/uniprot/Q53TD5|https://www.uniprot.org/uniprot/Q52MC1|https://www.uniprot.org/uniprot/Q0PP65|https://www.uniprot.org/uniprot/P42072|https://www.uniprot.org/uniprot/P16410|https://www.uniprot.org/uniprot/P09793|https://www.uniprot.org/uniprot/O95653|https://www.uniprot.org/uniprot/E9PDH0|https://www.uniprot.org/uniprot/A0N1S0
T671 51298-51302 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T679 51613-51617 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T695 51957-51962 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T704 52770-52775 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T713 52799-52809 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T715 53215-53219 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T723 54721-54725 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T726 55370-55374 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T735 56011-56015 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T738 58242-58265 Protein denotes costimulatory molecules https://www.uniprot.org/uniprot/Q9BXR1|https://www.uniprot.org/uniprot/Q8VE98|https://www.uniprot.org/uniprot/Q8NCB6|https://www.uniprot.org/uniprot/Q8NC34|https://www.uniprot.org/uniprot/Q8NBI8|https://www.uniprot.org/uniprot/Q7TPB4|https://www.uniprot.org/uniprot/Q6UXI2|https://www.uniprot.org/uniprot/Q6P5Y4|https://www.uniprot.org/uniprot/Q5ZPR3
T747 58311-58315 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T773 58625-58629 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T799 58879-58883 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T825 59583-59588 Protein denotes CD137 https://www.uniprot.org/uniprot/Q07011|https://www.uniprot.org/uniprot/P20334
T827 61936-61940 Protein denotes full https://www.uniprot.org/uniprot/Q8N1N2

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T1 15-28 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T2 246-260 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T3 261-266 Body_part denotes (Ig)G http://purl.org/sig/ont/fma/fma62872
T4 262-264 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T5 687-692 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T6 702-710 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T7 845-854 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T8 1603-1610 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T9 1879-1882 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T10 2019-2033 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T11 2034-2039 Body_part denotes (Ig)G http://purl.org/sig/ont/fma/fma62872
T12 2035-2037 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T13 2447-2455 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T14 3289-3298 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T15 3376-3390 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T16 3391-3396 Body_part denotes (Ig)E http://purl.org/sig/ont/fma/fma62875
T17 3392-3394 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T18 3438-3442 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T19 3601-3604 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T20 3712-3718 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T21 3903-3915 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T22 3903-3907 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T23 4027-4030 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T24 4752-4756 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T25 4760-4768 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T26 4779-4783 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T27 4827-4835 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T28 4846-4850 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T29 5042-5050 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T30 5243-5251 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T31 5336-5341 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T32 5351-5375 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T33 5370-5375 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T34 5741-5745 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T35 5818-5837 Body_part denotes Natural killer cell http://purl.org/sig/ont/fma/fma63147
T36 5833-5837 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T37 5838-5846 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T38 5857-5861 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T39 5902-5910 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T40 5921-5925 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T41 6209-6233 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T42 6228-6233 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T43 6260-6264 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T44 6307-6315 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T45 6364-6368 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T46 6441-6446 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T47 6455-6466 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T48 6471-6480 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T49 6497-6500 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T50 6649-6657 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T51 6803-6807 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T52 7069-7073 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T53 7118-7126 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T54 7146-7150 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T55 7195-7199 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T56 7277-7282 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T57 7309-7318 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T58 7369-7377 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T59 7391-7399 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T60 7410-7414 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T61 7458-7462 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T62 7473-7475 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T63 7477-7491 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T64 7684-7692 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T65 7703-7707 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T66 7756-7760 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T67 7771-7779 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T68 7790-7794 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T69 7857-7861 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T70 7996-8000 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T71 8025-8029 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T72 8044-8052 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T73 8083-8087 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T74 8421-8425 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T75 8481-8485 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T76 8524-8528 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T77 8560-8568 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T78 9009-9013 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T79 9074-9077 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T80 9103-9112 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T81 9190-9193 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T82 9234-9244 Body_part denotes antibody’s http://purl.org/sig/ont/fma/fma62871
T83 9268-9273 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T84 9511-9520 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T85 9961-9965 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T86 10322-10326 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T87 10366-10370 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T88 10674-10683 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T89 11283-11286 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T90 11300-11304 Body_part denotes Cell http://purl.org/sig/ont/fma/fma68646
T91 11376-11385 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T92 11387-11398 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T93 11400-11411 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T94 11413-11427 Body_part denotes dendritic cell http://purl.org/sig/ont/fma/fma273565
T95 11423-11427 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T96 11444-11454 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T97 11449-11454 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T98 11550-11560 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T99 11565-11574 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T100 11588-11601 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T101 11636-11644 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T102 11639-11644 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T103 11673-11681 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T104 11676-11681 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T105 11683-11694 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T106 11725-11734 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T107 11744-11759 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T108 11754-11759 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T109 11761-11772 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T110 11866-11877 Body_part denotes Neutrophils http://purl.org/sig/ont/fma/fma62860
T111 11910-11923 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T112 11930-11939 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T113 11962-11971 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T114 11973-11984 Body_part denotes eosinophils http://purl.org/sig/ont/fma/fma62861
T115 12011-12026 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T116 12021-12026 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T117 12028-12036 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T118 12031-12036 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T119 12071-12075 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T120 12112-12118 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T121 12126-12134 Body_part denotes placenta http://purl.org/sig/ont/fma/fma63934
T122 12136-12161 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T123 12157-12161 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T124 12162-12164 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T125 12166-12180 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T126 12182-12189 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T127 12185-12189 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T128 12191-12210 Body_part denotes natural killer cell http://purl.org/sig/ont/fma/fma63147
T129 12206-12210 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T130 12602-12605 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T131 12629-12632 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T132 13351-13354 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T133 13373-13375 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T134 13377-13391 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T135 13744-13761 Body_part denotes hemopoietic cells http://purl.org/sig/ont/fma/fma83598
T136 13756-13761 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T137 13766-13772 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T138 13799-13808 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T139 14067-14071 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T140 14109-14119 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T141 14125-14134 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T142 14339-14344 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T143 14374-14382 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T144 14487-14495 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T145 14550-14561 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T146 14649-14658 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T147 14750-14759 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T148 14784-14793 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T149 14795-14806 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T150 14808-14819 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T151 14821-14837 Body_part denotes microglial cells http://purl.org/sig/ont/fma/fma54539
T152 14832-14837 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T153 14845-14850 Body_part denotes brain http://purl.org/sig/ont/fma/fma50801
T154 14852-14867 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T155 14862-14867 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T156 14872-14882 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T157 14877-14882 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T158 15284-15294 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T159 15318-15327 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T160 15596-15607 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T161 15681-15691 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T162 15881-15891 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T163 15914-15916 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T164 16007-16017 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740
T165 16155-16160 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T166 16181-16185 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T167 16319-16330 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T168 16669-16673 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T169 16736-16744 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T170 16739-16744 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T171 16787-16798 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T172 16859-16870 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T173 17002-17015 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T174 17002-17006 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T175 17104-17115 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T176 17222-17233 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T177 17366-17370 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T178 17548-17552 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T179 17643-17648 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T180 17716-17722 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T181 17781-17794 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T182 17809-17819 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T183 17820-17831 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T184 17900-17904 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T185 17986-17995 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T186 18000-18011 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T187 18045-18055 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T188 18050-18055 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T189 18057-18072 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T190 18067-18072 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T191 18082-18091 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T192 18092-18103 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T193 18124-18135 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T194 18315-18320 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T195 18348-18354 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T196 18397-18402 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T197 18493-18505 Body_part denotes T‐lymphocyte http://purl.org/sig/ont/fma/fma62870
T198 18542-18547 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T199 18574-18579 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T200 18695-18703 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T201 18774-18779 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T202 18869-18887 Body_part denotes hematopoietic cell http://purl.org/sig/ont/fma/fma83598
T203 18883-18887 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T204 18997-19002 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T205 19197-19222 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T206 19218-19222 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T207 19238-19244 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T208 19249-19254 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T209 19255-19266 Body_part denotes endothelium http://purl.org/sig/ont/fma/fma63916
T210 19295-19300 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T211 19301-19311 Body_part denotes sinusoidal http://purl.org/sig/ont/fma/fma63131
T212 19312-19329 Body_part denotes endothelial cells http://purl.org/sig/ont/fma/fma66772
T213 19324-19329 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T214 19518-19523 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T215 19616-19622 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T216 20219-20223 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T217 20247-20250 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T218 20270-20273 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T219 20543-20556 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T220 20543-20547 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T221 20577-20585 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T222 20750-20754 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T223 20910-20918 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T224 20945-20956 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T225 21041-21049 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T226 21134-21142 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T227 21160-21168 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T228 21218-21223 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264
T229 21227-21234 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T230 21235-21243 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T231 21297-21301 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T232 21673-21676 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T233 21731-21736 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T234 21901-21904 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T235 22584-22589 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T236 22618-22636 Body_part denotes actin cytoskeleton http://purl.org/sig/ont/fma/fma84684
T237 22659-22676 Body_part denotes glycosaminoglycan http://purl.org/sig/ont/fma/fma63011
T238 22677-22687 Body_part denotes glycocalyx http://purl.org/sig/ont/fma/fma66838
T239 22732-22745 Body_part denotes glycoproteins http://purl.org/sig/ont/fma/fma62925
T240 22918-22922 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T241 23171-23175 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T242 23559-23567 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T243 23694-23702 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T244 23851-23864 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T245 23851-23855 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T246 24223-24228 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T247 24505-24518 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T248 24505-24509 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T249 25140-25148 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T250 25143-25148 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T251 25185-25196 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T252 25237-25244 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T253 25240-25244 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T254 25688-25692 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T255 25813-25817 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T256 26072-26076 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T257 26249-26253 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T258 26265-26275 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T259 26363-26366 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T260 26392-26395 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T261 26563-26567 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T262 26606-26611 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T263 26692-26696 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T264 26877-26881 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T265 27400-27406 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T266 27646-27649 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T267 27751-27760 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T268 27764-27767 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T269 27794-27802 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T270 27856-27864 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T271 28728-28736 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T272 28831-28855 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T273 28850-28855 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T274 28888-28903 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T275 28898-28903 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T276 28917-28930 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T277 28957-28989 Body_part denotes major histocompatibility complex http://purl.org/sig/ont/fma/fma84079
T278 29037-29043 Body_part denotes stroma http://purl.org/sig/ont/fma/fma81494
T279 29052-29078 Body_part denotes follicular dendritic cells http://purl.org/sig/ont/fma/fma83037
T280 29073-29078 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T281 29090-29098 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T282 29129-29137 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T283 29155-29167 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T284 29155-29159 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T285 29208-29213 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T286 29344-29355 Body_part denotes lymphocytes http://purl.org/sig/ont/fma/fma62863
T287 29456-29460 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T288 29481-29486 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T289 29503-29508 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T290 29610-29613 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T291 29652-29664 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T292 29652-29656 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T293 29677-29681 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T294 29796-29800 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T295 29903-29907 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T296 30009-30013 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T297 30071-30075 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T298 30196-30200 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T299 30248-30253 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T300 30271-30280 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T301 30298-30302 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T302 30317-30325 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T303 30386-30391 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T304 30691-30695 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T305 30808-30812 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T306 30924-30929 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T307 30969-30972 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T308 31114-31117 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T309 31150-31153 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T310 31300-31312 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T311 31300-31304 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T312 31611-31614 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T313 31724-31727 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T314 31854-31857 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T315 31955-31958 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T316 31969-31972 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T317 32095-32100 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T318 32214-32217 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T319 32283-32293 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T320 33004-33017 Body_part denotes phenylalanine http://purl.org/sig/ont/fma/fma82754
T321 33018-33024 Body_part denotes valine http://purl.org/sig/ont/fma/fma82766
T322 33058-33061 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T323 33534-33543 Body_part denotes histidine http://purl.org/sig/ont/fma/fma82755
T324 33567-33570 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T325 33764-33772 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T326 33797-33800 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T327 33862-33865 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T328 34084-34087 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T329 34127-34130 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T330 34338-34341 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T331 34907-34910 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T332 35107-35110 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T333 35188-35194 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T334 35212-35227 Body_part denotes oligosaccharide http://purl.org/sig/ont/fma/fma82742
T335 36327-36338 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T336 36387-36395 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T337 36401-36404 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T338 37745-37752 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T339 37821-37829 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T340 38074-38077 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T341 38130-38135 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T342 38576-38579 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T343 38740-38743 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T344 38802-38805 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T345 39217-39225 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T346 39439-39447 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T347 39868-39871 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T348 39902-39905 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T349 40424-40428 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T350 40449-40453 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T351 40750-40758 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T352 41065-41070 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T353 41173-41183 Body_part denotes macrophage http://purl.org/sig/ont/fma/fma63261
T354 41218-41222 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T355 41400-41404 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T356 41436-41440 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T357 41599-41603 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T358 42237-42242 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T359 42823-42833 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T360 43001-43004 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T361 43005-43013 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T362 43463-43476 Body_part denotes Interleukin 5 http://purl.org/sig/ont/fma/fma264830
T363 43463-43474 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T364 43564-43567 Body_part denotes ear http://purl.org/sig/ont/fma/fma52780
T365 43568-43572 Body_part denotes nose http://purl.org/sig/ont/fma/fma46472
T366 43573-43579 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T367 43806-43813 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T368 43964-43986 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T369 44020-44031 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T370 44274-44283 Body_part denotes chemokine http://purl.org/sig/ont/fma/fma241981
T371 44369-44391 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T372 45623-45645 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T373 45667-45669 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T374 45671-45685 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T375 46137-46143 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T376 46147-46157 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T377 46173-46179 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T378 46851-46858 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T379 46854-46858 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T380 46886-46896 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T381 46972-46982 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T382 47245-47256 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T383 47296-47302 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T384 47507-47518 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T385 47537-47548 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 47581-47584 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T387 47646-47654 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T388 47736-47747 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T389 48200-48211 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T390 48524-48529 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T391 48796-48807 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T392 49212-49215 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T393 49336-49339 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T394 49712-49715 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T395 50014-50023 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T396 50170-50173 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T397 50312-50321 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T398 50593-50601 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T399 50895-50903 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T400 50925-50933 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T401 50976-50981 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T402 51183-51193 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T403 52089-52099 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T404 52236-52243 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T405 52311-52318 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749
T406 52548-52558 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T407 52724-52735 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T408 53220-53228 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T409 53650-53652 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T410 53929-53938 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T411 54312-54320 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T412 54551-54559 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T413 54639-54644 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T414 54707-54716 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T415 54721-54730 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T416 54726-54730 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T417 54803-54813 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T418 54817-54825 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T419 54835-54841 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T420 54978-54990 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T421 54978-54982 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T422 55641-55646 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T423 55659-55662 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T424 55946-55949 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T425 55998-56006 Body_part denotes basophil http://purl.org/sig/ont/fma/fma62862
T426 56011-56020 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T427 56016-56020 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T428 56135-56138 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T429 56160-56164 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T430 56165-56168 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T431 56210-56213 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T432 56227-56239 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T433 56227-56231 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T434 56351-56354 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T435 56369-56372 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T436 56376-56381 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T437 56423-56426 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T438 56514-56517 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T439 56647-56655 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T440 56674-56677 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T441 57545-57555 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T442 57569-57577 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T443 57648-57651 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T444 57655-57664 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T445 57881-57884 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T446 57940-57943 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T447 58116-58121 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T448 58269-58293 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T449 58288-58293 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T450 58299-58304 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T451 58389-58394 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T452 59589-59597 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T453 59915-59923 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T454 60055-60058 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T455 60410-60418 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T456 60694-60702 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T457 61869-61882 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T458 61968-61976 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-MAT

Id Subject Object Predicate Lexical cue
T1 12105-12118 http://purl.obolibrary.org/obo/MAT_0000303 denotes smooth muscle
T2 12112-12118 http://purl.obolibrary.org/obo/MAT_0000025 denotes muscle
T3 12126-12134 http://purl.obolibrary.org/obo/MAT_0000279 denotes placenta
T4 14283-14288 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T5 14845-14850 http://purl.obolibrary.org/obo/MAT_0000098 denotes brain
T6 19231-19244 http://purl.obolibrary.org/obo/MAT_0000303 denotes smooth muscle
T7 19238-19244 http://purl.obolibrary.org/obo/MAT_0000025 denotes muscle
T8 19249-19254 http://purl.obolibrary.org/obo/MAT_0000097 denotes liver
T9 19295-19300 http://purl.obolibrary.org/obo/MAT_0000097 denotes liver
T10 24269-24277 http://purl.obolibrary.org/obo/MAT_0000491 denotes proximal
T11 25791-25796 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T12 26676-26681 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T13 43564-43567 http://purl.obolibrary.org/obo/MAT_0000317 denotes ear
T14 43564-43567 http://purl.obolibrary.org/obo/MAT_0000233 denotes ear
T15 43564-43567 http://purl.obolibrary.org/obo/MAT_0000138 denotes ear
T16 43568-43572 http://purl.obolibrary.org/obo/MAT_0000139 denotes nose
T17 43964-43986 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T18 43972-43986 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T19 44369-44391 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T20 44377-44391 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T21 45623-45645 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T22 45631-45645 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T23 56113-56118 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T24 56607-56612 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T25 58767-58775 http://purl.obolibrary.org/obo/MAT_0000491 denotes proximal

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T1 732-744 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T2 2176-2192 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T3 3438-3453 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 3512-3534 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 3525-3534 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 3731-3752 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 4807-4811 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 4860-4872 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 4874-4886 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 5094-5103 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 5411-5431 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 5935-5947 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 6176-6196 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 6246-6275 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 6260-6275 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 6349-6358 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 6427-6440 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 6603-6618 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 6718-6730 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 6761-6770 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 6927-6943 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 7214-7236 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 7227-7236 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 7296-7305 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 7385-7389 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 7804-7816 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 7888-7908 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 7994-8014 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 7996-8014 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 8025-8040 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 8083-8098 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 8353-8362 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T33 8353-8362 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T34 13147-13155 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 13364-13372 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 15075-15091 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 17408-17417 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 17476-17486 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 17538-17563 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 17546-17563 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 17548-17563 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 17865-17874 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 19465-19474 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 19635-19657 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 20028-20037 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 20114-20123 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 20586-20601 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 20793-20802 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 21070-21079 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 21169-21184 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 21244-21256 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 21297-21312 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 21745-21757 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 22414-22418 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 22918-22933 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 23073-23088 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 23328-23332 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 23345-23349 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 23461-23472 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 23606-23610 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 23627-23660 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 24035-24039 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 24964-24968 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 24973-24985 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 24986-24990 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 25245-25249 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 25688-25700 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 25799-25828 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 25813-25828 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 25942-25951 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 26044-26053 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 26070-26087 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 26072-26087 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 26690-26707 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 26692-26707 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 27146-27158 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 27159-27170 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 27775-27781 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T79 27829-27844 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T80 28048-28054 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T81 28325-28331 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T82 28490-28510 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T83 28957-28989 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T84 29000-29020 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T85 29422-29438 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T86 30298-30312 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T87 30317-30335 http://purl.obolibrary.org/obo/GO_0050663 denotes cytokine secretion
T88 30326-30335 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T89 30790-30795 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T90 32181-32193 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T91 36406-36414 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T92 36736-36744 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 37634-37645 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T94 38999-39017 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T95 39202-39206 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T96 40225-40229 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 40233-40245 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T98 40414-40434 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T99 40424-40434 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T100 40429-40434 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T101 40498-40507 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 40525-40529 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 40589-40593 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 40713-40717 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 41301-41310 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 42206-42210 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 46542-46546 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 46868-46872 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 46906-46918 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 47954-47958 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 47963-47975 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 48007-48013 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 48050-48054 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 48505-48509 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 48971-48975 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 50818-50826 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 50953-50957 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 51183-51204 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 51209-51218 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T120 51209-51218 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T121 52041-52062 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 53653-53661 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 53774-53795 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 54509-54527 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 54509-54518 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 54590-54599 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 54883-54892 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 55056-55065 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 55596-55605 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 56011-56031 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 56016-56031 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 58137-58146 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 58341-58350 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T134 58341-58350 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T135 58363-58368 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T136 59196-59201 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T137 59222-59228 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 680-686 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T2 1136-1157 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T3 1170-1180 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T4 1189-1236 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T5 1238-1248 Disease denotes SARS‐CoV‐2 http://purl.obolibrary.org/obo/MONDO_0100096
T6 2796-2817 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T7 3302-3320 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T8 3354-3372 Disease denotes virus in infection http://purl.obolibrary.org/obo/MONDO_0005108
T9 3400-3407 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T10 4282-4288 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T11 8756-8764 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T12 12348-12356 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 13498-13506 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 15413-15437 Disease denotes immune thrombocytopenias http://purl.obolibrary.org/obo/MONDO_0002048
T15 15756-15784 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T16 15899-15910 Disease denotes anaphylaxis http://purl.obolibrary.org/obo/MONDO_0100053
T17 25336-25342 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T18 28183-28188 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T19 32181-32193 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T20 40296-40302 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T21 40442-40448 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T22 40601-40606 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T23 41154-41159 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T24 41211-41217 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T25 42231-42236 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T26 42649-42655 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T27 43564-43589 Disease denotes ear nose throat disorders http://purl.obolibrary.org/obo/MONDO_0024623
T28 43852-43871 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T29 44097-44122 Disease denotes musculoskeletal disorders http://purl.obolibrary.org/obo/MONDO_0002081
T30 44583-44601 Disease denotes Infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T31 44891-44900 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T32 45003-45026 Disease denotes Hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T33 45209-45228 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T34 45792-45800 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T35 46497-46502 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T36 47237-47265 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T37 47728-47756 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T38 47998-48006 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T39 48605-48610 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T40 48763-48783 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0018908
T41 48788-48816 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T42 50544-50549 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T43 50691-50697 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T44 54664-54692 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T45 55322-55340 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T46 55723-55731 Disease denotes allergic http://purl.obolibrary.org/obo/MONDO_0004980
T47 56484-56491 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T48 58382-58388 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T49 59216-59221 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T50 60978-60996 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T51 61104-61122 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T52 61131-61178 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T53 61180-61190 Disease denotes SARS‐CoV‐2 http://purl.obolibrary.org/obo/MONDO_0100096
T54 61192-61201 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T55 61457-61475 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T56 61509-61523 Disease denotes adenocarcinoma http://purl.obolibrary.org/obo/MONDO_0004970

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 680-686 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T2 3302-3320 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T3 3400-3407 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T4 7369-7383 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T5 15413-15437 Phenotype denotes immune thrombocytopenias http://purl.obolibrary.org/obo/HP_0001973
T6 15756-15784 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T7 15899-15910 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T8 25336-25342 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 28183-28188 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T10 40296-40302 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T11 40442-40448 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T12 40601-40606 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T13 41154-41159 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T14 41211-41217 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 42231-42236 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 42649-42655 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T17 43178-43186 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T18 43430-43438 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T19 43754-43762 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T20 43988-43996 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T21 44235-44243 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T22 44393-44401 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T23 44511-44519 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T24 44603-44611 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T25 44715-44723 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T26 44815-44823 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T27 44902-44910 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T28 45440-45448 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T29 45523-45531 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T30 45647-45655 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T31 46497-46502 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T32 47237-47265 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T33 47728-47756 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 47998-48006 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 48605-48610 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 48763-48783 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 48788-48816 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T38 50544-50549 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T39 50691-50697 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T40 54664-54692 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T41 55322-55340 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T42 56484-56491 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T43 58382-58388 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T44 59216-59221 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T1 732-744 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T2 2176-2192 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T3 3438-3453 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 3512-3534 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 3525-3534 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 3731-3752 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 4807-4811 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 4860-4872 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 4874-4886 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 5094-5103 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 5411-5431 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 5935-5947 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 6176-6196 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 6246-6275 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 6260-6275 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 6349-6358 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 6427-6440 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 6603-6618 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 6718-6730 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 6761-6770 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 6927-6943 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 7214-7236 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 7227-7236 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 7296-7305 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 7385-7389 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 7804-7816 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 7888-7908 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 7994-8014 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 7996-8014 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 8025-8040 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 8083-8098 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 8353-8362 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T33 8353-8362 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T34 13147-13155 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 13364-13372 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 15075-15091 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 17408-17417 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 17476-17486 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 17538-17563 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 17546-17563 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 17548-17563 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 17865-17874 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 19465-19474 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 19635-19657 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 20028-20037 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 20114-20123 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 20586-20601 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 20793-20802 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 21070-21079 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 21169-21184 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 21244-21256 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 21297-21312 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 21745-21757 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 22414-22418 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 22918-22933 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 23073-23088 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 23328-23332 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 23345-23349 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 23461-23472 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 23606-23610 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 23627-23660 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 24035-24039 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 24964-24968 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 24973-24985 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 24986-24990 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 25245-25249 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 25688-25700 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 25799-25828 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 25813-25828 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 25942-25951 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 26044-26053 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 26070-26087 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 26072-26087 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 26690-26707 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 26692-26707 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 27146-27158 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 27159-27170 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 27775-27781 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T79 27775-27781 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T80 27829-27844 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T81 28048-28054 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T82 28325-28331 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T83 28325-28331 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T84 28490-28510 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T85 28957-28989 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T86 29000-29020 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T87 29422-29438 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T88 30298-30312 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T89 30317-30335 http://purl.obolibrary.org/obo/GO_0001816 denotes cytokine secretion
T90 30326-30335 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T91 32181-32193 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T92 36406-36414 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 36736-36744 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T94 37634-37645 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T95 38999-39017 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T96 39202-39206 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 40225-40229 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T98 40233-40245 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T99 40414-40434 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T100 40424-40434 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T101 40498-40507 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 40525-40529 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 40589-40593 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 40713-40717 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 41301-41310 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 42206-42210 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 46542-46546 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 46868-46872 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 46906-46918 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 47954-47958 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 47963-47975 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 48007-48013 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 48050-48054 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 48505-48509 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 48971-48975 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 50818-50826 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 50953-50957 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 51183-51204 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 51209-51218 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T120 51209-51218 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T121 52041-52062 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 53653-53661 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 53774-53795 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 54509-54527 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 54509-54518 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 54590-54599 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 54883-54892 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 55056-55065 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 55596-55605 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 56011-56031 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 56016-56031 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 58137-58146 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 58341-58350 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T134 58341-58350 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T135 59222-59228 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 732-744 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T2 2176-2192 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T3 3438-3453 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 3512-3534 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 3525-3534 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 3731-3752 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 4807-4811 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 4860-4872 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 4874-4886 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 5094-5103 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 5411-5431 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 5935-5947 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 6176-6196 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 6246-6275 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 6260-6275 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 6349-6358 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 6427-6440 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 6603-6618 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 6718-6730 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 6761-6770 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 6927-6943 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 7214-7236 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 7227-7236 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 7296-7305 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 7385-7389 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 7804-7816 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 7888-7908 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 7994-8014 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 7996-8014 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 8025-8040 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 8083-8098 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 8353-8362 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T33 8353-8362 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T34 13147-13155 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 13364-13372 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 15075-15091 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 17408-17417 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 17476-17486 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 17538-17563 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 17546-17563 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 17548-17563 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 17865-17874 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 19465-19474 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 19635-19657 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 20028-20037 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 20114-20123 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 20586-20601 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 20793-20802 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 21070-21079 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 21169-21184 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 21244-21256 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 21297-21312 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 21745-21757 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 22414-22418 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 22918-22933 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 23073-23088 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 23328-23332 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 23345-23349 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 23461-23472 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 23606-23610 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 23627-23660 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 24035-24039 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 24964-24968 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 24973-24985 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 24986-24990 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 25245-25249 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 25688-25700 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 25799-25828 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 25813-25828 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 25942-25951 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 26044-26053 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 26070-26087 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 26072-26087 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 26690-26707 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 26692-26707 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 27146-27158 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 27159-27170 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 27775-27781 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T79 27775-27781 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T80 27829-27844 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T81 28048-28054 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T82 28325-28331 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T83 28325-28331 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T84 28490-28510 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T85 28957-28989 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T86 29000-29020 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T87 29422-29438 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T88 30298-30312 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T89 30317-30335 http://purl.obolibrary.org/obo/GO_0001816 denotes cytokine secretion
T90 30326-30335 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T91 32181-32193 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T92 36406-36414 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 36736-36744 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T94 37634-37645 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T95 38999-39017 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T96 39202-39206 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 40225-40229 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T98 40233-40245 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T99 40414-40434 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T100 40424-40434 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T101 40498-40507 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 40525-40529 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 40589-40593 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 40713-40717 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 41301-41310 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 42206-42210 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 46542-46546 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 46868-46872 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 46906-46918 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 47954-47958 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 47963-47975 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 48007-48013 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 48050-48054 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 48505-48509 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 48971-48975 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 50818-50826 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 50953-50957 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 51183-51204 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 51209-51218 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T120 51209-51218 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T121 52041-52062 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 53653-53661 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 53774-53795 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 54509-54527 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 54509-54518 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 54590-54599 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 54883-54892 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 55056-55065 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 55596-55605 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 56011-56031 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 56016-56031 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 58137-58146 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 58341-58350 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T134 58341-58350 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T135 59222-59228 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-92 Sentence denotes Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
T2 93-120 Sentence denotes FcγR and mAb immune therapy
T3 121-140 Sentence denotes AM Chenoweth et al.
T4 142-150 Sentence denotes Abstract
T5 151-159 Sentence denotes Abstract
T6 160-447 Sentence denotes The human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens.
T7 448-633 Sentence denotes More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees.
T8 634-868 Sentence denotes This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs.
T9 869-1085 Sentence denotes The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects.
T10 1086-1322 Sentence denotes The still unmet therapeutic need in many cancers, inflammatory diseases or emerging infections such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) requires increased effort on the development of improved and novel mAbs.
T11 1323-1544 Sentence denotes A more mature appreciation of the immunobiology of individual FcγR function and the complexity of the relationships between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies.
T12 1545-1828 Sentence denotes Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for selective engagement of individual activating FcγRs or the inhibitory FcγRIIb or alternatively, for the ablation of FcγR interaction altogether.
T13 1829-1974 Sentence denotes This review touches on recent aspects of FcγR and IgG immunobiology and its relationship with the present and future actions of therapeutic mAbs.
T14 1976-2193 Sentence denotes Fragment crystallizable (Fc) receptors for immunoglobulin (Ig)G activate and modulate a powerful network of inflammatory, host‐protective effector functions that are central to effective and balanced immune responses.
T15 2194-2277 Sentence denotes These responses are also harnessed—or avoided—by therapeutic monoclonal antibodies.
T16 2278-2469 Sentence denotes The use and manipulation of IgG2, IgG4 as well as IgG1 for optimized activating or inhibitory FcγR effector functions will underpin the development of potent "next‐gen" antibody therapeutics.
T17 2471-2483 Sentence denotes Introduction
T18 2484-2619 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 2620-2745 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 2746-3199 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1
T21 3200-3574 Sentence denotes The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity.
T22 3575-3967 Sentence denotes Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review.
T23 3968-4301 Sentence denotes In normal homeostatic immunity, there is a balance between IgG immune complex activation of proinflammatory responses through the activating‐type FcγRs—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host.
T24 4302-4490 Sentence denotes Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7
T25 4491-4654 Sentence denotes Many therapeutic mAbs depend, to varying degrees, on FcγR function (Figure 1, Table 1) for their mechanism of action (MOA) and/or their pharmacokinetic properties.
T26 4655-4907 Sentence denotes For some mAbs interaction with FcγR is central to their MOA, such as the destruction of a target cell by antibody‐dependent cell‐mediated cytotoxicity (ADCC; Figure 1a) or antibody‐dependent cell‐mediated phagocytosis (phagocytosis or ADCP; Figure 1b).
T27 4908-5126 Sentence denotes This also includes mAbs that may harness the inhibitory action of FcγRIIb to modulate the proinflammatory responses of immunoreceptor tyrosine activation motif (ITAM)‐dependent receptor signaling complexes (Figure 1c).
T28 5127-5453 Sentence denotes For other mAbs, FcγR may play a secondary role, such as the removal or “sweeping” of all immune complexes formed by cytokine or virus‐specific neutralizing antibodies or of opsonized fragments of lysed target cells which in antigen‐presenting cells may also feed the antigen into the antigen‐presentation pathways (Figure 1d).
T29 5454-5746 Sentence denotes In addition, FcγRs, particularly FcγRIIb (Figure 1e), are also key participants in the MOA of immune‐stimulating agonistic mAbs or apoptotic mAbs by acting as a scaffold for the additional cross‐linking of mAbs already bound to a cellular target, thereby inducing a signal in the target cell.
T30 5747-6072 Sentence denotes Figure 1 Graphical representation of the FcγR effector functions. (a) Natural killer cell antibody‐dependent cell‐mediated cytotoxicity via FcγRIIIa. (b) Antibody‐dependent cell‐mediated phagocytosis, and/or trogocytosis of large immune complexes, by professional phagocytes via activating FcγR such as FcγRIIIa and FcγRIIa.
T31 6073-6287 Sentence denotes Biological sequelae include the destruction of the ingested complexes which may also feed antigen into antigen‐presentation pathways of antigen‐presenting cells (APCs). (c) Inhibition of cell activation by FcγRIIb.
T32 6288-6588 Sentence denotes The immunoreceptor tyrosine activation motif (ITAM)‐mediated signaling of B‐cell antigen receptors (left) or of activating FcγR (right) on innate immune cells such as macrophages and basophils is inhibited by IgG Fc‐mediated co‐cross‐linking of these activating receptors with the inhibitory FcγRIIb.
T33 6589-7000 Sentence denotes This leads to phosphorylation of the FcγRIIb immunoreceptor tyrosine‐based inhibitory motif (ITIM) and consequently recruits the phosphatases that modulate the ITAM‐driven signaling responses leading to diminished cell responses. (d) Sweeping or internalization of small immune complexes leading to their removal and, in APC, to enhanced immune responses. (e) Scaffolding in which the FcγRs play a passive role.
T34 7001-7319 Sentence denotes Typically involving FcγRIIb, no signal is generated in the effector cell but “super‐cross‐linking” of the opsonizing antibody by the FcγR on one cell generates a signal in the conjugated target cell, for example, induction of apoptosis or activation in agonistic expansion of cells and/or their secretion of cytokines.
T35 7320-7384 Sentence denotes In extreme cases, this leads to life‐threatening cytokine storm.
T36 7385-7512 Sentence denotes ADCC, antibody‐dependent cell‐mediated cytotoxicity; Ag, antigen; BCR, B‐cell receptor; Ig, immunoglobulin; NK, natural killer.
T37 7513-7590 Sentence denotes Table 1 FcγR responses relevant to therapeutic monoclonal antibodies (mAbs).
T38 7591-7671 Sentence denotes FcγR‐mediated mechanism of action Effector responses Action Dominant receptor
T39 7672-7770 Sentence denotes Activation Antibody‐dependent cell‐mediated cytotoxicity Direct killing of target cell FcγRIIIa
T40 7771-7887 Sentence denotes Antibody‐dependent cell‐mediated phagocytosis, trogocytosis Direct killing of target cell FcγRIIIa, FcγRIIa, FcγRI
T41 7888-7974 Sentence denotes Antigen presentation Vaccine‐like immunity post‐mAb therapy FcγRIIa, FcγRI, FcγRIIIa
T42 7975-8159 Sentence denotes Inhibition Reduce B‐cell proliferation or innate cell activation by antibody complexes Inhibition of ITAM cell activation (i.e. BCR) or activating‐type FcR (i.e. FcγR, FcεRI, FcαRI).
T43 8160-8240 Sentence denotes Note that the FcγRIIb must be co‐cross‐linked with the ITAM activating receptor.
T44 8242-8249 Sentence denotes FcγRIIb
T45 8250-8321 Sentence denotes Sweeping Internalization Removal of small immune complexes FcγRIIb a
T46 8322-8516 Sentence denotes Scaffolding Target agonism or apoptosis Passive “super‐cross‐linking” of mAb on opsonized target cell, for example, CD40, CD28, CD20, by FcγR on an adjacent cell FcγRIIb; also FcγRIIa, FcγRI?
T47 8517-8586 Sentence denotes BCR, B‐cell receptor; ITAM, immunoreceptor tyrosine activation motif.
T48 8587-8650 Sentence denotes a Activating FcγR can also contribute to removal of complexes.
T49 8651-8798 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T50 8799-8981 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T51 8982-9469 Sentence denotes This review focuses on the cell‐based effector functions that arise from the interaction of IgG with the classical human leukocyte FcγR.7 Although beyond the scope of this review, it should be noted that the IgG‐Fc portion dictates other aspects of an antibody’s biology, including its serum half‐life mediated by the neonatal FcR (FcRn), 3 the activation of complement C1,8 antiviral protection via the intracellular receptor TRIM219 and interactions with the Fc receptor‐like family.10
T52 9471-9500 Sentence denotes Human FcγR General Properties
T53 9501-9868 Sentence denotes The human leukocyte receptors fall into two functional groups, namely, proinflammatory, activating‐type receptors (FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb, which are also known as CD64, CD32a, CD32c, CD16a and CD16b, respectively) and the anti‐inflammatory, inhibitory‐receptor group (FcγRIIb also called CD32b) which was the first immune checkpoint described.
T54 9869-9976 Sentence denotes These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses.
T55 9977-10185 Sentence denotes In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1).
T56 10186-10333 Sentence denotes These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types.
T57 10334-10589 Sentence denotes Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses.
T58 10590-10732 Sentence denotes In this review, we address only key aspects of the extensive knowledge of the human leukocyte FcγR family as it relates to effector functions.
T59 10733-11233 Sentence denotes A number of other reviews more comprehensively explore FcγR biology physiology, biochemistry, genetics and structure.7, 11, 12, 13, 14 Notwithstanding the recognized differences between the immunobiology of human FcγR and of rodents or nonhuman primates, animal models of FcR effector function in vivo have helped shape the strategies for the development of current therapeutic mAbs and are well reviewed.12, 15 Furthermore, humanized FcγR models will provide even greater insights into the future.16
T60 11234-11262 Sentence denotes Table 2 Properties of FcγR.
T61 11263-11317 Sentence denotes Receptor Affinity IgG specificity Cell distribution
T62 11318-11454 Sentence denotes FcγRI High IgG1, IgG3, IgG4 Induced by interferon‐γ on monocytes, neutrophils, macrophages, dendritic cell subpopulations; mast cells
T63 11455-11601 Sentence denotes FcγRIIa Low IgG1, IgG3, but IgG2 binding limited to the FcγRIIa‐H131 form, ~70% people) All leukocytes and platelets except T and B lymphocytes
T64 11602-11644 Sentence denotes FcγRIIc a Low IgG1, IgG3, IgG4 NK cells
T65 11645-11671 Sentence denotes FcγRIIIa Low IgG1, IgG3.
T66 11673-11791 Sentence denotes NK cells, macrophages, subpopulation of circulating monocytes, myeloid dendritic cells, neutrophils at very low levels
T67 11792-11838 Sentence denotes Binding avidity reduced by Phe at position 158
T68 11839-11877 Sentence denotes FcγRIIIb Low IgG1, IgG3 Neutrophils
T69 11878-11985 Sentence denotes FcγRIIb Low IgG1, IgG3, IgG4 B lymphocytes, some monocytes (can be upregulated); basophils; eosinophils?
T70 11986-12097 Sentence denotes Plasmacytoid and myeloid dendritic cells; NK cells only of individuals with FcγRIIIb gene copy number variation
T71 12098-12161 Sentence denotes Airway smooth muscle, LSEC, placenta, follicular dendritic cell
T72 12162-12211 Sentence denotes Ig, immunoglobulin; NK cell, natural killer cell.
T73 12212-12242 Sentence denotes a Expressed in 20% of people.
T74 12243-12390 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T75 12391-12573 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T76 12574-12628 Sentence denotes Table 3 Unique features of IgG subclass Fc and hinge.
T77 12629-12729 Sentence denotes IgG subclass FcγR specificity Light‐chain attachment Hinge characteristics Fc stability Comment
T78 12730-12840 Sentence denotes IgG1 All FcγR Upper hinge Light‐chain attachment Stable Fc is >100× times more stable than IgG4 and IgG2.
T79 12841-12858 Sentence denotes Stable core hinge
T80 12859-12995 Sentence denotes IgG2 FcγRIIa His131 CH1 of Fab and/or upper hinge Stable core hinge with additional inter H‐chain disulfide bonds in the upper hinge.
T81 12997-13078 Sentence denotes Unstable CH3:CH3 Alternative light‐chain attachment creates distinct conformers.
T82 13079-13210 Sentence denotes Unlike IgG4, the CH3:CH3 instability does not lead to half‐molecule exchange as a result of stable core and upper hinge disulfides.
T83 13211-13372 Sentence denotes IgG4 FcγRI, FcγRIIb, FcγRIIc CH1 of Fab Labile core hinge Unstable CH3:CH3 Combined instability of core hinge and CH3:CH3 permits half‐IgG molecule exchange
T84 13373-13392 Sentence denotes Ig, immunoglobulin.
T85 13393-13540 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T86 13541-13723 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T87 13725-13761 Sentence denotes FcγR expression on hemopoietic cells
T88 13762-14026 Sentence denotes The tissue distribution of the human leukocyte FcγR is well documented and reviewed comprehensively elsewhere.7, 11, 17 In the context of effector functions harnessed by therapeutic mAbs, several aspects of the cellular distribution (Table 2) should be emphasized.
T89 14027-14172 Sentence denotes FcγR expression profiles differ between cell lineages but almost all mature human leukocytes, and platelets, express at least one FcγR (Table 2).
T90 14173-14614 Sentence denotes It should also be appreciated that the cellular expression levels and receptor diversity as will be described later is also influenced by the activation state of the cells, anatomical location and the cytokine environment which modulates FcγR expression, particularly for FcγRI and FcγRIIb.18 For example, resting monocyte subpopulations may express only FcγRIIa but activated macrophages express FcγRI, FcγRIIa and FcγRIIIa and/or FcγRIIb.7
T91 14615-14701 Sentence denotes Thus, specific characteristics of leukocyte FcγR expression are summarized as follows:
T92 14702-14883 Sentence denotes FcγRI is not usually expressed until induced by cytokines such as interferon‐γ on monocytes, neutrophils, macrophages, microglial cells in the brain, dendritic cells and mast cells.
T93 14884-15169 Sentence denotes The sensitivity of FcγRI to interferon‐γ suggests that its in vivo activity is closely tied to immune activation events, and mouse studies have suggested that it has a critical role early in immune responses.19, 20 Its role in the MOA of antibodies may vary with anatomical location.21
T94 15170-15295 Sentence denotes FcγRIIa is expressed only in primates and shows the broadest expression of all FcγRs, being present on all innate leukocytes.
T95 15296-15438 Sentence denotes It is also present on platelets but its role in effector functions is not established but it is important in certain immune thrombocytopenias.
T96 15439-15517 Sentence denotes A polymorphic form of this receptor is the only human receptor for human IgG2.
T97 15518-15692 Sentence denotes This, together with its limited species expression and unique ITAM‐containing cytoplasmic tail (reviewed by Anania et al. 11), suggests a unique function in human leukocytes.
T98 15693-15939 Sentence denotes Interestingly, polymorphism of the receptor is associated with systemic lupus erythematosus and resistance to Gram‐negative organisms.11 A rare, hyper‐responsive form is a risk factor for neutrophil‐driven anaphylaxis in Ig replacement therapy.22
T99 15940-16379 Sentence denotes FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa.
T100 16380-16498 Sentence denotes Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals.
T101 16499-16631 Sentence denotes Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this.
T102 16632-16706 Sentence denotes FcγRIII forms are two highly related gene products, FcγRIIIa and FcγRIIIb.
T103 16707-16799 Sentence denotes The FcγRIIIa is expressed on NK cells and professional phagocytes, particularly macrophages.
T104 16800-17047 Sentence denotes It is only recently apparent that FcγRIIIa is expressed on neutrophils, albeit at low levels, but plays a role in their function.23 FcγRIIIb is unique to humans and unlike other FcγRs it is attached to cell membrane via a glycophosphatidyl anchor.
T105 17048-17189 Sentence denotes It is expressed, predominantly and abundantly, on human neutrophils.7 Its effector function depends in part on its coexpression with FcγRIIa.
T106 17190-17303 Sentence denotes The lack of FcγRIIIb on macaque neutrophils appears to be compensated for by an increase in FcγRIIa expression.15
T107 17304-17371 Sentence denotes FcγRIIbs are the inhibitory‐type FcγR and arise from a single gene.
T108 17372-17453 Sentence denotes They lack intrinsic proinflammatory signaling and are instead immune checkpoints.
T109 17454-17584 Sentence denotes They provide feedback regulation by antibodies, in the form of immune complexes, to inhibit B‐cell activation by specific antigen.
T110 17585-17649 Sentence denotes They also control activating‐type FcγR function on innate cells.
T111 17650-17743 Sentence denotes Two major splice variant forms of FcγRIIb exist with differential tissue expression profiles.
T112 17744-17928 Sentence denotes FcγRIIb1 preferentially expressed on B lymphocytes contains a 20‐amino acid cytoplasmic insertion necessary for membrane retention and cocapping with the B‐cell antigen receptor (BCR).
T113 17929-18104 Sentence denotes FcγRIIb2 is the predominant inhibitory receptor found on basophils and neutrophils, as well as on subpopulations of mast cells, dendritic cells and some monocytes/macrophages.
T114 18105-18321 Sentence denotes FcγRIIb2 lacks the cytoplasmic insertion of FcγRIIb1 and consequently can internalize rapidly including with the activating FcR when they are co‐cross‐linked.11 It is not clear which form is present on human T cells.
T115 18322-18449 Sentence denotes One additional comment on tissue distribution is that FcγR expression on T cells has been difficult to establish unequivocally.
T116 18450-18531 Sentence denotes However, there is increasing evidence that T‐lymphocyte populations express FcγR.
T117 18532-18743 Sentence denotes Some γδ T cells express FcγRIIIa and αβ T cells reportedly express FcγRIIa, FcγRIIb or FcγRIIIa but the significance with respect to effector function mediated by antibody is presently unclear.24, 25, 26, 27, 28
T118 18745-18779 Sentence denotes Expression on nonhemopoietic cells
T119 18780-19003 Sentence denotes The immunobiology of FcγR is studied and understood almost exclusively in the context of hematopoietic cell function but relatively recent investigations have identified and explored FcγR expression on nonhemopoietic cells.
T120 19004-19108 Sentence denotes These studies suggest important roles in normal immune function and in the MOA of some therapeutic mAbs.
T121 19109-19267 Sentence denotes The most extensively characterized receptor expression is FcγRIIb which is expressed on follicular dendritic cell, airway smooth muscle and liver endothelium.
T122 19268-19658 Sentence denotes Its abundant expression on liver sinusoidal endothelial cells (LSECs) is estimated to represent the majority of in vivo FcγRIIb expression.17, 29, 30, 31 As FcγRIIb lacks intrinsic proinflammatory signaling function, its role on these nonhemopoietic cells involves immune complex handling without the danger of, or the need for, induction of local tissue destructive inflammatory responses.
T123 19659-19996 Sentence denotes On LSEC its major role appears to be immune complex sweeping, a process of removal of small immune complexes such as opsonized virus or macromolecules.17 This scavenging role by FcγRIIb on LSEC can be exploited in principle by mAbs forming small soluble complexes with their targets such as antiviral, anticytokine or similar antibodies.
T124 19998-20037 Sentence denotes FcγR activating or inhibitory signaling
T125 20038-20165 Sentence denotes Effector functions that are initiated via the activating‐type FcγR occur by signaling via the ITAM pathway of immune receptors.
T126 20166-20350 Sentence denotes This well‐characterized pathway is used by BCR and T‐cell antigen receptors, the IgE receptor FcεRI and IgA receptor FcαRI (reviewed extensively by Hogarth and Pietersz 7 Anania et al.
T127 20351-20518 Sentence denotes 11 and Getahun and Cambier 32) Induction of an activating signal requires the aggregation of activating FcγR by immune complexes, or by antigen in the case of the BCR.
T128 20519-20679 Sentence denotes This aggregation at the cell membrane results in specific tyrosine phosphorylation of the ITAM by Src kinases, thus initiating the activation cascade.32, 33, 34
T129 20680-21313 Sentence denotes The inhibitory‐type FcγRs, FcγRIIb1 and FcγRIIb2, whose expression is cell lineage restricted, modulate the ITAM signaling of the BCR or the activating‐type FcγRs, respectively.11 Their function is dependent on the immunoreceptor tyrosine inhibition motif in their cytoplasmic tail.32, 33 This checkpoint action requires that FcγRIIbs are coaggregated with the tyrosine‐phosphorylated ITAM‐signaling receptor complex which results also in immunoreceptor tyrosine inhibition motif tyrosine phosphorylation and consequential recruitment of lipid or protein tyrosine phosphatases that powerfully dampen the ITAM‐induced cell activation.
T130 21315-21348 Sentence denotes FcγR‐Dependent Effector Responses
T131 21350-21441 Sentence denotes Not all opsonized targets are equal: size, distance, valency and Fc geometry affect potency
T132 21442-21737 Sentence denotes To understand the immunobiology of FcγR effector responses particularly in the therapeutic mAb context, it is important to appreciate that the quality and potency of such effector responses is greatly affected by the nature of the IgG immune complex and/or the state of potential effector cells.
T133 21738-21881 Sentence denotes First, opsonization, per se, of a target is not necessarily sufficient to ensure FcγR interaction in a way that initiates an effector response.
T134 21882-22556 Sentence denotes Although it is the IgG Fc that interacts with and clusters the FcγR to induce a response, the nature of the Fab interaction with its epitope can strongly influence the likelihood or potency of FcγR effector responses by influencing the density of appropriately presented Fc portions.35 and also the size of the immune complex.36 Furthermore, the display/orientation and geometry of the Fc portions, as a consequence of the fragment antigen‐binding (Fab) interaction with the target epitope, can result in effector responses such as ADCC that differ substantially in potency, presumably because the orientation of the Fc makes FcγR engagement more, or less, accessible.37, 38
T135 22557-22912 Sentence denotes Second, in innate effector cells at rest, the largely linear actin cytoskeleton and the extracellular glycosaminoglycan glycocalyx regulate function by interacting with large glycoproteins, such as CD44, arranging these into ordered “picket” fences.39, 40 These corral receptors, including the FcγRs, and sterically inhibit their interaction with ligands.
T136 22913-23611 Sentence denotes Upon cell activation, cytoskeletal remodeling is associated with the loss of the receptor corrals, allowing FcγRs and other receptors to freely diffuse, engage ligand, cluster and signal.39 The influence of such surface constraints on receptors and effector cell function helps explain some of the observed epitope distance requirements for optimal mAb function,39, 41 which were apparent in a comparative study of ADCC and ADCP.42 ADCC was optimal when the epitope was displayed close, 0.3 nm “flush” or 1.5 nm, to the target membrane where close conjugation of effector and target by the mAb presumably facilitates the delivery of pore‐forming proteins to the target membrane as required by ADCC.
T137 23612-23757 Sentence denotes Interestingly, complement‐dependent cytotoxicity which also utilizes pore‐forming proteins for its cytotoxicity has similar distance constraints.
T138 23758-24051 Sentence denotes By contrast, ADCP was poor  when targeting epitopes displayed close or "flush" to the target cell membrane (within ~0.3 nm) but ADCP activity was restored when the epitope was displayed 1.5 nm off the membrane, demonstrating different optimal epitope distance requirements for ADCC and ADCP.42
T139 24052-24247 Sentence denotes Although the action of agonistic/antagonistic mAbs is mechanistically distinct to those eliciting cytotoxicity and ADCP, the distance segregation between target and FcγR+ cells is also important.
T140 24248-24379 Sentence denotes Indeed, the membrane proximal epitopes of CD28 and CD40 are important for the FcγR function in the complex MOA of these mAbs.43, 44
T141 24380-24624 Sentence denotes Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use.
T142 24625-24741 Sentence denotes Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone.
T143 24742-24962 Sentence denotes A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive.
T144 24964-24985 Sentence denotes ADCC and phagocytosis
T145 24986-25197 Sentence denotes ADCC and ADCP are the most widely appreciated FcγR‐dependent effector functions (Figure 1a, b) and are, respectively, mediated primarily via  FcγRIIIa on NK cells and professional phagocytes such as macrophages.
T146 25198-25351 Sentence denotes These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy.
T147 25352-25525 Sentence denotes In addition, ADCP can also occur via FcγRIIa and FcγRI,45 but the extent to which cytotoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear.
T148 25526-25797 Sentence denotes The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later.
T149 25799-25839 Sentence denotes Inhibition of cell activation by FcγRIIb
T150 25840-25964 Sentence denotes FcγRIIb is an immune checkpoint46, 47 and its splice variants are potent modulators of ITAM‐dependent signaling (Figure 1c).
T151 25965-26063 Sentence denotes This modulatory function occurs only when FcγRIIb is coaggregated with an ITAM signaling receptor.
T152 26064-26477 Sentence denotes Thus, B‐cell activation by the binding of the antigen in the immune complex to the BCR is regulated by the simultaneous binding of the Fcs of the immune complex to FcγRIIb1 on the same cell. In innate leukocytes, the activating‐type FcR (i.e. FcγRI, FcγRIIa, FcγRIIc, FcγRIII) and the high‐affinity IgE receptor, FcεRI, and the IgA receptor, FcαRI, are all modulated by immune complex co‐engagement with FcγRIIb2.
T153 26478-26683 Sentence denotes The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later).
T154 26684-26882 Sentence denotes Thus, B‐cell activation is modulated by the simulatenous binding of the antigen in the immune complex to the BCR and the binding of the Fcs, also in the immune complex, to FcγRIIB1 on the same cell.
T155 26884-26929 Sentence denotes Sweeping: clearance of small immune complexes
T156 26930-27057 Sentence denotes The removal of immune complexes in humans depends primarily on the complement receptor pathway and to a lesser degree the FcγR.
T157 27058-27195 Sentence denotes Among the FcγRs, it has been widely believed that immune complex removal only occurs by phagocytosis/endocytosis of activating‐type FcγR.
T158 27196-27516 Sentence denotes Surprisingly, the inhibitory FcγRIIb, which lacks intrinsic activating function, plays a major role in clearance, and rapidly “sweeps” away small complexes from the circulation (Figure 1d).48, 49 A major tissue involved in the clearance is likely to be the LSEC, where FcγRIIb is expressed abundantly in mice and humans.
T159 27517-27768 Sentence denotes This role is potentially important in resistance to viruses and toxins but may also be key to optimal performance of therapeutic IgG mAbs whose primary MOA is believed to be only neutralization of soluble macromolecules, for example, cytokines or IgE.
T160 27770-27844 Sentence denotes FcγR uptake of antigen: antibody complexes and shaping the immune response
T161 27845-27907 Sentence denotes Monoclonal antibody therapy is a form of passive immunization.
T162 27908-28229 Sentence denotes Indeed, longer‐term vaccine‐like or vaccinal immunity has been demonstrated in anti‐CD20‐treated mice via FcγRIIa50, 51 and in vitro recall memory responses from CD20‐treated patients.52 Although this is dependent on FcγR and anti‐CD20, the mechanism by which long‐term anti‐tumor response is established remains unclear.
T163 28230-28931 Sentence denotes Nonetheless, the active involvement of FcγR in the enhancement of antigen‐specific immunity by uptake of immune complexes through FcγR is historically well documented in experimental systems where FcγRs bind immune complexes and thereby feed antigens into the antigen‐presentation pathways.53 This has been demonstrated in vivo for small immune complexes via human FcγRI on human antigen‐presenting cells54 and in mice.19 Similarly, the capacity of FcγRIIbs to bind and rapidly internalize antigen–antibody complexes suggests that it too may significantly influence feeding antigens into professional antigen‐presenting cells of hematopoietic origin such as dendritic cells and possibly B lymphocytes.
T164 28932-29216 Sentence denotes Although not a classical major histocompatibility complex‐dependent antigen presentation, FcγRIIb on the stroma‐derived follicular dendritic cells influences antibody immunity by recycling antigen–antibody complexes to the cell surface for presentation of intact antigen to B cells.55
T165 29217-29439 Sentence denotes Although somewhat speculative, FcγRIIb’s rapid internalization/sweeping of complexes by the abundant LSEC, which interact with lymphocytes and can present antigen,56 may have a significant role in shaping immune responses.
T166 29441-29486 Sentence denotes Scaffolding of cell‐bound mAbs by FcγR+ cells
T167 29487-29588 Sentence denotes FcγR‐expressing cells can be critical, but passive, participants in the MOA of some mAbs (Figure 1e).
T168 29589-29801 Sentence denotes In FcγR scaffolding, IgG mAb molecules that have opsonized the cell surface of a target cell are additionally cross‐linked by their Fc portions engaging the FcγRs that are arrayed on the surface of a second cell.
T169 29802-30014 Sentence denotes This “super‐cross‐linking” of the target‐bound mAb by the FcγR lattice or “scaffold” on the adjacent cell greatly exceeds the target cross‐linking by the mAb alone, thereby inducing a response in the target cell.
T170 30015-30608 Sentence denotes Scaffolding was originally identified as the basis of T‐cell mitogenesis induced by anti‐CD3 mAb.57, 58 The CD3 mAbs alone were poor mitogens but the “super‐cross‐linking” of the T‐cell‐bound CD3 mAb by the membrane FcγR on adjacent cells, particularly by monocytes, induced rapid T‐cell expansion and cytokine secretion but did not require activation of FcγR‐expressing cells.57 Regrettably, FcγR scaffolding came to prominence and clinical relevance because of its causal role in the catastrophic adverse events resulting from the administration of anti‐CD357 and anti‐CD28 (TGN1412)59 mAbs.
T171 30609-30744 Sentence denotes Nonetheless, FcγR scaffold‐based induction of intracellular responses in a target cell can also lead to beneficial therapeutic effects.
T172 30745-30967 Sentence denotes Such examples are the induction of apoptotic death in a target cell, which is likely part of the MOA of daratumumab in multiple myeloma60 or the controlled agonistic expansion of cells, for example, via CD40 mAb agonism.43
T173 30969-31018 Sentence denotes IgG subclasses: specificity and affinity for FcγR
T174 31019-31242 Sentence denotes Most FcγRs (Table 2) are weak, low‐affinity receptors (affinities in the micromolar range) for IgG‐Fc, irrespective of whether the IgG is uncomplexed, monomeric or when it is complexed with antigen (i.e. an immune complex).
T175 31243-31484 Sentence denotes The very avid binding of immune complexes to an effector cell surface that displays an array of FcγR molecules is the result of the collective contributions of the low‐affinity interactions of each Fc of the IgGs in the complex with an FcγR.
T176 31485-31637 Sentence denotes This avidity effect is necessary as the FcγRs operate in vivo in environments of high concentrations of uncomplexed monomeric IgG (normally 3–12 g L–1).
T177 31638-31728 Sentence denotes Thus, the avid multivalent binding of the complex out competes uncomplexed, monomeric IgG.
T178 31729-31782 Sentence denotes The notable exception to this is the enigmatic FcγRI.
T179 31783-31959 Sentence denotes This receptor shows high, nanomolar affinity for uncomplexed monomeric IgG and thus would be expected to be constantly occupied in vivo by the normal circulating monomeric IgG.
T180 31960-32027 Sentence denotes However, IgG dissociation permits engagement with immune complexes.
T181 32028-32194 Sentence denotes Furthermore, FcγRI is not expressed or expressed poorly on resting cells, requiring interferon‐γ for induction of its expression, presumably at sites of inflammation.
T182 32195-32376 Sentence denotes Although the human IgG heavy‐chain constant domains have greater than 90% identity, key amino acid differences confer each subclass with unique structural and functional properties.
T183 32377-32448 Sentence denotes IgG1 and IgG3 are “universal” ligands, that is, they bind to all FcγRs.
T184 32449-32771 Sentence denotes Formal measurement of the weak, micromolar KD interactions of the low‐affinity receptors with monomeric IgG1 also revealed differing affinities between the low‐affinity FcγRs, with inhibitory FcγRIIb generally having the lowest affinity and FcγRIII the higher, sometimes referred to as a “moderate” affinity receptor.7, 61
T185 32772-32935 Sentence denotes The strength of IgG1 interaction can also be affected by FcγR polymorphism and in the context of therapeutic mAbs, variation in FcγRIIIa is particularly important.
T186 32936-33147 Sentence denotes The most common and possibly clinically significant polymorphism is phenylalanine/valine variation at position 158 in the IgG‐binding site, wherein FcγRIIIa‐F158 binds IgG1 less well than the FcγRIIIa‐V158 form.
T187 33148-33200 Sentence denotes IgG4 and IgG2 have more restricted FcγR specificity.
T188 33201-33338 Sentence denotes IgG4 has low affinity (KA = ~2 × 105 m –1) for the inhibitory FcγRIIb, but is also a high‐affinity ligand for FcγRI (KA = ~4 × 108 m –1).
T189 33339-33584 Sentence denotes IgG2 exhibits a highly restricted specificity, showing functional activity with only one polymorphic form of FcγRIIa (binding affinity KA = ~4.5 × 105 m –1) which is permitted by the presence of histidine at position 131 of its IgG‐binding site.
T190 33585-33795 Sentence denotes This FcγRIIa–H131 form is expressed in approximately 70% of the population, whereas IgG2 has no functional activity on the other common allelic form, FcγRIIa‐R131, which contains arginine at position 131.11, 61
T191 33797-33812 Sentence denotes IgG Subclasses:
T192 33813-33837 Sentence denotes Structure and Properties
T193 33839-33887 Sentence denotes The molecular basis of IgG and FcγR interactions
T194 33888-33951 Sentence denotes The extracellular regions of the FcγR are structurally similar.
T195 33952-34098 Sentence denotes Each low‐affinity FcγR has two ectodomains, whereas the high‐affinity FcγRI has a third domain but this is not directly involved in IgG binding.62
T196 34099-34393 Sentence denotes The interaction between the IgG subclasses and the FcγR is most comprehensively defined for human IgG1 by both X‐ray crystallographic7, 62, 63 and mutagenesis structure/function analyses.64, 65, 66 These studies defined key regions of the IgG sequence required for interaction with their FcγRs.
T197 34394-34560 Sentence denotes Crystallographic analyses of the human IgG1‐Fc complexed with FcγRI, FcγRII or FcγRIII show that these interactions are similar in topology, and asymmetric in nature.
T198 34561-34642 Sentence denotes The second extracellular domain of the FcγR inserts between the two heavy chains.
T199 34643-34793 Sentence denotes Here it makes contacts with the lower hinge of both H chains and with residues of the adjacent BC loop of one CH2 domain and the FG loop of the other.
T200 34794-34975 Sentence denotes The N‐linked glycan at asparagine 297 (N297) of the heavy chain is essential for the structural integrity of the IgG‐Fc by affecting the spacing and conformation of the CH2 domains.
T201 34976-35230 Sentence denotes Indeed, its removal ablates FcγR binding.67 Of particular relevance to therapeutic mAb development is that the normal low‐affinity IgG interaction with FcγRIIIa is profoundly increased by the removal of the core fucose from the N297 Fc oligosaccharide.68
T202 35231-35482 Sentence denotes No crystallographic data are available for IgG2 or IgG4 Fc in complex with FcγR, but mutagenesis studies of the Fc and the FcγR revealed general similarity, but with critical differences, in the interaction of these subclasses with their cognate FcγR.
T203 35484-35531 Sentence denotes Unique features of the IgG2 and IgG4 subclasses
T204 35532-35739 Sentence denotes In IgG1, the stable interaction of the two heavy chains results from the combined effects of stable covalent inter H‐chain disulfide bonds and strong noncovalent interaction of the two CH3 domains (Table 3).
T205 35740-35835 Sentence denotes In stark contrast, in IgG2 and IgG4 the interaction of the CH3 domains of each H‐chain is weak.
T206 35836-35931 Sentence denotes Residues 392, 397 and 409 (Eu numbering) profoundly affect the stability of these interactions.
T207 35932-36128 Sentence denotes The difference at position 409 (R409 in IgG4 and K409 in IgG1) confers a 100‐fold decrease in stability of the interface between the two CH3 domains of IgG4 compared with that of IgG1 (Table 3).69
T208 36129-36288 Sentence denotes Furthermore, the core hinge of IgG4 differs from IgG1 at position 228 (P228 in IgG1 and S228 in IgG4), resulting in unstable inter‐heavy‐chain disulfide bonds.
T209 36289-36757 Sentence denotes This, together with the destabilizing amino acids in the CH3, confers the unique property of half‐antibody (Fab arm) exchange between different IgG4 antibodies,69 thereby creating monovalent, bispecific IgG4 antibodies in vivo.69, 70 The similarly unstable interactions between the CH3 domains in IgG2 are conferred by the interface residue M397; however, the stable inter‐H‐chain disulfide bonds of the core and upper hinge prevent half‐molecule exchange (Table 3).69
T210 36758-36831 Sentence denotes In addition, IgG2 uniquely has three disulfide bond conformers (Table 3).
T211 36832-37441 Sentence denotes The distinct conformers are formed when (1) each light chain is attached to the Cys131 residue of CH1 in the heavy chain (IgG2‐A conformer), (2) both light chains attach to the upper hinge (IgG2‐B) or (3) one light chain is attached to the CH1 Cys131 and one to the upper hinge of the other heavy chain (IgG2‐AB).71 This results in distinct positioning of the Fabs relative to the Fc portions in the different conformers, which has implications for the interaction with antigen and the capacity of IgG2 to cross‐link target molecules in the absence of FcγR binding, for example, in an agonistic mAb setting.72
T212 37442-37541 Sentence denotes It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology.
T213 37542-37807 Sentence denotes The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73
T214 37809-37859 Sentence denotes Therapeutic antibody design: improving mAb potency
T215 37860-37950 Sentence denotes Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy.
T216 37951-38257 Sentence denotes The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.
T217 38258-38556 Sentence denotes Therapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical.
T218 38558-38587 Sentence denotes The nature of the IgG isotype
T219 38588-38755 Sentence denotes Different capabilities for the recruitment and activation of the different immune effector functions are naturally found in the Fc regions of the human IgG subclasses.
T220 38756-38903 Sentence denotes Thus, to achieve a desired MOA, the different IgG subclasses are important starting points for the selection and engineering of the optimal mAb Fc.
T221 38904-39234 Sentence denotes IgG1 is, in many ways, a proinflammatory or “effector‐active” subclass, as it can initiate the complement cascade and is a “universal” FcγR ligand.74 Notwithstanding it is also a ligand for the inhibitory FcγRIIb, IgG1 elicits proinflammatory responses through all activating‐type FcγRs, including ADCC, ADCP and cytokine release.
T222 39235-39411 Sentence denotes Because of their more restricted FcγR‐binding profile, IgG2 and IgG4 have offered some choice in potentially avoiding FcR effector function without the need for Fc engineering.
T223 39412-39881 Sentence denotes They have been used as the backbone for therapeutic mAbs either because recruitment of patients’ effector functions was unlikely to be necessary for the primary MOA of the mAb or is possibly detrimental to the desired therapeutic effect.75 However, the use of these unmodified “inert” subclasses is not without consequences and underscores the need for Fc engineering to modify FcγR interactions—See the “Attenuating and ablating FcγR related functions of IgG” section.
T224 39882-40048 Sentence denotes Thus, the choice of IgG subclass for therapeutic mAb engineering is an important first step for engineering of novel mAbs of improved specificity, potency and safety.
T225 40050-40101 Sentence denotes Fc engineering for enhanced anticancer therapeutics
T226 40102-40281 Sentence denotes IgG1 is the predominant subclass used in the development of cytotoxic mAbs where induction of an activation‐type response, ADCC or phagocytosis, is considered desirable.45, 76, 77
T227 40282-40374 Sentence denotes Cytotoxic mAb cancer therapeutics can control disease progression by one or more mechanisms.
T228 40375-40531 Sentence denotes Their MOAs include direct induction of apoptotic cell death of the cancer cell (anti‐CD20, anti‐CD52) or blocking receptor signaling (anti‐HER2, anti‐EGFR).
T229 40532-40944 Sentence denotes They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design.
T230 40945-41034 Sentence denotes IgG1 antibodies bind both the activating FcγR (e.g. FcγRIIIa) and the inhibitory FcγRIIb.
T231 41035-41184 Sentence denotes In some environments effector cells will coexpress FcγRIIb together with FcγRI, FcγRIIa and FcγIIIa, as may occur on a tumor‐infiltrating macrophage.
T232 41185-41441 Sentence denotes Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell.
T233 41442-41488 Sentence denotes This leads to reduced therapeutic mAb potency.
T234 41489-41938 Sentence denotes Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response.
T235 41939-42050 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 42051-42243 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 42244-42310 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 42311-42385 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 42386-42656 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.
T240 42657-42742 Sentence denotes At the time of writing, some mAbs with improved potency are coming into clinical use.
T241 42743-42875 Sentence denotes Their improved action has been achieved by modifying the N‐linked glycan or the amino acid sequence of the heavy‐chain Fc (Table 4).
T242 42876-42982 Sentence denotes Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development.
T243 42983-43092 Sentence denotes mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage
T244 43093-43197 Sentence denotes Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III
T245 43198-43358 Sentence denotes Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III
T246 43359-43448 Sentence denotes Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed
T247 43449-43642 Sentence denotes Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed
T248 43643-43772 Sentence denotes Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed
T249 43773-43882 Sentence denotes Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III
T250 43883-44007 Sentence denotes Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T251 44008-44132 Sentence denotes Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed
T252 44133-44254 Sentence denotes Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III
T253 44255-44411 Sentence denotes Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed
T254 44412-44530 Sentence denotes Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III
T255 44531-44621 Sentence denotes Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed
T256 44622-44733 Sentence denotes Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed
T257 44734-44834 Sentence denotes Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III
T258 44835-44920 Sentence denotes Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed
T259 44921-45037 Sentence denotes Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III
T260 45038-45150 Sentence denotes Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III
T261 45151-45238 Sentence denotes Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II
T262 45239-45459 Sentence denotes Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III
T263 45460-45542 Sentence denotes Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III
T264 45543-45666 Sentence denotes Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T265 45667-45686 Sentence denotes Ig, immunoglobulin.
T266 45687-45834 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T267 45835-46017 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T268 46019-46048 Sentence denotes Modification of the Fc glycan
T269 46049-46329 Sentence denotes The typical complex N‐linked glycan attached to N297 of the heavy chain includes a core fucose.85 Antibodies that lack this fucose have approximately 50‐fold improved binding to FcγRIIIa and FcγRIIIb and importantly retain the weak, low‐affinity binding to the inhibitory FcγRIIb.
T270 46330-46704 Sentence denotes Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding.
T271 46705-47030 Sentence denotes Compared with their unmodified counterparts, the afucosyl mAbs showed dramatic improvement of FcγRIII‐related effector responses such as stronger NK cell‐mediated ADCC, or enhanced neutrophil‐mediated phagocytosis through FcγRIIIb and/or FcγRIIIa.23 However, certain neutrophil functions via FcγRIIa may be compromised.90, 91
T272 47031-47135 Sentence denotes There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4).
T273 47136-47486 Sentence denotes Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments.
T274 47488-47518 Sentence denotes Mutation of the Fc amino acids
T275 47519-47631 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 47632-47912 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 47913-48030 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 48031-48410 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 48411-48625 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 48626-48997 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 48998-49159 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.
T282 49161-49215 Sentence denotes Attenuating and ablating FcγR‐related functions of IgG
T283 49216-49324 Sentence denotes There are circumstances where binding to FcγR is unnecessary or undesirable in the MOA of a therapeutic mAb.
T284 49325-49662 Sentence denotes Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FcγR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.57, 59 Clearly reducing or eliminating FcγR interactions, when they are not required for therapeutic effect, may be desirable.
T285 49663-49755 Sentence denotes Indeed, this had been addressed by the choice of IgG subclass or by modifying the Fc region.
T286 49756-49917 Sentence denotes Indeed, most efforts in Fc engineering mAbs that have translated to an approved drug have focused on the reduction or elimination of FcγR interactions (Table 4).
T287 49918-50185 Sentence denotes One approach to minimize interactions with the activating FcγR has been the use of IgG4 or IgG2 backbones, which show a more restricted specificity for the activating FcγR and consequently have been traditionally, and simplistically, viewed as “inert” IgG subclasses.
T288 50186-50367 Sentence denotes Notwithstanding the unexpected, and FcγR‐dependent, severe adverse reaction induced by the IgG4 TGN1412 mAb, the IgG4 or IgG2 backbones have been successfully used in many settings.
T289 50368-50602 Sentence denotes Indeed, checkpoint inhibitors, such as mAbs targeting CTLA‐4 or the PD‐L1/PD‐1 interaction for the suppression of inhibitory signals that contribute to immune tolerance in the tumor microenvironment, are formatted on an IgG4 backbone.
T290 50603-50827 Sentence denotes Pembrolizumab, nivolumab and cemiplimab are all anti‐PD‐1 antibodies currently used for cancer therapy and have been formatted on an IgG4 backbone95, 96, 97 with a stabilized core hinge (S228P) to prevent half‐IgG4 exchange.
T291 50828-50984 Sentence denotes Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98
T292 50985-51056 Sentence denotes However, the use of IgG2 and IgG4 as “inert” subclasses is problematic.
T293 51057-51452 Sentence denotes Both bind to the activating receptors FcγRIIa‐H131 and FcγRI, respectively (Table 2), and initiate effector functions such as neutrophil activation and apoptosis induction.75, 99 Interestingly, in experimental systems, cross‐linking of anti‐PD‐1 IgG4‐based mAb by FcγRI switched its activity from blocking to activatory.10 Moreover, IgG4 binds to FcγRIIb, which may scaffold the therapeutic mAb.
T294 51453-51770 Sentence denotes Although scaffolding may be beneficial in some contexts, for example, in immune agonism,43 it can be disastrous and unexpected in others as it was for the anti‐CD28 TGN1412 mAb.59 Thus, the IgG2 and IgG4 subclasses are not the optimum choice for “FcR‐inactive” mAbs, and so modifying the Fc is a more direct approach.
T295 51771-52065 Sentence denotes The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13
T296 52066-52177 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 52178-52333 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 52334-52502 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).
T299 52503-52707 Sentence denotes A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations.
T300 52708-52886 Sentence denotes The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F).
T301 52887-53104 Sentence denotes They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16
T302 53105-53200 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 53201-53475 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 53476-53693 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 53694-53798 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 53799-54061 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 54063-54093 Sentence denotes Improving FcγRIIb interactions
T308 54094-54263 Sentence denotes Preferential or specific Fc engagement of FcγRIIb over the activating FcγR offers several potential therapeutic advantages for new mAbs in distinct therapeutic settings.
T309 54265-54367 Sentence denotes Improved recruitment of FcγRIIb immunoreceptor tyrosine inhibition motif‐dependent inhibitory function
T310 54368-54854 Sentence denotes Harnessing the physiological inhibitory function of FcγRIIb by mAbs that target ITAM receptors has the potential to shut down ITAM‐dependent signaling pathways of major importance in antibody pathologies.32, 108 Such ITAM signaling receptors include the BCR complex on B cells which is active in systemic lupus erythematosus, the FcεRI on basophils and mast cell subsets in allergies or the activating‐type FcγR on a variety of innate leukocytes in antibody‐mediated tissue destruction.
T311 54855-55019 Sentence denotes In such scenarios, the ITAM signaling receptor complex that is targeted by the therapeutic mAb must be co‐expressed on the cell surface with the inhibitory FcγRIIb.
T312 55020-55223 Sentence denotes This permits coengagement with ITAM signaling receptor by the Fab of the mAb and inhibitory FcγRIIb by its Fc which is the critical requirement in the inhibitory MOA for such therapeutic mAbs (Figure 1).
T313 55224-55649 Sentence denotes Obexelimab (also known as XmAb5871; Table 4), currently in early clinical testing in inflammatory autoimmune disease, is an IgG1 mAb that targets CD19 of the BCR complex.19 It contains two Fc modifications, S267E and L328F (also known as “SELF” mutations), that selectively increased FcγRIIb binding by 400‐fold to about 1 nm, which results in powerful suppression of BCR signaling and the proliferation of primary B cells.19
T314 55650-56614 Sentence denotes The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later).
T315 56615-56846 Sentence denotes One cautionary note is that the arginine 131 (R131) of the IgG‐binding site in FcγRIIb is critical for the enhanced affinity binding of “SELF”‐mutated Fcs but it is also present in the activating‐type “high responder” FcγRIIa‐R131.
T316 56847-57109 Sentence denotes Thus, antibodies modified with “SELF” have very‐high‐affinity binding to FcγRIIa‐R131 115 with a potentially increased risk of FcγRIIa‐dependent complications in patients expressing this allelic form, although, so far, none have been reported in clinical trials.
T317 57110-57300 Sentence denotes However, an alternative set of six Fc mutations, termed “V12” (P238D, E233D, G237D, H268D, P271G and A330R), potently enhanced FcγRIIb binding without increasing FcγRIIa–R131 interaction.115
T318 57302-57350 Sentence denotes Enhancing the sweeping of small immune complexes
T319 57351-57723 Sentence denotes The expression of FcγRIIb on LSEC and its action in the “sweeping” or removal of small immune complexes has opened up new possibilities for the application of FcγRIIb‐enhancing modifications.17 Antibodies or Fc fusion proteins, whose primary MOA is the neutralization of soluble molecules such as IgE or cytokines, are particularly attractive candidates for this approach.
T320 57724-58032 Sentence denotes Proof‐of‐concept for this strategy has been demonstrated in experimental models.48 Indeed, this may be a significant component of the rapid disappearance of IgE from the circulation of patients treated with the anti‐IgE XmAb7195 containing the FcγRIIb enhancing “SELF” modifications, as described previously.
T321 58034-58073 Sentence denotes Immune agonism through FcγR scaffolding
T322 58074-58173 Sentence denotes Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target.
T323 58174-58419 Sentence denotes Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116
T324 58420-58512 Sentence denotes The role of FcγR in the action of these types of mAbs appears to be primarily as a scaffold.
T325 58513-58609 Sentence denotes FcγRIIb is often the predominate receptor involved and the extent of its involvement is complex.
T326 58610-58930 Sentence denotes In the case of CD40, the degree of FcγRIIb scaffolding potency is linked to the epitope location of the targeting mAb with greater potency seen for membrane proximal epitopes.43, 117 It is also noteworthy that depending on the epitope location, the scaffolding of anti‐CD40 mAbs may convert antagonist mAbs to agonistic.
T327 58931-59423 Sentence denotes Engineering of the IgG1 Fc region for enhanced and/or specific binding to FcγRIIb can greatly improve agonistic function.72, 118, 119, 120 Such mutations induced significantly greater agonistic activity in an anti‐DR5 model through increased induction of apoptotic death and decreased tumor growth compared with unmodified IgG1.121 The “SELF” modifications that dramatically and selectively increase affinity for FcγRIIb have also been used to enhance immune agonism in an anti‐OX40 model.122
T328 59424-59627 Sentence denotes The incorporation of the "V12" Fc mutations into IgG1 specifically enhance FcγRIIb interaction 200‐fold, conferring the enhanced agonistic activity of an anti‐CD137 antibody and an anti‐OX40 mAb.115, 122
T329 59629-59658 Sentence denotes Future Engineering Strategies
T330 59659-59755 Sentence denotes Monoclonal antibodies are potent therapeutics in a number of chronic or once incurable diseases.
T331 59756-59885 Sentence denotes However, there is still extensive unmet clinical need as well as considerable room for improvement in many existing therapeutics.
T332 59886-60026 Sentence denotes Further understanding of how antibody structure affects FcγR function is essential for future development of more potent and effective mAbs.
T333 60027-60294 Sentence denotes Already, engineering of the IgG Fc and its glycan has proved a potent and effective approach for increasing the clinical effectiveness, functional specificity and safety of therapeutic mAbs and is an emerging pathway to the development of the “next‐gen” therapeutics.
T334 60295-60638 Sentence denotes Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors.
T335 60639-60892 Sentence denotes Furthermore, the mixed subclass nature of these normal antibody responses suggests that circumstances may arise in therapeutic strategies where there is value in having distinctly modified Fcs for the nuanced engagement of different FcγR family members.
T336 60893-61044 Sentence denotes Treatments comprising multiple mAbs and immune stimulants are under investigation in infectious disease for neutralization coverage of variant strains.
T337 61045-61202 Sentence denotes Indeed, such an approach may be most effective in emerging infectious disease such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection.
T338 61203-61401 Sentence denotes The use of multiple mAbs tailored for distinct effector functions and targeting different epitopes will maximize the opportunity for cocktailing of effector functions in different types of diseases.
T339 61402-61605 Sentence denotes Indeed, in a small but contemporary example outside of infectious disease, the FDA‐approved combination in adenocarcinoma therapy uses a cocktail of two mAbs, pertuzumab and trastuzumab, against Her2.123
T340 61606-61883 Sentence denotes Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system.
T341 61884-62087 Sentence denotes Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases.
T342 62089-62109 Sentence denotes Conflict of Interest
T343 62110-62115 Sentence denotes None.
T344 62117-62132 Sentence denotes Acknowledgments
T345 62133-62190 Sentence denotes We thank Halina Trist for assistance with the manuscript.
T346 62191-62319 Sentence denotes We also thank NHMRC, Janina and Bill Amiet Trust, Margaret Walkom Trust and Nancy E Pendergast Trust, Genmab, for their support.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 680-686 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T2 3302-3320 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T3 3400-3407 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T4 7369-7383 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T5 15413-15437 Phenotype denotes immune thrombocytopenias http://purl.obolibrary.org/obo/HP_0001973
T6 15756-15784 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T7 15899-15910 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T8 25336-25342 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 28183-28188 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T10 40296-40302 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T11 40442-40448 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T12 40601-40606 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T13 41154-41159 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T14 41211-41217 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 42231-42236 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 42649-42655 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T17 43178-43186 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T18 43430-43438 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T19 43754-43762 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T20 43988-43996 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T21 44235-44243 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T22 44393-44401 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T23 44511-44519 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T24 44603-44611 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T25 44715-44723 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T26 44815-44823 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T27 44902-44910 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T28 45440-45448 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T29 45523-45531 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T30 45647-45655 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T31 46497-46502 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T32 47237-47265 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T33 47728-47756 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 47998-48006 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 48605-48610 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 48763-48783 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 48788-48816 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T38 50544-50549 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T39 50691-50697 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T40 54664-54692 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T41 55322-55340 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T42 56484-56491 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T43 58382-58388 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T44 59216-59221 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-Glycan

Id Subject Object Predicate Lexical cue
T1 11546-11549 https://glytoucan.org/Structures/Glycans/G05518TD denotes All
T2 12736-12739 https://glytoucan.org/Structures/Glycans/G05518TD denotes All